   
 
Confidential    Page 1 of 109  
  
  
 
 
 
  
CLINICAL STUDY PROTOCOL  
   
Lerapolturev (formerly known as  PVSRIPO ) with and without Immune Checkpoint 
Blockade in Advanced PD -1 Refractory Melanoma  
    
 
 
CONFIDENTIAL  
 
This document contains confidential, proprietary information 
 
Confidentiality Statement  
This study will be performed in compliance with Good Clinical Practices (GCP) and applicable 
regulatory requirements, including the archiving of essential documents.  Information contained in this 
protocol is confidential in nature, and may not be used, divulged, published or otherwise disclosed to others except to the extent necessary to obtain approval of the institutional review board or independent ethics committee, or as required by [CONTACT_2371].  Persons to whom this information is disclosed should be informed that  this information is confidential  and proprietary  and may not be further disclosed 
without the express written consent of Istari Oncology, Inc.  
 
Protocol Number  LUMINOS -102 (PVSRIPO ICI M201)  
Clinical Phase  Phase 2  
US IND Number  IND [ZIP_CODE]  
Protocol Date:  Amendment 4 
14JAN2022  
Sponsor:  Istari Oncology, Inc.  
[ADDRESS_1086155]  
Morrisville , NC [ZIP_CODE]  
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 2 of 109 
  
Sponsor Signatory:   
      
W. Garrett Nichols, MD , MS 
Chief Medical Officer  
Istari Oncology , Inc.   Date  
                         
 
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086156] the study as outlined 
herein, in accordance with Good Clinical Practice (GCP) requirements and the 
International Conference on Harmonization (ICH) guidelines, the Declaration of Helsinki and complying wi th the obligations and requirements of Clinical Investigators and all 
other requirements listed in 21 Code of Federal Regulations (CFR) part 312 and with all applicable local regulations. I agree to maintain the confidentiality of all information received or developed in connection with this protocol.  
  
Investigator Name (Print):   
Date Signed:   
Investigator Signature:   
 
  
[CONTACT_788948], Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086157] OF IN TEXT TABLES AND FIGURES  .................................................................... 7 
SYNOPSIS  ...................................................................................................................... 8 
CLINICAL TRIAL SCHEMATIC ..................................................................................... 19 
1 INTRODUCTION  ................................................................................................ 30 
1.1 Background  ........................................................................................................ 30 
1.2 Rationale  ............................................................................................................ 31 
1.2.1  Nonclinical Studies  ............................................................................................. 34 
1.2.2  Clinical Studies  ................................................................................................... 36 
1.3 Benefit/Risk Assessment  .................................................................................... 42 
1.3.1  Known Potential Risks  ........................................................................................ 42 
1.3.2  Known Potential Benefits  .................................................................................... 45 
1.3.3  Benefit -Risk Summary  ........................................................................................ 47 
2 OBJECTIVES And ENDPOINTS ........................................................................ 48 
2.1 Objectives and Endpoints  ................................................................................... 48 
2.2 Hypothesis  .......................................................................................................... 49 
3 TRIAL DESIGN  ................................................................................................... 50 
3.1 Overall Design  .................................................................................................... 50 
3.1.1  Crossover  ........................................................................................................... 51 
3.1.2  Considerations for Modification of Dose and/or Dosing Schedule for Participants 
receiving the Q3/4W Schedule of Injections.  ...................................................... 52 
3.1.3  Determination of the Recommended Lerapolturev Dose  .................................... 52 
3.1.4  Definition of Dose- Limiting Toxicity  ..................................................................... 54 
3.2 Evaluation of Lerapolturev Shedding  .................................................................. 55 
3.3 Justification for Lerapolturev Dose and Schedule  ............................................... 55 
3.4 End of Study Definition  ....................................................................................... 56 
4 STUDY POPULATION  ....................................................................................... 56 
4.1 Inclusion Criteria  .................................................................................................  56 
4.2 Exclusion Criteria  ................................................................................................ 58 
4.3 Screen Failures  .................................................................................................. 61 
5 STUDY DRUG (LErapolturev, Nivolumab or pembrolizumab)  ............................ 61 
5.1 Lerapolturev: Packaging, labeling and how supplied  .......................................... 61 
5.2 Preparation/Handling/Storage/Accountability  ..................................................... 61 
5.3 Lerapolturev Dose, Schedule, and Administration  .............................................. 62 
5.4 Prior/Concomitant Therapy  ................................................................................. 64 
5.5 Dose Modification/Toxicity Management Guidelines  .......................................... 65 
5.5.1  Lerapolturev ........................................................................................................ 65 
5.5.2  Anti-PD-1 Therapy  .............................................................................................. 66 
6 DISCONTINUATION OF STUDY TREATMENT, TREATMENT BEYOND PROGRESSION, PARTICIPANT COMPLETION AND WITHDRAWAL, AND STUDY TERMINATION ...................................................................................... 70
 
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086158] and Serious Adverse Events  ................................................. 78 
7.3.4  Regulatory Reporting Requirements for Serious Adverse Events  ...................... 78 
7.3.5  Notification of Pregnancy  .................................................................................... 78 
7.4 Tissue and Blood- Based Biomarker and Cytokine Analyses  .............................. 79 
8 STATISTICAL CONSIDERATIONS  .................................................................... 80 
8.1 Stratification Factors  ........................................................................................... 80 
8.2 Statistical Hypotheses  ........................................................................................ 80 
8.3 Sample Size Determination  ................................................................................ 80 
8.4 Populations for Analyses  .................................................................................... 81 
8.5 Statistical Analyses  ............................................................................................. 81 
8.5.1  Efficacy Analyses  ............................................................................................... 81 
8.5.2  Translational Analyses  ....................................................................................... 82 
8.5.3  Safety Analyses  .................................................................................................. 82 
8.5.4  Exploratory Analyses  .......................................................................................... 82 
8.6 Interim Analysis (IA) ........................................................................................... 83 
9 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  84 
9.1 Regulatory, Ethical, and Trial Oversight Considerations  .................................... 84 
9.1.1  Regulatory and Ethical Considerations  ............................................................... 84 
9.1.2  Financial Disclosure  ........................................................................................... 84 
9.1.3  Informed Consent Process  ................................................................................. 84 
9.1.4  Data Protection  ................................................................................................... 85 
9.1.5  Data and Safety Monitoring Committee  .............................................................. 85 
9.1.6  Data Quality Assurance ...................................................................................... 86 
9.1.7  Protocol Deviations  ............................................................................................. 87 
9.1.8  Source Documents  ............................................................................................. 87 
9.1.9  Study and Site Closure  ....................................................................................... 88 
9.1.10  Confidentiality and Publication Policy  .................................................................  88 
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 6 of 109 
 9.2 Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow -
up, and Reporting  ............................................................................................... 90 
10 ABBREVIATIONS  ............................................................................................... 98 
11 REFERENCES  .................................................................................................  100  
12 Appendix I  ........................................................................................................ 105  
13 Appendix II ........................................................................................................ 107  
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086159] OF IN TEXT TABLES AND FIGURES  
 
Tables  
Table 1.  Schedule of Assessments for Lerapolturev Monotherapy or Lerapolturev + Pembrolizumab  ......................................................................................... 20
 
Table 2.  Schedule of Assessments for Lerapolturev + Nivolumab  ............................. [ADDRESS_1086160] and melanoma cell lines, yet 
lerapolturev infection of DCs is sublethal and induces sustained proinflammatory cytokine production.  ........................................................... 33
 
Figure 2.  Lerapolturev restricts tumor growth and produces antigen- specific anti -
tumor immunity25 .......................................................................................... 35 
   
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 8 of 109  
 SYNOPSIS  
Protocol Title  Lerapolturev  (formerly known as PVSRIPO)  with and without 
Immune Checkpoint Blockade in Advanced PD -1 Refractory 
Melanoma  
Protocol 
Number  LUMINOS -102 (PVSRIPO ICI M201)  
Rationale and 
Background  Currently approve d systemic immunotherapi[INVESTIGATOR_788881] a significant portion of  patients  with unresectable 
melanoma . Less than 40% of patients respond to anti -programmed 
cell death receptor -1 (PD-1) therapy (ie, have primary PD -1 
resistance)1,2, and o f those who do respond, up to 25% may 
develop an acquired resistance over time3. While combining  
anti-PD-1 with anti -cytotoxic T -lymphocyte- associated protein 4 
(CTLA -4) therapy can increase response rate s, this combination is 
associated with significant toxicity4. Options for follow -on therapy 
remain limited , and outcomes are poor for those with advanced 
disease5. Lerapolturev (formerly PVSRIPO ) is a recombinant 
rhinovirus/polio virus  (PV) chimera which has  demonstrated clinical 
anti-tumor activity in  primary brain tumors and  in a Phase 1 study of  
unresectable,  anti-PD-1 refractory (as per  investigator 
determination) melanoma6 which warrants further investigation. 
Preliminary data from the current study in unresectable, anti -PD-
1/L1 refractory melanoma (as defined by [CONTACT_788907]’s  [SITC] Immunotherapy Resistance 
Taskforce Guidance7) show  that lerapolturev given every (Q) 3 to 4 
weeks , alone or in combination with anti -PD-1, at a dose of up to 
6 x 108 tissue culture infectious dose 50% (TCID 50) is very well 
tolerated (regimen referred to as Q3/4W  hereafter) ; all adverse 
events (AEs) related to lerapolturev and/or anti -PD-1 remain Grade 
1 or 2, with no dose -limiting toxicities  (DLTs) , treatment -related 
serious AEs (SAEs) or sign/symptoms of cytokine release syndrome reported as of th e 10DEC2021 data cutoff  (
Table 3 and 
Table 4).  However, the anti -tumor activity noted in Phase 1 has not 
yet been duplicated. In addition,  a literature review shows that other  
innate immune agonists  with clinical activity in anti- PD-1/L1 
refractory melanoma, including other oncolytic viruses , use an 
“induction/maintenance” dose schedule, with  more frequent (eg, 
weekly) injections for 1 to 2 months, followed by [CONTACT_788908] (eg, Q3 or 4 week) maintenance thereafter to induce an upfront anti-tumor immune reaction that can be maintained across time. 
Therefore, LUMINOS -[ADDRESS_1086161] the safety and efficacy of weekly 
x7 lerapolturev followed by Q3 to 4 -week administration at a dose of 
up to 1.6  x 109 TCID 50, as monotherapy and in combination with 
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 9 of 109  
 anti-PD-1 therapy , in a  more homogeneous unresectable melanoma 
population  that has failed 1 prior line of anti -PD-1/L1- based therapy.   
Key 
Objectives  Objectives  Endpoints/Evaluation Criteria  
Primary  
To evaluate the anti -tumor 
activity of  lerapolturev  with 
and without anti -PD-1, in 
participants  who have 
failed anti -PD-1/L1-based 
therapy    • Overall Response Rate (ORR): 
the proportion of participants  
achieving complete (CR) or partial response (PR), per RECIST  1.1 
To evaluate the 
safety/tolerability of  lerapolturev  with and 
without anti -PD-1, in 
participants  who have 
failed anti -PD-1/L1-based 
therapy      • The frequency and severity of 
treatment -emergent adverse 
events (AE) via Common Terminology Criteria for Adverse Events (CTCAE, v5.0)  
• Changes in laboratory (hematology, chemistry) and vital sign parameters  
• Lerapolturev  AESIs  
• Anti-PD-1 immune -related AEs 
(irAEs)  
• Study treatment discontinuation 
due to AEs  
To evaluate the effect of  
lerapolturev  on the tumor 
microenvironment  of 
injected and non- injected 
lesions when administered with and without anti -PD-1 
therapy  • Changes from baseline in the 
number of CD8+ tumor infiltrating lymphocytes (TILs) 
• Changes from baseline in PD -L1 
expression  
Secondary  
To evaluate survival and 
disease control outcomes of lerapolturev  with and 
without  anti-PD-1, in 
participants  who have 
failed anti -PD-1/L1-based 
therapy   • Overall survival (OS): time from 
treatment group assignment until 
death from any cause  
• Duration of Response (DOR): time from confirmed objective 
response (CR or PR per 
RECIST 1.1 ) until unequivocal 
disease progression or death, whichever occurs first  
• Disease control rate (DCR): the proportion of participants  
achieving confirmed CR, 
confirmed PR, or stable disease 
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 10 of 109 
 (SD) per RECIST  1.1, as best 
response  
• Disease control rate- 6months 
(DCR- 6mo): the proportion of 
participants  achieving confirmed 
CR (any duration), confirmed PR 
(any duration) or SD (≥ 6 
months) per RECIST 1.[ADDRESS_1086162] response  
• Durable Response Rate (DRR): the proportion of participants with confirmed CR or PR (per 
RECIST  1.1) lasting at least 6 
months  
• Progression- free survival  (PFS) : 
time (number of months) from treatment group assignment  until 
date of documented radiologic 
disease progression per RECIST 1.[ADDRESS_1086163]  
 
Study Design  This multi -center, open -label, randomized, Phase 2 study will 
investigate the efficacy and safety of  lerapolturev  alone (Arm 1) or 
in combination with an anti -PD-1 inhibitor  (Arm 2). Following a 6-
participant safety run- in period, u p to approximately 50 participants 
with unresectable cutaneous melanoma who previously failed an 
anti-PD-1/L1-based therapy  will be randomized 1:1 to receive either 
lerapolturev  or lerapolturev  plus an anti-PD-1. Based on updated 
eligibility criteria, p articipants  will be stratified based on type of  anti-
PD-1/L1 resistance (primary versus secondary  as per Kluger et al7.) 
and baseline lactate dehydrogenase ( LDH)  levels  (normal versus 
>ULN) .  
 As of 10DEC2021, the safety run- in has been completed and a total 
of [ADDRESS_1086164] been enrolled (safety run- in, n=6; Arm 1, 
n=5; Arm 2, n=6). Upon review of the safety profile for lerapolturev administered as monotherapy or in combination with anti -PD-1 
therapy ( Section 1.2.2 ), and in agreement with the data safety 
monitoring committee (DSMC ), the total lerapolturev dose to be 
administered will be a maximum of 1.6 x 10
9 TCID 50/visit, with up to 
6 lesions injected/visit. Th is dose  schedule  of administration  
(referred to hereafter as QW ) will include weekly injections x 7 
followed by [CONTACT_5640] Q3W dosing (lerapolturev monotherapy or in combination with pembrolizumab) or Q4W dosing (combination with 
nivolumab) .  
 
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 11 of 109 
 Participants enrolled in the safety run -in, or those randomized to  
Arm 1  (lerapolturev  only), are allowed to  crossover to Arm 2 
following  disease progressi on (per RECIST  1.1), once a PR lasts ≥ 
[ADDRESS_1086165] -defined 
progression  (ie, SD or unconfirmed PR or CR) , as described in 
Section 3. In Arm 2, anti-PD-1 will be administered per the 
manufacturer’s prescribing information concurrently with 
lerapolturev beginning Day 1.  After [ADDRESS_1086166] been 
treated  under Study Protocol Amendment 4 and on study  
approximately 21 days (ie, once n= [ADDRESS_1086167] completed the DLT  evaluation 
period) , an additional safety review will be performed by [CONTACT_788909] -PD-1 and/or 
to make recommendations related to lerapolturev dose  and/or 
schedule adjustment s as described in  Section  3.1.3.   
 Participants currently receiving the Q3/4W  schedule of injections 
will be given the option to change to the QW  schedule 
(Section 3.1.2 ). 
 Participants will be evaluated for key primary and secondary anti-
tumor response endpoints based on RECIST 1.1. Additional primary 
endpoints include characterization of  the immun ologic response 
(eg, changes in CD8+ TIL levels  and PD -L1 expression)  to 
lerapolturev with and without anti -PD-[ADDRESS_1086168] to treatment decisions (eg, confirmation of PD  for study 
discontinuation) will occur based on iRECIST  criteria . However, 
partic ipants in the safety run- in or Arm [ADDRESS_1086169] are exploratory endpoints.   
Planned Number of 
Participants  Up to approximately 56 participants  
Study Entry Criteria  Inclusion Criteria:  
1. ≥ [ADDRESS_1086170] 
poliovirus ( PV), and has received a boost immunization with 
trivalent IPOL® ([COMPANY_011] -Pasteur SA) at least 1 week, but less 
than 6 weeks, prior to Day 1   
a. NOTE: Patients who are unsure of their vaccination 
status must provide evidence of anti -PV immunity prior 
to enrollment, as applicable  
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086171] dose of study 
drug(s) and at prespecified intervals during the study. Note the following details:  
a. Patients with ocular, acral or mucosal melanoma are 
not eligible  
b. Patients with M1c or M1d disease are NOT eligible  
c. Submission of an archival biopsy sample is allowed in lieu of the baseline tumor biopsy, provided the tissue is ≤4 months old and the participant received no intervening systemic/intratumoral anti -
cancer therapy 
since the biopsy was acquired.  
d. Must have at least [ADDRESS_1086172] be safely accessible as determined by [CONTACT_788910]. Examples of sites considered to be of significant risk include but are not limited to 
the following: the brain, lung, 
mediastinum, pancreas, or endoscopic procedures 
extending beyond the esophagus, stomach, or bowel 
wall.  
4. Has ≥ [ADDRESS_1086173] be injectable--defined as a visible or palpable cutaneous, subcutaneous , 
or nodal 
melanoma lesion ≥ 10mm in longest diameter or 
multiple injectable melanoma lesions which in 
aggregate have a longest diameter of ≥ 10mm and where the minimal lesion size is ≥ 5mm.   
b. Note that visceral lesions (eg,  liver, lung, 
retroperitoneal, subpleural lesions) are not considered injectable for the purposes of this trial.  
5. Has had confirmed progression of disease (PD)  while  
receiving at least 6 weeks  (> 1 dose)  of an FDA -approved anti -
PD-1/L1 therapy (as monotherapy or in combination)  for the 
treatment of melanoma.   Note the following details:    
a. Initial PD as defined by [CONTACT_393] v1.[ADDRESS_1086174] occur by [CONTACT_179698] ≥ 4 weeks from initial evidence of PD, in the absence of rapid clinical progression.  
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 13 of 109 
 c. Those who discontinue anti -PD-1/L1 therapy after at 
least 6 weeks (> 1 dose)  and have confirmed PD  per 
iRECIST  within [ADDRESS_1086175] anti -PD-1/L1 
dose are also eligible, provided the anti -PD-1/L1 was 
not stopped due to toxicity requiring permanent 
discontinuation  
a. Those treated with anti -PD-1/L1 in the adjuvant setting 
and who have biopsy -confirmed progression either 
while receiving anti -PD-1/L1- based therapy or ≤ [ADDRESS_1086176] dose of anti -PD-1/L1 therapy are 
allowed  
NOTE: Adjuvant is defined as therapy received after surgical 
resection of disease such that the patient has no evidence of disease 
when the anti -PD-1/L1 therapy is initiated . Patients with known BRAF 
mutation must have also failed or refused to receive BRAF -targeted 
therapy (alone or in combination with MEK inhibitor) to be eligibl e. 
6. Eastern Cooperative Oncology Group (ECOG) status of 0- 1 
7. Serum lactate dehydrogenase (LDH) levels ≤ 3 x upper limit of 
normal (ULN)  
8. Adequate bone marrow, liver and renal function as assessed by [CONTACT_716]:  
a. Hemoglobin ≥9.0 g/dl, patients may be transfused  
b. Lymphocyte count ≥0.5 x 10
9/L (500 µL)  
c. Absolute neutrophil count (ANC) ≥1.5 x 109/L (1500 µL)  
d. Platelet count ≥100 x 109/L (100,000 µL) without 
transfusion  
e. AST, ALT, and alkaline phosphatase (ALP) ≤2.5 x 
upper limit of normal (ULN), with the following 
exceptions:  
i. Patients with documented liver metastases:  
AST and ALT ≤[ADDRESS_1086177]  
ii. Patients with documented liver or bone 
metastases:  ALP ≤[ADDRESS_1086178]  
f. Serum bilirubin ≤1.[ADDRESS_1086179] with the following exception:  
i. Patients with known Gilbert disease:  serum 
bilirubin level ≤[ADDRESS_1086180]  
g. Measured or calculated (per institutional standards)  
creatinine clearance ≥ 30 ml/min  (GFR can also be used 
in place of creatinine clearance)  
h. For patients not receiving therapeutic anticoagulation:  
INR, PT, PTT ( or aPTT ) ≤1.[ADDRESS_1086181]  
9. Life expectancy of >12 weeks  
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 14 of 109 
 10. Signed informed  consent form (ICF) indicating that 
participant understands the purpose of, and procedures 
required for the study, and is willing/able to participate in the 
study   
 Exclusion Criteria:  
1. Has biopsy -proven ocular , acral or mucosal  melanoma  
2. Has M1c or M1d disease 
3. No more than one prior systemic anti -cancer regimen 
(monotherapy or combination) for management of melanoma. Additional details noted below:  
a. Adjuvant anti -cancer therapy administered ≥ [ADDRESS_1086182] received ≤ 2 prior lines of systemic anti -
cancer therapy only if one of those lines of therapy was a BRAF -targeted regimen (alone or in combination with 
MEK inhibitor) . 
c.  A line of therapy is defined as a regimen in which at 
least 2 doses of systemic anti -cancer therapy 
(monotherapy or combination) was administered, and 
the regimen was discontinued because of progressive  
disease  
4. Uncontrolled tumor -related pain.  Participants requiring pain 
medication must be on a stable regimen at study entry  
a. Symptomatic lesions amenable to palliative 
radiotherapy (eg, bone metastases or metastases 
causing nerve impi[INVESTIGATOR_20804]) should be treated prior to 
enrollment.  Patients should be recovered from the 
effects of radiation.  There is no required minimum 
recovery  period  
b. Asymptomatic metastatic lesions that would likely 
cause functional deficits or intractable pain with further 
growth (eg, epi[INVESTIGATOR_788882]) should be 
considered for loco- regional therapy if appropriate prior 
to enrollment  
5. Grade ≥ 2 pleural effusion, pericardial effusion, or ascites  
6. Active or history of autoimmune disease or immune deficiency 
within previous 2 years, with the following exceptions:  
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 15 of 109 
 a. History of autoimmune -related endocrinopathy (e.g. 
adrenal insufficiency, hypothyroidism, Type 1 diabetes 
mellitus, etc.) that is managed by [CONTACT_141523] (e.g. hydrocortisone, thyroid hormone, insulin, etc.) 
b. Eczema, psoriasis, or lichen simplex chronicus with 
dermatologic manifestations only (eg, patients with 
psoriatic arthritis are excluded), provided all of the following conditions are met:  
i. Rash must cover <10% of body surface area 
ii. Disease is well- controlled at baseline and 
requires only low -potency topi[INVESTIGATOR_788883]. No occurrence of acute exacerbations of the 
underlying condition requiring psoralen plus 
ultraviolet A radiation, methotrexate, retinoids, 
biologic agents, oral calcineurin inhibitors, or 
high potency or oral corticosteroids within 
12 months of Day 1  
7. History of idiopathic pulmonary fibrosis, organizing pneumonia (eg, bronchiolitis obliterans), drug-
induced or idiopathic 
pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan  
a. History of radiation pneumonitis in the radiation field 
(fibrosis) is allowed  
8. History of a positive HIV RNA test (HIV 1 or 2 RNA by [CONTACT_954])  
9. Known active hepatitis B virus (HBV) infection (chronic or 
acute)  
a. NOTE: Participants with a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test are allowed  
10. Known active hepatitis C virus (HCV) infection  
a. NOTE: History of a positive HCV antibody test, but 
negative HCV RNA test, is allowed  
11. Active tuberculosis  
12. Significant cardiovascular disease, such as [LOCATION_001] Heart 
Association Class II or greater cardiac disease, myocardial 
infarction, or cerebrovascular accident within 3 months of 
Day 1, unstable arrhythmia, or unstable angina  
13. Has received prior systemic anti -cancer therapy including 
investigational agents within 4 weeks  or 5 elimination half -
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 16 of 109 
 lives—whichever is shorter —prior to treatment, or has not 
recovered from all AEs due to previous therapi[INVESTIGATOR_24305] ≤Grade 1 
or baseline. Participants with ≤Grade 2 neuropathy are eligible  
a. Note: Anti-PD-1/L1 within [ADDRESS_1086183] 
recovered adequately from the toxicity and/or 
complications from the intervention prior to starting study treatment  
14. History of other malignancy within 2 years prior to  Day 1, with 
the exception of those with a negligible risk of metastasis or death (eg, resected cutaneous basal cell carcinoma, or other cancers with 5-year OS of >90%)  
15. Severe infection within 4 weeks prior to  Day 1, including, but 
not limited to, hospi[INVESTIGATOR_33377], 
bacteremia, or severe pneumonia  
a. Prophylactic antibiotics (eg, to prevent a urinary tract 
infection or chronic obstructive pulmonary disease 
exacerbation) are allowed  
16. Prior allogeneic stem cell or solid organ transplantation  
17. Treatment with a live, attenuated vaccine within 4 weeks prior to Day 1  
18. Treatment with systemic immunosuppressive medication 
within 4 weeks prior to  Day 1, with the following exceptions:  
a. Participants who received acute, low -dose systemic 
immunosuppressant medication or a one- time pulse 
dose of systemic immunosuppressant medication (eg, 
[ADDRESS_1086184] allergy) are 
eligible  
b. Patients receiving  mineralocorticoids (eg, 
fludrocortisone), or systemic prednisone equivalent 
corticosteroid doses of <10mg per day are eligible for the study  
19. Known hypersensitivity to pembrolizumab, nivolumab,  or any  
of the  respective excipi[INVESTIGATOR_840]  
20. Requires therapeutic anticoagulation and cannot discontinue anticoagulation safely during the day prior, day of, and day after each lerapolturev  injection  
a. NOTE: Participants  receiving anticoagulation with 
warfarin at the time of study entry  are allowed if they 
can be transitioned to an alternative anticoagulant (eg,  
low molecular weight heparin or direct oral 
anticoagulants) prior to the first dose of lerapolturev . 
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086185] an INR <1.5x upper limit of normal in order to participate.  Antiplatelet agents (eg,  aspi[INVESTIGATOR_248], 
clopi[INVESTIGATOR_7745], etc.) are not considered anticoagulants for the purposes of this study  (ie, are allowed)  
21. A pregnant or nursing female, or women of child- bearing 
potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception starting from signed ICF through [ADDRESS_1086186] of the participant (eg, compromises the participant’s well-
being) or that could prevent, limit, or confound protocol -
specified assessments  
Concomitant 
Treatment  Pembrolizumab or nivolumab (Arm 2 only)  
Investigational 
Drugs  Lerapolturev (formerly PVSRIPO ): Oncolytic Polio/Rhinovirus 
Recombinant  
Planned Study 
Sites  Up to approximately 30 sites 
Criteria for Assessments  Efficacy:  Changes in skin lesion and/or radiographic tumor 
measurements and survival will be assessed per RECIST  1.1 at 
regular intervals to evaluate efficacy: participants  achieving 
objective response (along with associated durations) or disease control by [CONTACT_10585] 26 or upon anti -PD-1 re-challenge (Arm 1  and 
safety run -in participants  that crossover to Arm 2 , analyzed from 
time of crossover but separately from Arm 2) through study 
completion . Assessment of anti -tumor response by [CONTACT_788911] . 
 Safety:  Laboratory and spontaneously reported AEs , to evaluate 
safety and tolerability to determine incidence and severity of treatment -emergent AE s for duration of the study  
 
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 18 of 109 
  Biomarkers:  Biological samples will be collected as indicated in the 
schedule of assessments (SOA) to evaluate immune , genetic , or 
cytologic  factors impacting lerapolturev mechanism of action 
(MOA ), anti-tumor  response,  and/or to evaluate immune -related 
AEs 
Statistical 
Methods  The primary endpoint for measuring anti -tumor activity will be ORR , 
based on RECIST  1.1, which will be summarized  as the overall 
number (%) of participants with CR or PR  in each treatment  arm, 
along with 95% confidence interval (CI). Participants will be 
analyzed based on  the treatment arm to which they were 
randomized , as well as by [CONTACT_788912]/schedule (ie, QW and 
Q3/4W ).  
 
Other endpoints  will be summarized by  [CONTACT_9086], as 
appropriate. Further details for these and other analyses will be 
described in the statistical analysis plan (SAP).  
Determination 
of Sample Size Sample size was determined based on feasibility and logistical 
considerations . Based on a n estimated  sample size of 15  
participants  in Arm 2  receiving lerapolturev QW in combination with 
anti-PD-1, five objective responses are needed for the 95% 
confidence interval (CI) to be above 10% ( 33% ORR; 95% CI: 
11.8% to 61.6%) , which would indicate the combination has anti -
tumor activity in this anti -PD-1 resistant population. See Section 8.3 
for additional details regarding sample size determination.  
Study 
Duration  Up to approximately 24 months (104 weeks)  
Istari Oncology, Inc.                                                                                                  
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 19  of 109  
 CLINICAL TRIAL SCHEMATIC 
 
  
.

Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 20  of 109  
 Table 1. Schedule of Assessments for Lerapolturev  Monotherapy or Lerapolturev + Pembrolizumab  
NOTE : Cycle length for lerapolturev monotherapy or lerapolturev + pembrolizumab is 3 weeks. Lerapolturev is 
administered weekly during Cycles 1 & 2  and every 3 weeks thereafter on the days indicated in the table below. Refer to  
the table below  for the timing of other study assessments to be completed within each cycle.    
 
Study Procedure3 Screening 
Period  Treatment EOT 
Visit15 Survival 
Follow -
up16 
Cycle 1  Cycle 2  ≥ Cycle 3    
(≤ 28D prior 
to C1D1)  +3W  
(+7D) Q3W (+7D) ≤28D 
after last 
treatment   
Informed Consent1 X      
Medical History  X      
Physical Exam 2,3 X C1D1  C2D1  Day 1 of each Cycle  X  
Vital Signs3 
X C1D1, 
C1D8, 
C1D15  C2D1, 
C2D8, 
C2D15  Day 1 of each Cycle  X  
ECOG Performance Status3 X C1D1  C2D1  Day 1 of each Cycle  X  
PV Immunization Booster1 ≥1W, but 
≤6W before 
C1D1       
Adverse Events  Continuous from signing ICF until [ADDRESS_1086187] dose of study therapy  or resolution/stabilization   
Hematology 3,4 X C1D1  C2D1  C3D1  then Q6W ( ie, at every other visit)  and as clinically 
indicated  X  
Chemistry3,4 X C1D1  C2D1  C3D1  then Q6W ( ie, at every other visit)  and as clinically 
indicated  X  
INR, PT, PTT (or aPTT)  X As clinically indicated   
Thyroid Monitoring  3,5 X Q6W (±7D) and as clinically indicated   
Pregnancy Test3,6 ≤2D before 
C1D1  Q12W (±14D)  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 21  of 109  
 Cutaneous , Subcutaneous and 
Nodal  Lesion Measurement and 
Photographs3,7 X C1D1, 
C1D8, 
C1D15  C2D1, 
C2D8, 
C2D15  Day 1 of each Cycle  X per SOC  
Tumor Imaging8 ≤6W before 
C1D1  6 & 12W after C1D1 , then Q12W thereafter . Crossover participants must have re -baseline imaging 
within 28D prior to administration of crossover C1D1  (i.e. first dose of anti -PD-1 therapy)  per SOC  
Tissue Biopsy9  
All samples to be collected prior to 
dosing at the given timepoint  Prior to PV 
Immunization 
Booster  C1D8  C2D1  At the time of PD ± 1 week  (per RECIST)  
Crossover Only:  within 1 week  prior to crossover C1D1 , 1 
week  after crossover C1D1  (pre-dose, if applicable) , 3 week s 
(+7d; pre-dose)  after crossover C1D1 , and at the time of PD ± 
1 week (per RECIST)  on the crossover regimen    
Blood Collection10 
All samples to be collected prior to dosing at the given timepoint
 Prior to  PV 
Immunization 
Booster  C1D1, 
C1D8  C2D1  C3D1 and at the time of  PD ± 1 week  (per RECIST)  
Crossover Only:  within 1 week  prior to crossover C1D1 , 1 
week  after crossover C1D1  (pre-dose, if applicable) , 3 weeks  
(+7d; pre-dose) after crossover C1D1 , and at the time of PD ± 
1 week (per RECIST)  on the crossover regimen    
Lerapolturev  Administration12 
 C1D1, 
C1D8, 
C1D15  C2D1, 
C2D8, 
C2D15  C3D1 and Q3W thereafter    
ARM 2:  Anti-PD-1 
Administration (pembrolizumab)  
11  C1D1  C2D1  
(if given 
Q3W)  C3D1 and Q3W or Q6W thereafter per pembrolizumab 
package insert    
Crossover from Arm 1 to Arm 
2 13  If participant meets protocol -defined criteria    
Lerapolturev  Shedding : Injected 
Lesion14 
 C1D1 
(post -
injection), 
C1D4, 
C1D8, 
C1D15 
(post -
injection), 
C1D18  C2D1, 
C2D15  
(post -
injection) , 
C2D1 8 C3D1    
Lerapolturev Shedding : Stool   C2D8 
(±3D)     
AESI = adverse event of special interest; aPTT = activated partial thromboplastin time; C= cycle; CBC = complete blood count; CMP = comprehensive 
metabolic panel; CT = computed tomography; D = day; ECOG = Eastern Cooperative Oncology Group; EOT = End of Treatment; ICF = Informed consent 
form; IgG  = immunoglobulin G; INR = international normalized ratio; LDH = lactate dehydrogenase; MRI = magnetic resonance imaging; PD -1 = Programmed 
cell death protein 1; PT = prothrombin time; PTT = partial thromboplastin time; PV = poliovirus; T3 = triiodothyronine; T4 = thyroxine; TSH = thyroid stimulating hormone; SAE = serious adverse event; W = weeks  
1. Informed Consent must be signed prior to initiation of screening activities .  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 22  of 109  
 2. Physical Exam: The screening physical examination should be a complete physical exam of major body systems and include the general appearance 
of the participant , height  and weight, vital signs (temperature,  respi[INVESTIGATOR_697],  blood pressure (systolic and diastolic [mmHg]), and heart rate [ bpm]), 
examination of the skin, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, lymphatic system, and nervous system. 
During treatment  and at the end of treatment  (EOT) visit, weight assessment and limited symptom- directed physical examination are required.  An 
evaluation of all skin lesions, including those injected with lerapolturev at the previous treatment visit, should be performed prior to subsequent lerapolturev injection.  
3. Procedures and/or A ssessments unless otherwise specified should occur on D1 of each Cycle. Any assessment or procedure scheduled on the 
same day as lerapolturev  and/or anti -PD-1 administration should always precede receipt of study treatments. Note that laboratory assessments (e.g. 
hematology, chemistry, thyroid monitoring) may be done up to 2 calendar days prior to Day 1 of the cycle.  
4. Hematology and Chemistry : Blood draws for hematology and chemistry occurring on the same day as study treatment should be collected prior to 
lerapolturev  injection and/or prior to anti -PD-1 infusion (as applicable).  Hematology  should include hemoglobin, white blood cell (WBC) count with 
differential and platelet count. C hemistry  measured in serum should include the following: LDH, glucose, calcium, sodium, potassium, bicarbonate, 
chloride, BUN,  creatinine, total protein, albumin, ALP, AST, ALT, total bilirubin , amylase, and lipase.  
5. Thyroid Monitoring:  Should include  TSH, free T4, and free T3.  
6. Pregnancy Test:  A pregnancy test  (urine- based allowed)  must be performed for all female participants of childbearing potential during Screening (≤2 
days of lerapolturev  injection ) and approximately every [ADDRESS_1086188] should be performed.  
7. Measurement of Cutaneous, Subcutaneous and Nodal L esions:  Measurement  by [CONTACT_282478]  (along with photographs)  should occur prior to 
lerapolturev  administration to determine/verify lerapolturev  injection volumes for each lesion. For timepoint response assessment of target lesions  not 
visible by [CONTACT_485622] , ruler/caliper measurement  with photographs should be performed prior to lerapolturev  injection.  
8. Tumor Imaging: Baseline imaging assessments should include CT of the chest, abdomen, and pelvis, a brain MRI, as well as photography of all cutaneous/visible lesions. Participants without evidence of central nervous system (CNS) disease at screening are not required to have brain imaging on study, provided clinical evidence of CNS disease does not emerge. All imaging should be performed with and without IV contrast (oral contrast can be used per institutional guidelines), provided participant can tolerate contrast agent (brain CT —preferably with IV contrast --is acceptable for those 
who cannot tolerate MRI). Photographic evaluation of visible lesions should precede lerapolturev  injection, if occurring in the same visit. All qualifying 
scans prior to and during screening used to determine enrollment eligibility  (ie, baseline scans prior to initiating anti- PD-1, as well as initial and 
confirmatory scans demonstrating disease progression  per iRECIST  prior to enrollment) should be provided to the central imaging vendor, where 
possible. Imaging should be performed using identical techniques and equipment, where possible.  
9. Tissue Biopsy  for Biomarker Assessment : Participants are required to provide a qualifying biopsy. Archival tissue collected ≤4 months prior to Day 
1 is allowed in lieu of the qualifying biopsy, provided the participant has not received intervening systemic/intratumoral anti -cancer therapy since the 
biopsy was performed; if not available, the participant should have a qualifying biopsy taken during the Screening Period prior to polio boost 
vaccination. Biopsy of a previously irradiated lesion is not allowed unless there is documented disease progression in that lesion.   
• NOTE:  At all timepoints, biopsies from all three sites (injected lesion, noninjected lesions and draining lymph nodes) should be collected if the 
biopsy is technically feasible and does not put the participant at significant risk. Examples of sites considered to be of significant risk include, 
but are not limited to, the following : biopsies of the brain, lung, mediastinum, pancreas, or endoscopic procedures extending beyond the 
esophagus, stomach, or bowel wall.  For situations where the investigator determines  biopsy of a lesion would (1)  result in a 
significant  decrease in the size of the lesion  such  that RECIST 1.1 response assessment would be confounded,  or (2) increase the risk of 
lerapolturev leakage from the lesion,  the mandatory  biopsy for that timepoint can be waived.  In addition, complete resection of target lesions is 
prohibited unless  necessary for  participant’s  safety as determined by [CONTACT_093].  
• Tissue from additional biopsies taken as part of standard of care may also be collected for analysis.  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 23 of 109 
 10. Blood Collection: Participants who experience an AE of Special Interest (AESI) of cytokine release syndrome (CRS) or immune effector cell -
associated neurotoxicity syndrome (ICANS) should have a blood sample drawn as soon as possible upon learning of the AESI, in order to al low for the 
profiling of cytokine changes related to the event.  
11. Arm 2 Anti -PD-1 Administration: Participants randomized  to Arm [ADDRESS_1086189] anti -PD-1 dose should begin  on C1D1 (+2 days) . Where possible, participants should receive the same anti -PD-1 therapy 
that they previously failed prior to enrollment, dosed according to manufacturer’s prescribing information.  
12. Lerapolturev Administration: Up to 6 lesions may be injected with lerapolturev injection volume proportional to lesion size as determined from  
Table  7. The same or different lesion(s) may be injected at each treatment visit, as described in Section 5.3. The lerapolturev treatment cycle is Q3W 
for participants on Arm 1 and for Arm 2 or crossover participants receiving pembrolizumab, whether pembrolizumab is given Q3 or Q6W.   
• After Cycle 3, lerapolturev should be administered Q3 W. If pembrolizumab is administered Q6W , lerapolturev should be continued Q3 W.  
• NOTE:  Participants previously treated with the Q3/4W  lerapolturev schedule are allowed to receive the QW lerapolturev schedule  per the guidance 
in Section 3.1.2.  
• Where possible, at least one target lesion should remain uninjected for as long as feasible while on study to facilitate the anti -tumor response 
assessment of non- injected target lesions  
13. Crossover  from Arm 1  to Arm 2: Participants  enrolled in the safety run- in or randomized to Arm 1 are allowed to crossover to Arm 2 following 
radiologic disease progression (per RECIST criteria), once a PR lasts ≥ 6 months, or after 26 weeks on study without progression or confirmed PR 
(per RECIST criteria).  Where possible, participants should receive the same anti -PD-1 therapy on which they had disease progression prior to 
enrollment, which should be administered according to manufacturer’s prescribing information. The below assessments should be completed for 
participants at the time of crossover:  
• Tumor Imaging: All participants crossing over to Arm [ADDRESS_1086190] a complete tumor assessment (ie, scans and ruler/caliper measurement of 
skin lesions with photography) within [ADDRESS_1086191] cycle of the lerapolturev /anti-PD-1 combination. Scans and photographic 
ruler/caliper assessments performed to document  disease progression prior to crossover are acceptable, provided they occur within 28 days prior 
to the initial treatment with the lerapolturev /anti-PD-1 combination.  
• Cutaneous  and Subcutaneous Measurements and Imaging : For participants crossing over from Arm 1 to Arm 2, ruler/caliper measurement 
with photographs should be performed within [ADDRESS_1086192] treatment with the lerapolturev /anti-PD-1 combination (along with scans).  
• Lerapolturev Administration : See Section 3.1.2 for guidance.  
• Tissue Biopsy: Prior to crossover, a  mandatory  tissue biopsy (injected lesions, noninjected lesions and draining lymph nodes ) should be 
performed, within [ADDRESS_1086193] cycle of the lerapolturev/anti -PD-1 combination (see Section 7.4); the biopsy taken at the time of PD can 
be used as the biopsy prior to the first crossover treatment cycle.  Additional mandatory biops ies (injected lesions, noninjected lesions, and 
draining lymph nodes) should be performed 1 week  (±2days ) and 3 weeks  (+7d) after Day 1 of crossover , and within 7 days of confirmed 
crossover PD . Any biopsy scheduled on same day as lerapolturev injection should be collected prior to treatment. .  
14. Lerapolturev Viral Shedding :  
• The individual lesion receiving the largest injection volume of lerapolturev  at C1D1, C1D15, and C2D15 should be designated for  swabb ing during 
that treatment cycle on the day s indicated above (ie, the same lesion should be swabbed at each timepoint within a given cycle) . Separate swabs 
should be used to test each area in triplicate (ie, samples are not to be combined or pooled), as described. Following sample collection, the 
swabbed lesion should be wiped with alcohol, and redressed with an occlusive dress ing as required.  
• The lesion injected with lerapolturev  at C1D1, C1D15, and C2D15 should be swabbed at least [ADDRESS_1086194] a ±1D 
window for collection, but those scheduled on the same day of a given treatment cycle must  be collected prior to lerapolturev  administration.   
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 24 of 109 
 • The injection site, as well as the inside and outside of the occlusive dressing should be swabbed independently (ie, samples are not to be 
combined or pooled into a single collection tube) in triplicate (ie, [ADDRESS_1086195]), with the corresponding swab for each 
tested area labeled and placed into its own container of viral transport medium, according to the laboratory manual. T he swabbed lesion should be 
cleaned and redressed with a new occlusive dressing once lesion swabbing has been completed, as described in Section  5.3.  
• Stool samples may be collected at the participant’s home up to [ADDRESS_1086196] dose of study drug(s).  The visit should include a focused and symptom-
directed physical assessment, cutaneous , subcutaneous, and nodal  tumor measurements (including photographs), as well as radiographic tumor 
imaging.  
16. Survival Follow -up: Scans and cutaneous , subcutaneous and nodal  lesion measurements performed per SOC should still be collected for 
participants  in post -EOT survival follow -up who discontinued study treatments for reasons other than disease progression. The collection of lesion 
measurement (cutaneous , subcutaneous, and nodal,  and scans) performed per SOC should continue until confirmed progression or the start of the 
next anti -cancer therapy. Sites should continue to collect post -study therapi[INVESTIGATOR_788884] -up duration  
 
 
  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 25  of 109  
 Table 2. Schedule of Assessments for Lerapolturev  + Nivolumab  
NOTE : Cycle length for lerapolturev + nivol umab is 4 weeks. Lerapolturev is administered weekly during Cycles 1 & 2 and 
every 4 weeks thereafter  on the days indicated in the table below. Refer to the table below for the timing of other study 
assessments to be completed within each cycle.    
 
Study Procedure3 Screening 
Period  Treatment EOT 
Visit15 Survival 
Follow -
up16 
Cycle 1  Cycle 2  ≥ Cycle 3    
(≤ 28D prior 
to C1D1)  +4W  
(+7D) Q4W (+7D) ≤28D 
after last 
treatment   
Informed Consent1 X      
Medical History  X      
Physical Exam 2,3 X C1D1  C2D1  Day 1 of each Cycle  X  
Vital Signs3 
X C1D1, 
C1D8, 
C1D15  
C1D22  C2D1, 
C2D8, 
C2D15  Day 1 of each Cycle  X  
ECOG Performance Status3 X C1D1  C2D1  Day 1  of each Cycle  X  
PV Immunization Booster1 ≥1W, but 
≤6W before 
C1D1       
Adverse Events  Continuous from signing ICF until [ADDRESS_1086197] dose of study therapy  or resolution/stabilization   
Hematology 3,4 X C1D1  C2D1  C3D1  then Q 8W (ie, at every other visit)  and as clinically 
indicated  X  
Chemistry3,4 X C1D1  C2D1  C3D1  then Q 8W (ie, at every other visit)  and as clinically 
indicated  X  
INR, PT, PTT (or aPTT)  X As clinicall y indicated   
Thyroid Monitoring  3,5 X  X Day 1 of each Cycle  X  
Pregnancy Test6 ≤2D before 
C1D1  Q12W (±14D)  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 26  of 109  
 Cutaneous , Subcutaneous, and 
Nodal Lesion Measurement and 
Photographs3,7 X C1D1, 
C1D8, 
C1D15  
C1D22  C2D1, 
C2D8, 
C2D15  Day 1 of each Cycle  X per 
SOC  
Tumor Imaging8 ≤6W before 
C1D1  6 & 12W after C1D1 , then Q12W thereafter . Crossover participants must have re -baseline imaging 
within 28D prior to administration of crossover C1D1 (i.e. first dose of anti -PD-1 therapy)  per 
SOC  
Tissue Biopsy9  
All samples to be collected prior to 
dosing at the given timepoint  Prior to PV 
Immunization 
Booster  C1D8,  
C1D22    At the time of PD ± 1 week (per RECIST ) 
Crossover Only:  within 1 week prior to crossover C1D1, 1 
week after crossover C1D1 (pre- dose, if applicable), 3 weeks 
(+7d; pre- dose) after crossover C1D1, and at the time of PD 
± 1 week (per RECIST) on the crossover regimen    
Blood Collection10 
All samples to be collected prior to dosing at the given timepoint
 Prior to  PV 
Immunization 
Booster  C1D1, 
C1D8,  
C1D22  C2D15  At the time of PD ± 1 week (per RECIST ) 
Crossover Only:  within 1 week prior to crossover C1D1, 1 
week after crossover C1D1 (pre- dose, if applicable), 3 weeks 
(+7d; pre- dose) after crossover C1D1, and at the time of PD 
± 1 week (per RECIST) on the crossover regimen    
Lerapolturev  Administration12 
 C1D1, 
C1D8, 
C1D15  
C1D22  C2D1, 
C2D8, 
C2D15  C3D1 and Q 4W thereafter    
ARM 2:  Anti-PD-1 
Administration (nivolumab)  11  C1D1  
(C1D15 if 
nivolumab 
Q2W) C2D1  
(C2D15 if 
nivolumab 
Q2W) C3D1 and Q2W or Q4W thereafter per nivolumab package 
insert    
Crossover from Arm 1 to Arm 
2 13  If participant meets protocol -defined criteria    
Lerapolturev  Shedding : Injected 
Lesion14 
 C1D1 
(post -
injection), 
C1D4, C1D8, 
C1D15 
(post -
injection), 
C1D18  
C1D22  C2D8 (post -
injection) , 
C2D11 , 
C2D1 5    
Lerapolturev Shedding : Stool   C2D1 
(±3D)     
AESI = adverse event of special interest; aPTT = activated partial thromboplastin time; C= cycle; CBC = complete blood count; CMP = comprehensive 
metabolic panel; CT = computed tomography; D= day; ECOG = Eastern Cooperative Oncology Group; EOT = End of Treatment; ICF = Informed consent 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 27  of 109  
 form; IgG  = immunoglobulin G; INR = international normalized ratio; LDH = lactate dehydrogenase; MRI = magnetic resonance imaging; PD -1 = 
Programmed cell death protein 1; PT = prothrombin time; PTT = partial thromboplastin time; PV = poliovirus; T3 = triiodothyronine; T4 = thyroxine; TSH = 
thyroid stimulating hormone; SAE = serious adverse event; W = weeks  
1. Informed Consent must be signed prior to initiation of screening activities .  
2. Physical Exam: The screening physical examination should be a complete physical exam of major body systems and include, the general 
appearance of the participant , height  and weight, vital signs (temperature,  respi[INVESTIGATOR_697],  blood pressure (systolic and diastolic [mmHg]), and heart 
rate [ bpm]), examination of the skin, ears, nose, throat, lungs, heart, abdomen, extremities, musculoskeletal system, lymphatic system,  and nervous 
system. During treatment  and at the  end of treatment  (EOT) visit, weight assessment and limited symptom- directed physical examination are required.  
An evaluation of all skin lesions, including those injected with lerapolturev at the previous treatment visit, should be performed prior to subsequent 
lerapolturev injection.  
3. Procedures and/or A ssessments unless otherwise specified should occur on D1 of each Cycle. Any assessment or procedure scheduled on the 
same day as lerapolturev  and/or anti -PD-1 administration should always precede receipt of study treatments. Note that laboratory assessments (e.g. 
hematology, chemistry, thyroid monitoring) may be done up to 2 calendar days prior to Day 1 of the cycle.  
4. Hematology and Chemistry : Blood draws for hematology and chemistry occurring on the same day as study treatment should be collected prior to 
lerapolturev  injection and/or prior to anti -PD-1 infusion (as applicable).  Hematology  should include hemoglobin, white blood cell (WBC) count with 
differential and platelet count. C hemistry  measured in serum should include the following: LDH, glucose, calcium, sodium, potassium, bicarbonate, 
chloride, BUN,  creatinine, total protein, albumin, ALP, AST, ALT, total bilirubin , amylase, and lipase.  
5. Thyroid Monitoring: Should include TSH, free T4, and free T3.  
6. Pregnancy Test:  A pregnancy test  (urine- based allowed)  must be performed for all female participants of childbearing potential during Screening (≤2 
days of lerapolturev  injection ) and approximately every [ADDRESS_1086198] should be performed.  
7. Measurement of Cutaneous, Subcutaneous, and Nodal L esions : Measurement  by [CONTACT_282478]  (along with photographs)  should occur prior to 
lerapolturev  administration to determine/verify lerapolturev  injection volumes for each lesion. For timepoint response assessment of target lesions  not 
visible by [CONTACT_485622] , ruler/caliper measurement  with photographs should be performed prior to lerapolturev  injection.  
8. Tumor Imaging: Baseline imaging assessments should include CT of the chest, abdomen, and pelvis, a brain MRI, as well as photography of all 
cutaneous/visible lesions. Participants without evidence of central nervous system (CNS) disease at screening are not required to have brain imaging 
on study, provided clinical evidence of CNS disease does not emerge. All imaging should be performed with and without IV contrast (oral contrast can be used per institutional guidelines), provided participant can tolerate contrast agent (brain CT —preferably with IV contrast --is acceptable for those 
who cannot tolerate MRI). Photographic evaluation of visible lesions should precede lerapolturev  injection, if occurring in the same visit. All qualifying 
scans prior to and during screening used to determine enrollment eligibility  (ie, baseline scans prior to initiating anti- PD-1, as well as initial and 
confirmatory scans demonstrating disease progression  per iRECIST  prior to enrollment) should be provided to the central imaging vendor, where 
possible. Imaging should be performed using identical techniques and equipment, where possible.  
9. Tissue Biopsy  for Biomarker Assessment : Participants are required to provide a qualifying biopsy. Archival tissue collected ≤4 months prior to Day 
1 is allowed in lieu of the qualifying biopsy, provided the participant has not received intervening systemic/intratumoral anti -cancer therapy since the 
biopsy was performed; if not available, the participant should have a qualifying biopsy taken during the Screening Period prior to polio boost 
vaccination. Biopsy of a previously irradiated lesion is not allowed unless there is documented disease progression in that lesion.   
• NOTE:  At all timepoints, biopsies from all three sites (injected lesion, noninjected lesions and draining lymph nodes) should be collected if the 
biopsy is technically feasible and does not put the participant at significant risk. Examples of sites considered to be of significant risk include, but 
are not limited to, the following: biopsies of the brain, lung, mediastinum, pancreas, or endoscopic procedures extending beyond the esophagus, 
stomach, or bowel wall.  For situations where  the investigator determines  biopsy of a lesion would (1)  result in a significant  decrease in the size of 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086199] 1.1 response assessment would be confounded,  or (2) increase the risk of lerapolturev leakage from the 
lesion,  the mandatory  biopsy for that timepoint can be waived.  In addition, complete resection of target lesions is prohibited unless  necessary 
for participant’ s safety as determined by [CONTACT_093].  
• Tissue from additional biopsies taken as part of standard of care may also be collected for analysis.  
10. Blood Collection: Participants who experience an AE of Special Interest (AESI) of cytokine release syndrome (CRS) or immune effector cell -
associated neurotoxicity syndrome (ICANS) should have a blood sample drawn as soon as possible upon learning of the AESI, in order to allow for the 
profiling of cytokine changes related to the event.  
11. Arm 2 Anti -PD-1 Administration: Participants randomized to Arm [ADDRESS_1086200] anti -PD-1 dose should begin  on C 1D1 (+2 days) . Where possible, participants should receive the same anti -PD-1 therapy 
that they previously failed prior to enrollment, dosed according to manufacturer’s prescribing information. The lerapolturev treatment cycle is Q4W for 
participants receiving nivolumab, whether nivolumab is given Q2 or Q4W.    
12. Lerapolturev Administration: Up to 6 lesions may be injected with lerapolturev injection volume proportional to lesion size as determined from  
Table  7. The same or different lesion(s) may be injected at each treatment visit, as described in Section 5.3.   
• After Cycle 3, lerapolturev should be administered Q4 W in Arm 2 participants receiving nivolumab. If nivolumab is administered Q2 W, lerapolturev 
should be continued Q4 W. 
• NOTE:  Participants previously treated with the Q3/4W  lerapolturev schedule are allowed to receive the QW  lerapolturev schedule per the 
guidance in Section 3.1.2 .  
• Where possible, at least one target lesion should remain uninjected for as long as feasible while on study to facilitate the anti -tumor response 
assessment of non- injected target lesions  
13. Crossover  from Arm 1  to Arm 2: Participants  enrolled in the safety run- in or randomized to Arm 1 are allowed to crossover to Arm 2 following 
radiologic disease progression (per RECIST criteria), once a PR lasts ≥ 6 months, or after 26 weeks on study without progression or confirmed PR 
(per RECIST criteria).  Where possible, participants should receive the same anti -PD-1 therapy on which they had disease progression prior to 
enrollment, which should be administered according to manufacturer’s prescribing information. The below assessments should be completed for 
participants at the time of crossover:  
• Tumor Imaging: All participants crossing over to Arm [ADDRESS_1086201] a complete tumor assessment (ie, scans and ruler/caliper measurement of skin lesions with photography) within [ADDRESS_1086202] cycle of the lerapolturev/anti -PD-1 combination. Scans and photographic 
ruler/caliper assessments performed to document  disease progression prior to crossover are acceptable, provided they occur within 28 days prior 
to the initial treatment with the lerapolturev/anti -PD-1 combination.  
• Cutaneous and Subcutaneous M easurements and Imaging : For participants crossing over from Arm 1 to Arm 2, ruler/caliper measurement 
with photographs should be performed within [ADDRESS_1086203] treatment with the lerapolturev /anti-PD-1 combination (along with scans).  
• Lerapolturev Administration : See Section 3.1.1 for guidance.  
• Tissue Biopsy: Prior to crossover, a mandatory  tissue biopsy (injected lesions, noninjected lesions and draining lymph nodes) should be 
performed, within [ADDRESS_1086204] cycle of the lerapolturev/anti -PD-1 combination (see Section 7.4); the biopsy taken at the time of PD can 
be used as the biopsy prior to the first crossover treatment cycle. A dditional mandatory biops ies (injected lesions, noninjected lesions, and 
draining lymph nodes) should be performed 1 week  (±2days ) and 3 weeks  (+7d) after Day 1 of crossover, and within 7 days of confirmed 
crossover PD . Any biopsy scheduled on same day as lerapolturev injection should be collected prior to  treatment.  
14. Lerapolturev Viral Shedding:   
• The individual lesion receiving the largest injection volume of lerapolturev  at C1D1, C1D15, and C2D8 should be designated for  swabb ing during 
that treatment cycle on the day s indicated above (ie, the same lesion should be swabbed at each timepoint within a given cycle). Separate swabs 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086205] each area in triplicate (ie, samples are not to be combined or pooled), as described. Following sample collection, the 
swabbed lesion should be wiped with alcohol, and redressed with an occlusive dressing as required.  
• The lesion injected with lerapolturev  at C1D1, C1D15, and C2D8  should be swabbed at least [ADDRESS_1086206] a ±1D 
window for collection, but those scheduled on the same day of a given treatment cycle must  be collected prior to lerapolturev  administration.  
• The injection site, as well as the inside and outside of the occlusive dressing should be swabbed independently (ie, samples are not to be 
combined or pooled into a single collection tube) in triplicate (ie, [ADDRESS_1086207]), with the corresponding swab for each 
tested area labeled and placed into its own container of viral transport medium, according to the laboratory manual. T he swabbed lesion should be 
cleaned and redressed with a new occlusive dressing once lesion swabbing has been completed, as described in Section  5.3.  
• Stool samples may be collected at the participant’s home up to [ADDRESS_1086208] dose of study drug(s) . The visit should include a focused and symptom-
directed physical assessment, cutaneous , subcutaneous, and nodal  tumor measurements (including photographs), as well as radiographic  tumor 
imaging.  
16. Survival Follow -up: Scans and cutaneous , subcutaneous, and nodal  lesion measurements performed per SOC should still be collected for participants  
in post -EOT survival follow -up who discontinued study treatments for reasons other than disease progression. The collection of lesion measurement 
(cutaneous , subcutaneous and nodal  and scans) performed per SOC should continue until confirmed progression or the start of the next anti -cancer 
therapy. Sites should continue to collect post -study therapi[INVESTIGATOR_788885] -up duration.  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 30  of 109  
 1 INTRODUCTION 
1.1 Background  
Metastatic melanoma is often  a fatal disease, with less than 28% of patients surviving 
5 years5. However , many  patients are diagnosed with early -stage disease, where if well 
managed, the chance of cure can be quite high.  Unfortunately , patients  who recur or  are 
diagnosed with advanced disease suffer a more aggressive disease course, making the 
likelihood of cure much less.  For patients with Stage III disease, over 70% of patients’ 
first recurrence was regional/nodal or systemic8, meaning localized therapi[INVESTIGATOR_014]  (eg, surgery 
or isolated limb perfusion)  are likely to have limited effect . Therefore, systemic therapi[INVESTIGATOR_788886], to mitigate further systemic spread and extend life.  
The past [ADDRESS_1086209] notable among these were the FDA 
approval of immune therapi[INVESTIGATOR_788887] -1/L1 and CTLA -4, which can 
be used alone or in combination in the front -line setting. When used as a single -agent , 
less than 40% of patients respond to anti -PD-1 therapy (ie, more than 60% have primary 
PD-1 resistance)1,2. Of those who do respond, 25% or more go on to develop an acquired 
resistance3. While combining PD -1 and CTLA -4 blockade can increase the response rate 
to around 50%, this combination is associated with significant toxicity, with clinical studies 
demonstrating ~55% of patients experience Gr 3/[ADDRESS_1086210]  BRAF and the mitogen- activated protein 
kinase /extracellular signal -regulated kinase (MEK)  pathway . Although BRAF/MEK based 
targeted ther apy has been shown to improve survival, progression free survival is often 
less than 1 year and systemic toxicities are common9–11.  
Recently, there has been interest in determining whether there is any potential for clinical 
benefit from anti-PD-1 re-challenge in patients who  previously progress ed on anti -PD-
1/L1 or from treating beyond progression (TBP) in patient s that are currently failing  an 
anti-PD-1/L1. To the Sponsor’s knowledge, no study has formally addressed whether 
anti-PD-[ADDRESS_1086211] -defined 
progression can result in an ORR of up to 19%13. However, 66% of those treated beyond 
progression in this analysis were deemed to have progressed at their first post -treatment 
visit, and the median duration of TBP was only 1. 41 months (IQR: 0 .69–4. 86 months ). Of 
these patients with RECIST -defined PD at their first scan, approximately 36% 
discontinued due to the appearance of a new lesion without target lesion progression, 
which can be an immunoprogressive  phenomenon that results in subsequent lesion 
contract ion. In addition, the protocols allowing TBP w ithin this pooled analysis  had 
specific criteria to identify which patients were allowed to continue anti-PD-1, including 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 31  of 109  
 absence of clinical progression (including laboratory values), no decline in performance 
status, and absence of disease progression in areas requiring immediate medical  
treatment13. Given median time to response to anti -PD-[ADDRESS_1086212], had the definition of anti -PD-1/L1 resistance 
from the Society for Immunotherapy of Cancer (SITC) Immunotherapy Resistance Task 
force been applied to the population of this study  (ie, ≥[ADDRESS_1086213] 4 weeks later ), many patients would not 
have been in cluded7. Thus, one can estimate that  the true ORR for anti -PD-1 treatment 
beyond progression in patients treated per the SITC Immunotherapy Resistance Task 
Force definition of anti -PD-1 resistance is no greater than 6% , as nearly two-thirds  of 
patients included within the TBP cohort would be excluded because of discontinuation 
without  confirmation of progression 4 weeks later .  
In addition, a recent study investigated ipi[INVESTIGATOR_788888] -PD-
1 in an anti -PD-1 refractory population. ORR in the combination arm was 31% vs 12% for 
ipi[INVESTIGATOR_165], and OS at 1- year for the combination was also superior versus 
ipi[INVESTIGATOR_165], suggesting that the addition of new immunotherapi[INVESTIGATOR_788889] -
PD-1 therapy improves outcomes when compared to a switch strategy16. However, G rade 
3 or greater toxicities occurred in over 30% of the patients receiving ipi[INVESTIGATOR_125], whether 
alone or in combination, meaning risk to patient safety remains a concern. Taken 
together , there is significant interest in the development of novel  immunotherapeutic 
agent s that can increase the anti-tumor response for the broad proportion of melanoma 
patients unable to benefit from currently approved options .  
Lerapolturev (formerly  known as  PVSRIPO ) is a recombinant rhinovirus/polio virus 
chimera that may affect anti-tumor activity through two  mechanisms:  direct tumor cell 
killing and induction of a secondary anti -tumor immune response17. Lerapolturev has 
demonstrated clinical activity in patients with primary brain tumors18.   Preliminary data 
suggest  lerapolturev has  activity , either alone or in combination with an anti -PD-1 
inhibitor,  in PD-1 refractory melanoma when injected intratumorally  (summarized below ). 
Therefore, this study  is designed  to further characterize lerapolturev activity in 
advanced/metastatic anti-PD-1/L1 refractory melanoma.  
1.[ADDRESS_1086214] tumor cell killing and secondary anti -tumor 
immune response. T alimogene laherparepvec (T -VEC, Imlygic ), a modified herpes 
simplex type 1 virus expressing human granulocyte macrophage colony -stimulating factor 
(GM- CSF) , has been approved to treat melanoma based on increased DRR  (defined as 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 32  of 109  
 the percent of patients with complete response (CR) or partial response (PR) maintained 
continuously for a minimum of 6 months ) compared to GM -CSF alone: The DRR was 
16.3% in the IMLYGIC arm and 2.1% in the GM -CSF arm in the overall study population.  
There was no statistically significant difference in overall survival (OS) between the 
IMLYGIC and the GM-CSF arms ; the median OS in the overall study population was 22.9 
months in the IMLYGIC arm  and 19.0 months in the GM -CSF arm (p  = 0.116)19.  
However, data from a Phase 1b trial investigating T -VEC (administered by [CONTACT_788913] 2 weeks)  in combination with pembrolizumab in advanced anti -PD-1 naïve 
melanoma showed >60% of  participants  achieved an objective response, with multiple 
responses ongoing at the time of publication (median OS and progression- free survival 
not reached)20. Response to the combination was associated with increased CD8+ T -cell 
infiltration and increased expression of programmed death- ligand 1 (PD -L1; the 
immunosuppressive ligand of PD -1) following treatment, suggesting an oncolytic virus in 
combination with anti -PD-1 could potentially overcome mechanisms of anti -PD-1 
resistance.  
Although these data are encouraging, the follow -on randomized , placebo- controlled 
Phase 3 study failed to show a survival benefit and was halted for futility21, suggesting 
alternative approaches  (such as optimized dosing schedules)  may be required to 
translate apparent immune activation into clinical benefit  – particularly in populations 
known to be refractory to anti -PD-1/L1-based therapi[INVESTIGATOR_014] . In support of this hypothesis, 
preliminary data from an ongoing Phase 2 study investigating intratumoral injection of 
BO-112 (a non- coding double- stranded RNA formulated with the cationic carrier 
polyethylenimine and administered weekly  x 7 followe d by [INVESTIGATOR_135] 3-week  main tenance)  in 
combination with pembrolizumab has shown activity in anti -PD-1 refractory melanoma. 
BO-112 induces innate immunity through activation of  RNA vir al response sensors (eg, 
RIG-I and MDA5), which  resulted in a 27% ORR when combined with pembrolizumab , 
suggesting a more persistent  stimulation of innate immunity may be required to improve 
immune- mediated anti-tumor response.   
Given th ese data, it is hypothesized that weekly administration of lerapolturev  in the 
setting of a vaccine- generated immune recall response will more effectively activate  
innate RNA viral response pathways  when  compared to oncolytic viruses like T -VEC or 
non-coding double- stranded RNA like BO -112. Lerapolturev is a live-attenuated, serotype 
1 poliovirus vaccine ( Sabin) that was genetically modified by [CONTACT_788914] (IRES) with that of  human rhinovirus type 2, thus eliminating 
its neurovirulence  potential22. Infection of cells by [CONTACT_788915] (PVR), CD155--a cell adhesion molecule of the Ig- like superfamily that 
is broadly  expressed in solid tumors, including melanoma23.  Upon infection, l erapolturev  
is directly  cytotoxic to neoplastic cells, which offer ideal conditions for viral IRES -mediated 
ribosome recruitment due to the unhinged protein synthesis required in cancer  cells24. In 
contrast, l erapolturev infection of antigen- presenting macrophages and dendritic cells 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 33  of 109  
 (DC)  results in a non- lethal infection, and activation of innate interferon gamma (IFN γ) 
pathways to increase immune effector responses directed against tumor neoantigens17, 
thus driving a secondary immune response. As shown in Figure 1, lerapolturev infection 
resulted in death of  breast and melanoma tumor cells without affecting DC viability. The 
principal elements determining lerapolturev  tumor tropi[INVESTIGATOR_8801], tumor -specific cell killing  
(Figure 1A & B), neuronal incompetence/safety, and immunogenicity are well established 
empi[INVESTIGATOR_3675]17,25. Notably, lerapolturev infection in DCs significantly increased PD -L1 
expression ( Figure 1C), suggesting lerapolturev in combination with anti -PD-1 blockade  
in the tumor  is rational, as  the combination could further enhance the immune system’s 
ability to specifically recognize and destroy tumor.  
 
Figure 1. Lerapolturev  is directly lethal to breast and melanoma cell lines, yet 
lerapolturev  infection of DCs is sublethal and induces sustained 
proinflammatory cytokine production. 
In further support of this rationale,  data from an ongoing P hase 1 dose- finding study  
investigating lerapolturev  in anti-PD-1 refractory melanoma ([STUDY_ID_REMOVED])  suggests 
that lerapolturev  is well-tolerated and has anti -tumor activity in  this difficult to treat 
population. As of 23 March 2021, 12  participants  were enrolled in the study, each 
receiving a single lerapolturev  injection into a single lesion in up to 3 separate treatments. 
There were no SAEs noted; all AEs were G rade 1 or 2, with all but two  lerapolturev -
related AE s (n=1 hot flash and n=1 fatigue; both Grade 1) localized to the injected 
cutaneous, subcutaneous or nodal lesion. Despi[INVESTIGATOR_788890], four of the 12 participants  achieved an objective response, including  2 PRs 
which were determined to be pathologic complete responses  (pCR)  upon biopsy  
(remaining lesions contained melanophages only, without evidence of melanoma) . 
Among participants who received 3 lerapolturev  injections (maximum number 
administered), objective responses were observed in 4/6 (67%) participants .  In addition, 
most participants  were subsequently re- challenged with anti -PD-1 after lerapolturev , 

Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086215] lera polturev injection in up to 6 lesions (or max dose of 6 x 108 TCID 50) 
given every 3 to 4 weeks , concurrent with or without anti -PD-1 antibody therapy , until 
progression. Despi[INVESTIGATOR_040] a 6- fold increase in lerapolturev dose relative to the dose evaluated 
in the Phase 1 study , all AEs considered related to lerapolturev , or anti -PD-1 remain 
Grade 1 or 2;  no dose- limiting toxicities (DLTs), treatment -related serious AEs (SAEs)  or 
signs and symptoms of cytokine release syndrome were reported in the 17 participants 
treated as of the 10 December  2021 data cutoff  (see Table 3 and Table 4). Therefore, 
based on  the encouraging safety data generated with lerapolturev to date , together with  
the observation that more frequent administration of intratumoral therapi[INVESTIGATOR_788891]-tumor responses in patients 
with anti -PD-1 resistant melanoma,  the safety and efficacy of lerapolturev given  weekly  
for 7 weeks followed by [CONTACT_428617] 3 or 4-week s (maintenance)  at a dose of up 
to 1.6 x 109 TCID 50, as monotherapy and in combination with anti -PD-1 therapy  will be 
tested .  
1.2.1  Nonclinical Studies  
Refer to the lerapolturev  Investigator's Brochure (IB) for details on nonclinical and 
preclinical studies. In animal tumor models, oncolytic PVs elicit efficient anti -neoplastic 
effects resulting in tumor regression and, eventually, destruction17. Th is includes  
histologic evidence for direct, virus -mediated tumor cell killing and indirect, host -mediated 
inflammatory responses directed against tumor.  
 
As described in the IB, a murine- specific version of lerapolturev called mRIPO  was highly 
active in a melanoma mouse model26.  B16 -F10.9 -OVA -CD155 tumor cells were 
implanted in the flank of mice and treated with a single intratumoral injection of DMEM 
(control) or mRIPO (5x107 TCID 50). mRIPO therapy significantly delayed tumor growth as 
measured by [CONTACT_490769] ( Figure 2B) and increased overall survival ( Figure 2C). 
mRIPO therapy, but not the DMEM control, produced anti -tumor cytotoxic T lymphocytes 
(CTLs ): cells harvested from draining inguinal lymph nodes exhibited cytotoxicity against 
EL4 thymoma cells expressing TRP -2 (B16 -F10 melanoma antigen), OVA (B16- F10-OVA 
antigen), or B16- F10.9- OVA -CD155 cells themselves ( Figure 2D). Effector T cells from 
control treated mice exhibited minimal cytotoxicity against any of the tested target cells  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 35 of 109 
 (Figure 2D). Analysis of cytokines in supernatant revealed increased granzyme B, IFN -γ, 
and TNF -α secretion only in the mRIPO -treated group (Figure 2E), which corroborates 
CTL activity observed in Figure 2D.  
 
Systemic T cell activation also occurred in spleens harvested [ADDRESS_1086216] B16-
F10.9- OVA -CD155 cells  (Figure 2F). 
 
 
Figure 2. Lerapolturev  restricts tumor growth and produces antigen- specific 
anti-tumor immunity
25 
A. Cytotoxicity characteristics of mRIPO in murine melanoma B16- F10.9- OVA- CD155 cells. B., C. 
Subcutaneous B16- F10.9- OVA- CD155 tumors were implanted in C57BL/6- CD155 mice and treated when 
the volume was ~50- 100 mm3 (~15- [ADDRESS_1086217] tumor implant). Tumors were injected with either control 
(DMEM) or mRIPO in a volume of 20 µl. Tumor volume was measured (n = 11 per group) on the days 
indicated. Mice were sacrificed when the tumor volume reached [ADDRESS_1086218] aining inguinal lymph nodes were harvested from mice (n=4) [ADDRESS_1086219] treatment with control DMEM/mRIPO and re- stimulated with antigen expressing cells for [ADDRESS_1086220] B16- F10.9- OVA cells or EL4 

Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 36 of 109 
 cells electroporated with RNA encoding: GFP (control), TRP -2 (melanoma antigen), or OVA.  E. 
Supernatant from the CTL assay in D . was tested for markers of T cell activation and lytic activity by [CONTACT_6428].  
F. B16 -F10.9- OVR -CD155 tumor bearing mice were treated with control DMEM/mRIPO and spleens were 
harvested 14 days after treatment (n=4). Splenocytes from individual mice were co- cultured with B16-
F10.9- OVA -CD155 cells (5:1 ratio) (48h). Supernatant was harv ested and tested for markers of T cell 
activation and lytic activity by [CONTACT_6428]. G. Tumor draining inguinal lymph nodes were harvested following 
treatment with control DMEM/mRIPO and individually re- stimulated in vitro . After 5 days, re- stimulated cells 
were harvested and analyzed for CD4 and CD8 T cells by [CONTACT_4133]. Melanoma antigen TRP -2 specific 
response was assessed using a H -2Kb TRP -2 tetramer (right panel). TRP -[ADDRESS_1086221] and p<0.05.  
 
Istari and collaborators have  conducted preclinical studies to support lerapolturev  plus 
anti-PD1 therapy in this setting, which in summary have produced the following results : 
• Up-regulation of PD -L1 expression in lerapolturev  infected macrophages and 
dendritic cells, suggesting lerapolturev  in combination with anti -PD-1 blockade in 
the tumor is rational17,26. 
• Lerapolturev  infection of tumor -associated macrophages (TAMs), and type- I/III 
interferon dominant antiviral inflammation of the nonmalignant tumor 
microenvironment  (TME) , instigate polyfunctional antitumor CD8 T cell 
responses27.  This leads to upregulation of the PD1 immune checkpoint on 
tumor -infiltrating T cells.  Thus, lerapolturev’s  mechanism of action is synergistic 
with blockade of PD -1/L1 interaction.  
• Synergy of lerapolturev  and anti -PD-1 therapy has been demonstrated in a 
mouse glioma model (refer to lerapolturev IB). 
Lerapolturev  was subjected to extensive dose- range finding, toxicology, biodistribution, 
shedding and neutralizing antibody tests with intrathalamic inoculation of up to 5 x 109 
TCID 50 of lerapolturev  in M. Fascicularis28. These revealed: (i) absence of morbidity and 
mortality; (ii) absence of neuropathological signs consistent with virus -induced central 
nervous system ( CNS ) damage; (iii) absence of virus dissemination from the brain or 
viremia; (iv) absence of extraneural replication; (v) absence of shedding with saliva, urine 
or stool; (vi) presence of a neutralizing antibody response.  
1.2.2  Clinical Studies  
[IP_ADDRESS]   Lerapolturev in patients with recurrent glioblastoma ( rGBM) 
The safety and efficacy of lerapolturev monotherapy and lerapolturev in combination with pembrolizumab  in patients with recurrent glioblastoma multiforme (rGBM) is currently 
under investigation. Lerapolturev monotherapy has been administered intratumorally to more than 190 rGBM participants via convection enhanced delivery (CED). The first -in-
human Phase I ( [STUDY_ID_REMOVED]) evaluated 7 lerapolturev doses, ranging from 1  x 10
7 and 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 37 of 109 
 1 x 1010 TCID 5018. Across all doses tested, one dose limiting toxicity (DLT) of intracranial 
hemorrhage due to removal of the infusion catheter post infusion was observed in a single  
participant . No other DLTs were reported. The most commonly (≥30% of total 
participants) reported treatment -related AEs were consistent with the signs and 
symptoms expected to be observed with increased peritumoral edema resulting from 
lerapolturev induced inflammation after intratumoral infusion of the brain tumor . There 
was no evidence of viral encephalomyelitis, poliomyelitis, meningitis, or systemic autoimmune reactions in any participant treated at any dose level.   
 For the follow -on Phase 2 study of lerapolturev monotherapy in rGBM (NCT 02986178), 
a dose of [ADDRESS_1086222] commonly (≥30% of 
total participants) reported treatment -related AEs were headache (62.0%), hemiparesis 
(57.9%), seizure (40.5%), and aphasia (30.6%) . This  AE profile  is consistent with  the 
treatment -related AEs observed during Phase 1, which are signs and symptoms expected 
to be observed with increased peritumoral edema resulting from lerapolturev -induced 
inflammation after intratumoral infusion of the brain tumor.  With a median follow -up of 
17.1 months (range: 13.1 to 46), six participants had PRs per investigator determination and median OS was 12.0 months. Landmark OS at 12 and 24 months were 50% and 
17%, which taken together is consistent with the efficacy resul ts observed in Phase 1.  
 LUMINOS -101 ([STUDY_ID_REMOVED]) is an ongoing single- arm Phase 2 study investigating the 
safety and efficacy of a single intratumoral infusion of  lerapolturev (5 x 10
7 TCID 50) in 
combination with intravenous pembrolizumab (200mg every three weeks) in adult s with 
rGBM. No DLTs were reported during the safety run- in (n=3). As of [ADDRESS_1086223] common AEs (≥25% of total participants) 
regardless of relatedness were headache (66.7%), nausea (33.3%), fatigue (26.7%), and peritumoural oedema (26.7%) . The most common lerapolturev -related A Es (≥15% of total 
participants) were headache (66.7%), peritumoural oedema (26.7%), cognitive disorder 
(20%), dizziness (20.0%), fatigue (20.0%), and hemiparesis (20.0%) . These data suggest 
that the addition of anti -PD-1 therapy (ie,  pembrolizumab)  does not significantly affect the 
safety profile of lerapoltur ev, and the combination of lerapolturev and anti -PD-1 therapy 
is tolerable.  Furthermore, there was  no evidence of viral encephalomyelitis, poliomyelitis, 
meningitis, or systemic autoimmune reactions in any participant receiving lerapolturev 
combined with pembrolizumab . For more information, consult the IB.  
 
[IP_ADDRESS]  Lerapolturev in patients with melanoma   
Lerapolturev  has been administered via intratumoral injection (1 x 10
8 TCID 50 per lesion 
per visit ) to 12 pa rticipant s in a Phase 1 open- label study with unresectable and/or 
metastatic anti-PD-1 refractory melanoma (as defined by [CONTACT_093])  as of 23  March  
2021 ([STUDY_ID_REMOVED]). No serious adverse events (SAEs) or dose- limiting toxicities 
(DLTs) were observed, and administration of 1  x 108 TCID 50 lerapolturev  to one  lesion/visit  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 38 of 109 
 for up to three successive visits  was well tolerated. This included 5 participants  that 
received 3 injections of lerapolturev  who had received  prior anti -PD-1 therapy within 30 
days prior to administration of lerapolturev  (and thus had anti -PD1 therapy  on board 
during lerapolturev ); none of these participan ts experienced systemic toxicities. All AEs 
were Grade 1 or 2 in severity  (pruritis [58%] and erythema [50%])  and primarily localized 
to the injected lesion(s) .  
 
Based on the favorable tolerability profile,  and encouraging preliminary anti-tumor activity 
(33% ORR per irRC) noted in Phase 1, this study  ([STUDY_ID_REMOVED]) was designed to test 
the safety and efficacy of lerapolturev  alone or in combination with anti -PD-1 therapy , in 
participants with unresectable melanoma who meet the more rigorous and objective definition for anti -PD-1 resistance, as described in the SITC Immunotherapy Resistance 
Task Force Guidance
7. Despi[INVESTIGATOR_040] a 6- fold increase in the total  maximum lerapolturev dose 
relative to Phase 1 (ie, 6 x 108 TCID 50 versus 1  x 108 TCID 50 in Phase 1) and/or injection 
of up to 6 lesions per treatment visit  (compared to 1 lesion/visit in Phase 1) , lerapolturev 
remains well tolerated, whether given alone or when combined with anti -PD-1 therapy .  
As summarized  in Table 3 and Table 4, 17 participants were treated with lerapolturev 
monotherapy (n=11) or lerapolturev combined with anti -PD-1 therapy  (n=6) as of the 10 
December 2021 data cutoff. Additionally,  7 lerapolturev monotherapy participant s 
crossed over to receive the lerapolturev/anti -PD-[ADDRESS_1086224], treatment -related Grade ≥[ADDRESS_1086225] common (of total participants)  AEs 
regardless of relationship were vomiting (17.6%), constipation (11.8%), fatigue (11.8%),  
hypertension (11.8%), nausea (11.8%), pain in extremity (11.8%), pyrexia (11.8%), and 
tumour  pain (11.8%). The only AE related to lerapolturev that was reported in more than 
1 participant was fatigue,  which was observed in 2 participants (11.8%)  (Table 4). There 
were no Grade ≥3 AEs that occurred in more than 1 participant and none were related to 
either lerapolturev  or anti-PD-1 therapy. No participant reported symptoms of CRS or 
immune effector cell associated neurotoxicity syndrome (ICANS).  (Table 3). With regards 
to efficacy, the b est anti-tumor  responses observed as of the data cutoff  have been stable 
disease . Together, these data suggest further optimization of  the lerapolturev dose and/or 
schedule may be required to rekindle immunotherapy responsiveness in the truly 
refractory population. For more information, consult the IB.  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 39  of 109  
 Table 3. LUMINOS -102 Overall Summary of Adverse Events as of 10DECEMBER2021  
 
Summary  Lerapolturev 
Monotherapy, 
Safety Run -in1 
(N=6)  Lerapolturev 
Monotherapy 
(Arm 1)1 
(N=5)  All 
Lerapolturev 
Monotherapy
1 
(N=11)  Lerapolturev/ 
Anti-PD-1 
(Arm 2)  
(N=6)  All 
Participants1 
(N=17)  Crossover2 
Lerapolturev 
Monotherapy to 
Lerapolturev/Anti -
PD-1 
(N=7)  All 
Lerapolture
v/ Anti -PD-1 
(N=13)  
Participants with one or more AEs,  
 n (%)  6 (100.0%)  2 (40.0%)  8 (72.7%)  2 (33.3%)  10 (58.8%)  5 (71.4%)  7 (53.8%)  
Participants with one or more 
treatment -related3 AEs, n (%)  
    Lerapolturev -related AEs, n (%)  
    Anti-PD-1-related AEs, n (%)  4 (66.7%)  
 
4 (66.7%)  
NA 1 (20.0%)  
 
1 (20.0%)  
NA 5 (45.5%)  
 
5 (45.5%)  
NA 2 (33.3%)  
 
1 (16.7%)  
1 (16.7%)  7 (41.2%)  
 
6 (35.3%)  
1 (5.9%)  2 (28.6%)  
 
2 (28.6%)  
2 (28.6%)  4 (30.8%)  
 
3 (23.1%)  
3 (23.1%)  
Participants with one or more serious  
AEs, n (%)  0 (0.0%)  0 (0.0%)  0 (0.0%)  1 (16.7%)  1 (5.9%)  0 (0.0%)  1 (7.7%)  
Total number of serious AEs, n  0 0 0 3 3 0 3 
Participants with one or more 
treatment -related3 serious AEs, n (%)  
    Lerapolturev -related serious AEs,   
        n (%)  
    Anti-PD-1-related serious AEs,  
        n (%)  0 (0.0%)  
 
 
0 (0.0%)  
 
NA 0 (0.0%)  
 
 
0 (0.0%)  
 
NA 0 (0.0%)  
 
 
0 (0.0%)  
 
NA 0 (0.0%)  
 
 
0 (0.0%)  
 
0 (0.0%)  0 (0.0%)  
 
 
0 (0.0%)  
 
0 (0.0%)  0 (0.0%)  
 
 
0 (0.0%)  
 
0 (0.0%)  0 (0.0%)  
 
 
0 (0.0%)  
 
0 (0.0%)  
Total number of treatment -related3 
serious AEs, n  
    Lerapolturev -related serious AEs,   
        n  
    Anti-PD-1-related serious AEs, n  0 
 
0  
 
NA 0 
 
0  
 
NA 0 
 
0  
 
NA 0 
 
0  
 
0 0 
 
0  
 
0 0 
 
0  
 
0 0 
 
0  
 
0 
Participants with one or more dose -
limiting toxicities AEs, n (%)  0 (0.0%)  0 (0.0%)  0 (0.0%)  0 (0.0%)  0 (0.0%)  0 (0.0%)  0 (0.0%)  
Participants with one or more Grade 
3 or 4 AEs, n (%)  2 (33.3%)  0 (0.0%)  2 (18.2%)  1 (16.7%)  3 (17.6%)  1 (14.3%)  2 (15.4%)  
Participants with any Grade 3 or 4 
Treatment -related3 AE, n (%)  
    Lerapolturev -related Grade 3 or 4  
         AEs, n (%)  
    Anti-PD-1-related Grade 3 or 4 
         AEs, n (%)  0 (0.0%)  
 
0 (0.0%)  
 
NA 0 (0.0%)  
 
0 (0.0%)  
 
NA 0 (0.0%)  
 
0 (0.0%)  
 
NA 0 (0.0%)  
 
0 (0.0%)  
 
0 (0.0%)  0 (0.0%)  
 
0 (0.0%)  
 
0 (0.0%)  0 (0.0%)  
 
0 (0.0%)  
 
0 (0.0%)  0 (0.0%)  
 
0 (0.0%)  
 
0 (0.0%)  
Participants with one or more Grade 
5 AEs, n (%)  0 (0.0%)  0 (0.0%)  0 (0.0%)  0 (0.0%)  0 (0.0%)  0 (0.0%)  0 (0.0%)  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 40  of 109  
  
Summary  Lerapolturev 
Monotherapy, 
Safety Run -in1 
(N=6)  Lerapolturev 
Monotherapy 
(Arm 1)1 
(N=5)  All 
Lerapolturev 
Monotherapy
1 
(N=11)  Lerapolturev/ 
Anti-PD-1 
(Arm 2)  
(N=6)  All 
Participants1 
(N=17)  Crossover2 
Lerapolturev 
Monotherapy to 
Lerapolturev/Anti -
PD-1 
(N=7)  All 
Lerapolture
v/ Anti -PD-1 
(N=13)  
Participants with any Grade 5 
treatment -related3 AE, n (%)  
    Lerapolturev -related Grade 5  
        AEs, n (%)  
    Anti-PD-1-related Grade 5 AEs,  
        n (%)  0 (0.0%)  
 
0 (0.0%)  
 
NA 0 (0.0%)  
 
0 (0.0%)  
 
NA 0 (0.0%)  
 
0 (0.0%)  
 
NA 0 (0.0%)  
 
0 (0.0%)  
 
0 (0.0%)  0 (0.0%)  
 
0 (0.0%)  
 
0 (0.0%)  0 (0.0%)  
 
0 (0.0%)  
 
0 (0.0%)  0 (0.0%)  
 
0 (0.0%)  
 
0 (0.0%)  
Participants with one or more 
lerapolturev AESIs  
    Participants with one or more AEs  
        with an ISR  
    Participants with one or more AEs  
        with signs of CRS/ICANs  0 (0.0%)  
 
0 (0.0%)  
 
0 (0.0%)  0 (0.0%)  
 
0 (0.0%)  
 
0 (0.0%)  0 (0.0%)  
 
0 (0.0%)  
 
0 (0.0%)  0 (0.0%)  
 
0 (0.0%)  
 
0 (0.0%)  0 (0.0%)  
 
0 (0.0%)  
 
0 (0.0%)  0 (0.0%)  
 
0 (0.0%)  
 
0 (0.0%)  0 (0.0%)  
 
0 (0.0%)  
 
0 (0.0%)  
AESI = adverse event of special interest; CRS = cytokine release syndrome; ICANS = immune effector cell associated neurotoxicity syndrome; ISR = injection site 
reaction; NA = not applicable; PD -1 = programmed cell death protein 1; AE = adverse event  
[ADDRESS_1086226] crossover cycle. Pooled data presented for all crossover participants.  
3 Treatment -related based on definite, possible, and probable relatedness to lerapolturev and/or anti -PD-1.  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 41  of 109  
 Table 4. LUMINOS -102 Lerapolturev- Related Adverse Events by [CONTACT_788916] 10DECEMBER2021  
 
Summary  Lerapolturev 
Monotherapy, 
Safety Run -in1 
(N=6)  Lerapolturev 
Monotherap
y (Arm 1)1 
(N=5)  All Lerapolturev 
Monotherapy1 
(N=11)  Lerapolturev/ 
Anti-PD-1 
(Arm 2)  
(N=6)  All 
Participants1 
(N=17)  Crossover2 Lerapolturev 
Monotherapy to 
Lerapolturev/Anti -PD-1 
(N=7)  All 
Lerapolture
v/ Anti -PD-1 
(N=13)  
Participants with one or 
more Lerapolturev -
Related3 AEs, n (%)  4 (66.7%)  1 (20.0%)  5 (45.5%)  1 (16.7%)  6 (35.3%)  2 (28.6%)  3 (23.1%)  
Preferred term, n (%)  
     Fatigue  
     Anaemia 
     Decreased appetite  
     Dyspnoea  
     Groin pain  
     Hyperglycaemia  
     Hypoalbuminaemia  
     Hypochloraemia 
     Hyponatraemia  
     Lymphadenopathy  
     Nausea  
     Oncologic complication 
     Pain in extremity  
     Paraesthesia  
     Peripheral swelling  
     Pyrexia  
     Tumour pain  
     Vomiting 
     Wound haemorrhage  
     Headache  
     Pruritus    
1 (16.7%)  
1 (16.7%)  
1 (16.7%)  
1 (16.7%)  
0 (0.0%)  
1 (16.7%)  
1 (16.7%)  
1 (16.7%)  
1 (16.7%)  
1 (16.7%)  
1 (16.7%)  
1 (16.7%)  
1 (16.7%)  
1 (16.7%)  
1 (16.7%)  
1 (16.7%)  
1 (16.7%)  
1 (16.7%)  
1 (16.7%)  
0 (0.0%)  
0 (0.0%)    
1 (20.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)    
2 (18.2%)  
1 (9.1%)  
1 (9.1%)  
1 (9.1%)  
0 (0.0%)  
1 (9.1%)  
1 (9.1%)  
1 (9.1%)  
1 (9.1%)  
1 (9.1%)  
1 (9.1%)  
1 (9.1%)  
1 (9.1%)  
1 (9.1%)  
1 (9.1%)  
1 (9.1%)  
1 (9.1%)  
1 (9.1%)  
1 (9.1%)  
0 (0.0%)  
0 (0.0%)    
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
1 (16.7%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)    
2 (11.8%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
1 (5.9%)  
0 (0.0%)  
0 (0.0%)    
1 (14.3%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
1 (14.3%)  
1 (14.3%)    
1 (7.7%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
1 (7.7%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
0 (0.0%)  
1 (7.7%)  
1 (7.7%)  
, PD-1 =  programmed cell death protein 1; AE = adverse event  
[ADDRESS_1086227] crossover cycle. Pooled data presented for all crossover participants.  
3 Includes AEs considered definitely, probably or possibly related to lerapolturev.
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Amendment 3.0 23APRIL2021  
Confidential   Page 42 of 109    
1.3 Benefit/Risk Assessment  
1.3.1  Known Potential Risks  
Risks related to lerapolturev  administration: For d etailed risks regarding use of 
lerapolturev , refer to the IB. Based on available data from  ongoing Phase [ADDRESS_1086228] managed with low dose dexamethasone and/or bevacizumab.  In contrast , 
lerapolturev  injection into solid tumors outside the  brain has resulted in treatment -related 
AEs that are only Grade 1 or 2. For the Phase 1 melanoma study in anti -PD-1 refractory 
melanoma, lerapolturev -related AEs were  primarily localized to the injected lesion(s) , with 
pruritis (45.5%) and erythema (27.3%) at the injection site most commonly reported. As 
discussed in Section  1.2.2, all treatment -related AEs in pa rticipants  enrolled in this study  
as of the 10 December 2021 data cutoff continue to be Grade 1 or 2, whether lerapolturev 
is given as monotherapy or in combination with anti -PD-1 therapy . Fatigue was the only 
lerapolturev -related AE reported in >10% of participants  (11.8%) .    
After oral uptake, poliovirus replicates in the gastrointestinal tract and is excreted by 
[CONTACT_788917]. Per the Istari IB, analysis of viral shedding  in non- human 
primates have shown that excretion of lerapolturev  does not occur after intracerebral 
administration, implying the absence of dissemination and subsequent gastrointestinal 
replication.  In addition, prior immunization  against poliovirus , as well as administration of 
a poliovirus booster  1 to 6 weeks prior to lerapolturev  administra tion, is required for study 
participation. Immunity to poliovirus following proper immuniz ation is believed to be 
lifelong29, which is  support ed by  a study from  Rumke et al , who showed that  92% (22 of 
24) of  participants previously immunized against poliovirus  with an undetectable 
poliovirus titer had a four -fold increase in neutralizing antibodies within 1 week of DT -IPV 
administration30. Therefore, lerapolturev dissemination in pa rticipants  treated with 
lerapolturev  is less likely given the high- titer immune response to poliovirus that is present 
following immunization and pre-  lerapolturev  boosting with the Salk poliovirus vaccine  
(Istari data on file) . Lerapolturev  has not been detected in the stool of participants  with 
rGBM treated with intratumoral injection. However,  lerapolturev  excretion within stool 
following subcutaneous injection of melanoma tumors cannot be categorically excluded , 
although viral shedding data from the Phase 1 melanoma study indicate lerapolturev  was 
undetectable in the stool of the tested melanoma participant s treated with lerapolturev  
(Istari data on file) .  Again, high- titer poliovirus immunity was demonstrated both pre-  and 
post-IPOL® vaccination in these participants .  Stool specimens and swabs of injected 
lesions and dressings will be collected  in the current study following lerapolturev  
administration to further rule out  risk of virus transmission, systemic dissemination , and 
gastrointestinal excretion during the study.   
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086229] to be considered part of the human environment, exposure to 
lerapolturev  would not represent an added risk beyond the possibility for exposure that 
already exists. Study participants will be advised of the risks of exposure to unvaccinated 
household contacts  (such as babies), or those who might be immunocompromised.   
Risks related to modifying the dose/schedule of lerapolturev : Review of all available 
safety data for this study ( Section  [IP_ADDRESS] ) indicate s that lerapolturev injected into multiple 
lesions/visit up to a maximum dose of 6  x 108 TCID50 every 3 weeks is safe and tolerable 
when administered as monotherapy or in combination with anti -PD-1 therapy. In addition, 
review of the published literature (Table 5) for other innate immune agonists (including 
oncolytic viruses ) delivered by [CONTACT_707256],  indicates that increasing the 
maximum possible dose of lerapolturev to 1.6  x 109 TCID 50 and changing the schedule of 
administration to an “induction” phase of weekly injections x 7 followed by a maintenance 
phase of less frequent administration is a common approach that is safe and tolerable  
and not predicted to substantially change the safety profile of the drug.  
 
 
 
 
 
 
 
 
 
 
 
 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086230] Total maximum 
dose delivered 
by [CONTACT_788918]-112  
(double- stranded 
RNA in carrier)  2mg Weekly x 7 
followed by [INVESTIGATOR_135] 3 week maintenance  No treatment -
related Grade ≥3 AEs Marquez -Rodas et al 
2021
31 
Vidutolimod (TLR9 agonist in virus -like particle)  10mg  Weekly x 7 followed by [INVESTIGATOR_135] 3 week maintenance  No treatment -
related Grade ≥4 AEs Kirkwood et al 2021
32 
CAVATAK 
(coxsackievirus)  3 x 108 TCID 50 Day 1, 3, 5, 8 , and 
22 followed by 
[INVESTIGATOR_135] 3 week maintenance  No DLTs or 
treatment -related 
Grade ≥3 AEs  Andtbacka et al 2021
33 
ONCOS -102 
(adenoviral vector  
with payload) 3 x 1011 viral 
particles  Day 1, 4, 8, 15, and 19 followed 
by [INVESTIGATOR_135] 4 week maintenance  No DLTs  Ranki et al 2016
34 
NG-350A  
(adenoviral vector with payload)  2 x 10
12 viral 
particles  Weekly x 4  No DLTs  Nain et al 202135 
ORCA -010 
(adenoviral vector)  1.5 x 10
12 viral 
particles  One dose  No DLTs  or 
treatment -related 
Grade ≥3 AEs  Brachtlova et al 2021
36 
ONCR- 177  
(HSV- 1 vector 
with payload)  4 x 108 pfu Every 2 weeks  No DLTs or treatment -related 
Grade ≥3 AEs Park et al 2021
37 
IMLYGIC  (HSV -1 
vector with payload)  4 x 10
8 pfu Every 2 weeks  No DLTs  Hu et al 200638 
 
 Risks related to anti -PD-1 administration:  Anti-PD-1 administration carries the risk of 
immune- related AEs (irAEs ) in various organ systems, including the skin. Consult the 
current pembrolizumab or nivolumab package insert for the most current information 
related to administration and safety, such as AE management and dose modifications. 
Per the respective package inserts for nivolumab and pembrolizumab, administration of 
either anti -PD-1 can be associated with rash, and pruritis has been reported in melanoma 
patients treated with nivolumab. Given lerapolturev ’s mechanism of action, and the 
monotherapy safety profile observed in melanoma participants  treated to date, it is 
possible that  concurrent use of lerapolturev  with anti -PD-[ADDRESS_1086231] s there is not an increased risk of cutaneous irAEs for 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 45 of 109 
 the combination (Table 3 and Table 4). Because co- administration of lerapolturev  with 
anti-PD-1 therapy has a theoretical risk for CRS and/or immune effector cell -associated 
neurotoxicity syndrome (ICANS)20, this study will monitor participants  for such events, 
and will obtain blood samples to determine the cytokine profile associated with any such 
events (if applicable) in order to inform treatment algorithms in subsequently treated study 
participants.  In addition, the study will employ a safety run- in (Section 3.1.2 ) to e stablish 
the safety of multiple lerapolturev  intratumoral injections  prior to proceeding the 
randomized portion of the trial . 
 
1.3.2  Known Potential Benefits  
Lerapolturev has demonstrated evidence of meaningful anti -tumor response in patients 
with rGBM, which is a near ly universally fatal disease. For participants treated with 
lerapolturev in the  Phase 1 study , based on an interim data summary,  overall survival 
reached a plateau of 21% (95% CI:  11 to 33) at 24 months that was sustained at 36 
months ; this  was a significant improvement relative to criteria -matched historical 
controls18. Lerapolturev  monotherapy  is currently being investigated in an ongoing multi -
center Phase 2 in rGBM, with preliminary evidence supporting the observations seen in 
Phase 1. Lerapolturev  is also being evaluated in combination with pembrolizumab in  
participants with rGBM  (LUMINOS -101); the data from this study  further suggest the 
combination of lerapolturev and anti -PD-1 therapy is safe and well tolerated.  
Lerapolturev has also shown anti -tumor activity in participants with anti- PD-1 refractory 
melanoma  in a Phase 1 study . Four of twelve  participants with anti-PD-1 refractory (and 
BRAF/MEK refractory, for those with BRAF -mutated melanoma) treated with intratumoral 
lerapolturev achieved an objective response with lerapolturev , despi[INVESTIGATOR_788892] a single lesion/visit every three weeks for a maximum of three 
visits . Of those who received 3  lerapolturev injections (maximum dose administered), 
responses were observed in 4/6 (67%) . Responses included two participants with in -
transit melanoma who had complete pathologic responses.  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086232]  the safety  and efficacy of lerapolturev 
administered as monotherapy and in combination with anti -PD-1 therapy where the dose 
of lerapolturev  was increased relative to the Phase 1 study  by [CONTACT_788919],  and increasing the number of injected lesions/visi t.  While this 
approach has been shown to be safe and tolerable ( Section [IP_ADDRESS] ), the level of clinical 
activity observed in the Phase [ADDRESS_1086233] likely 
explanation for this observation is differences in the enrolled patient populations ie,  the 
LUMINOS -102 protocol includes a more rigorous definition of anti -PD-1 resistance than 
what was implemented for the Phase 1 study .  Therefore, to improve the probability of  
participant  benefit and the result ant benefit/risk  profile , both the eligibility criteri a and 
dosing regimen are being updated in this amendment.  The changes in eligibility criteria  
will exclude those patients with a lower probability of receiving benefit (eg,  patients with 
mucosal melanoma or who are more heavily pretreated) while maintaining the more 
clinically relevant and rigorous definition of anti -PD-1 resistance.  
In addition, both the schedule and dose of lerapolturev injections will be altered to 
potentially improve the probability of response in this more anti -PD-1 resistant patient 
population (compared to the Phase 1) .  Both the change in schedule frequency , and 
increase in dose,  were chosen based on review of published literature for other innate 
immune agonists (including oncolytic viruses). For example, as outlined in Table 5, the 
majority of innate immune agonists employ an “induction/maintenance” type of approach 
to the schedule of injections where more frequent injections are given in the first 1  to 
2 months of the treatment period  to ignite the immune system,  followed by [CONTACT_358038] a 
less frequent schedule where the goal is to maintain the immune response. It is expected 
that the increase in injection frequency will result in an improvement in participant response without a significant increase in toxicity.  
The data summarized in Table 5 also indicates that  virus doses of ≈[ADDRESS_1086234] that lerapolturev injection upregulates the 
compensatory anti -PD-1/L1 pathway, such that concurrent blockade of that pathway is 
predicted to increase the potential benefit to patients. This hypothesis has been test ed in 
nonclinical experiments where the combination of a mouse adapted version of lerapolturev (mRIPO) administered in combination with a murine anti -PD-1 antibody 
results in mor e significant effects on tumor growth as compared to either drug alone (see 
lerapolturev IB).   
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086235] been mainly  local, and remain  Grade 1 or 2 in 
severity in all participants treated to date, regardless of treatment group. This suggests 
that systemic dissemination of lerapolturev does not occur (likely due to pre- existing anti -
polio immunity  and CD155 tropi[INVESTIGATOR_8801] ), which distinguishes lerapolturev from other oncolytic 
viruses such as T -VEC that are associated with systemic dissemination and systemic AEs 
such as CRS .  
Given that all currently available safety data indicate that lerapolturev -related AEs in 
participants with melanoma are  mild to moder ate despi[INVESTIGATOR_223464] a lerapolturev 
dose of up to 6 x 108 TCID 50 (alone and when combined with anti -PD-1 therapy ), it is 
reasonable to assume a lerapolturev dose of up to 1.6 x 109 TCID 50, and a weekly dosing 
regimen following by Q3/4W maintenance dosing would not result in DLT . In addition, 
because participants receiving lerapolturev monotherapy are allowed to crossover to the 
combination regimen, those participants randomized to lerapolturev  monotherapy have 
an opportunity to maximize their potential benefit upon crossover.    
  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 48  of 109  
 2 OBJECTIVES  AND ENDPOINTS  
2.1 Objectives and Endpoints  
Objectives  Endpoints/Evaluation Criteria  
Primary  
To evaluate the anti -
tumor activity of 
lerapolturev  with and 
without  anti-PD-1, in 
participants who have 
failed anti -PD-1/L1-
based  therapy  • Overall  Response Rate (ORR): the proportion  of 
participants  achieving confirmed complete (CR) or 
partial response (PR), per RECIST  1.1 criteria . 
To evaluate the 
safety/tolerability of lerapolturev  with and 
without anti -PD-1, in 
participants  who have 
failed anti -PD-1/L1-
based therapy   • The frequency and severity of treatment -emergent 
adverse events (AE) via Common Terminology Criteria for Adverse Events (CTCAE, v5.0)  
• Changes in laboratory (hematology, chemistry)  and 
vital sign parameters  
• Lerapolturev AESIs  
• Anti-PD-1 irAEs  
• Study treatment discontinuation due to AEs  
To evaluate the effect of 
lerapolturev on the TME  
of injected and non-injected lesions  when 
administered with and without anti -PD-1 
therapy  • Changes from baseline in the number of CD8+ tumor 
infiltrating lymphocytes (TILs)  
• Changes from baseline in PD -L1 expression  
Secondary  
To evaluate survival and 
disease control outcomes of lerapolturev  
with and without  anti-PD-
1, in participants who 
have failed anti -PD-1/L1-
based therapy  • Overall survival (OS): time from treatment group 
assignment  until death from any cause  
• Duration of Response (DOR): time from confirmed objective response ( CR or PR per RECIST 1.1)  until 
unequivocal disease progression or death, whichever occurs first  
• Disease control rate (DCR): the proportion of participants  achieving confirmed CR, confirmed PR, or 
stable disease (SD) per RECIST  1.1, as best response  
• Disease control rate- 6months (DCR -6mo): the 
proportion of participants  achieving confirmed  CR (any 
duration), confirmed PR (any duration) , or SD (≥ 6 
months) per RECIST 1.[ADDRESS_1086236] response  
• Durable Response Rate (DRR): the proportion of participants with confirmed CR or PR (per RECIST  1.1) 
lasting at least 6 months  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 49  of 109  
 • Progression -free survival  (PFS) : time  (number of 
months)  from treatment group assignment until date of 
documented radiologic disease progression per 
RECIST 1.[ADDRESS_1086237]   
Exploratory:  
To explore  lerapolturev 
mechanism of action and predictors of response to lerapolturev with or 
without anti -PD-[ADDRESS_1086238] 
failed anti -PD-1/L1-
based therapy  • Assessment and identification of genetic, cytologic, 
histologic and/or other markers in tumor biopsies and 
PBMC samples that may correlate with response. 
• Assessment of changes  over time in immune markers , 
including, but not limited to , immune cell density, T cell 
receptor repertoire, and chemokine and/or cytokine profile  in blood samples and/or tissue  
To evaluate anti -tumor 
response to lerapolturev 
with and without anti -PD-
1, based on iRECIST 
criteria  in participants  
who have failed anti -PD-
1/L1-based therapy  • ORR/DOR, DRR , DCR , and DCR -6mo based on 
iRECIST criteria  
To evaluate anti -tumor 
response outcomes  to 
lerapolturev  with and 
without anti -PD-1, based 
on subgroup in 
participants  who have 
failed anti -PD-1/L1-
based therapy  • ORR, DOR, DRR, DCR, and DCR -6mo in the following 
subgroups : 
o Acquired versus primary PD -1/L1 resistance, as 
defined by [CONTACT_788920], et al14 
o BRAF wild type and mutant  
o LDH levels at baseline  
o Time since last dose of anti -PD-1/L1 therapy 
prior to randomization (≤ or > 6 weeks) 
o Crossover to combination arm  from lerapolturev 
monotherapy  
To evaluate survival 
outcomes to lerapolturev  
with and without anti -PD-
1, based on subgroup  in 
participants  who have 
failed anti -PD-1/L1-
based therapy  • OS and PFS in the following subgroups:  
o According to treatment arm and AJCC stage at baseline  
o Primary versus acquired resistance, as defined by [CONTACT_788921]
[ADDRESS_1086239] dose of anti -PD-1/L1 therapy 
prior to randomization (≤ or > 6 weeks) 
o Crossover to combination from lerapolturev  
monotherapy  
2.2 Hypothesis  
Efficacy: Lerapolturev  administered in combination with anti -PD-1 therapy using the 
induction/maintenance schedule of injections (weekly x 7 followed by [CONTACT_788922] 3 to 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 50 of 109 
 4 weeks concurrent with anti -PD-1 therapy) to participants with anti -PD-1 refractory 
melanoma  will result in a n ORR of ≥ 33%.   
Translational: Lerapolturev administered in combination with anti-PD-1 therapy  will result 
in an increase in CD8+ T cells and PD -L1 expression in TME.  
[ADDRESS_1086240] the safety 
and efficacy of lerapolturev  alone and in combination with anti -PD-1 therapy  in 
participants with unresectable advanced anti -PD-1/L1 refractory melanoma.  Participants 
will be randomized 1:1 to receive lerapolturev  alone (Arm 1) or lerapolturev  and an FDA -
approved anti-PD-1 therapy (Arm 2).  Prior to starting the randomized portion of the study,  
a safety run -in cohort of at least six participants treated with l erapolturev  monotherapy  
was to have been enrolled to demonstrate the safety  and tolerability of the administration 
of multiple lerapolturev  injections  per visit.    
As of July 2021 , the safety run -in portion of the study has  been completed . Six participants 
were  enrolled and receiv ed total lerapolturev doses ranging from  1 x 108 to 6 x 108 TCID 50 
injected into between 1 and 6 lesions/visit.  The schedule of administration was for  
participants to receive a single lerapolturev  injection into the largest lesion on Day 1  
followed by [CONTACT_788923]/visit on Day 10.  For participants in Arm 
2, anti -PD-1 therapy was started on Day 10 concurrent with initiation of multiple  
lerapolturev  injections.  Upon initiation of multiple injections on Day 10, the timing of future 
injections was dependent upon anti -PD-1 dosing, ie,  for pembrolizumab the schedule was 
every 3 weeks starting from Day 10,  and for nivolumab the schedule was every 4 weeks 
starting from Day 10. For participants in Arm 1, the timing of future injections  was every 
3 weeks.  This schedule of injections will be abbreviated as the Q3/4W  schedule.   
Upon review of the safety profile for lerapolturev  administered as monotherapy or in 
combination with anti -PD-1 therapy  (Sectio n 1.2.2) , and in agreement with the DSMC, t he 
total lerapolturev dose to be administered will be a maximum of 1.6  x 109 TCID 50/visit, 
and the maximum number of lesions injected/visit will remain 6. The schedule of 
administration will include  weekly injections x 7 followed by [CONTACT_5640] Q3W dosing 
(lerapolturev monotherapy or in combination with pembrolizumab) or Q4W dosing 
(combination with nivolumab) ; this schedule of injections will be abbreviated as the QW  
schedule.   
Participants receiving the Q3/4W  schedule of injections  will be given t he opt ion to change 
to the QW schedule (Section 3.1.2) . Upon commencement of enrollment using the QW  
schedule, the DSMC will continue to review all available safety data at a minimum of 
every 4 months to ensure independent oversight of the safety of participants enrolled in 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 51 of 109 
 this study ( Section 9.1.5 ). This includes a meeting to review all safety data once the first 
12 participants receiving the new lerapolturev dose and QW schedule of injections clear 
the DLT period.  
Participants randomized to receive the Q3/4W  schedule of injections  were s tratifi ed based 
on time since prior anti -PD-1/L1 exposure (≤6 weeks versus >6 weeks) and baseline LDH 
levels (normal vs >ULN) . With the change in eligibility criteria , participants  randomized to 
the QW dosing schedule will be stratified based on the type of anti -PD-1/L1 resistance 
(primary versus secondary as defined in Kluger et al7), while the baseline LDH (normal 
versus >ULN) stratification factor will be retained.   
3.1.1  Crossover  
Participants receiv ing lerapolturev monotherapy (Safe ty Run -In Cohort or Arm 1)  may 
crossover to combination (lerapolturev and anti -PD-1) therapy if any of the following 
criteria are met  
o radiologic disease progression per RECIST v1.1 (progression does not need 
to be confirmed prior to crossover)  
o have not had progression or confirmed partial response per RECIST v1.1 by 
[CONTACT_5875] 26 on study  
o partial response ≥ [ADDRESS_1086241] a complete  assessment 
of tumor burden (ie, scans and caliper/ruler measurement of skin lesions with 
photographic documentation) ≤  28 days prior to  starting the combination. The dose of 
lerapolturev administered in combination will be the same as monotherapy and is detailed 
in Table 7. The schedule of lerapolturev injections at the time of initiation of combination 
therapy will depend on the timing of crossover  (Table 6).  
 
 
 
  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 52  of 109  
 Table 6. Lerapolturev Injection Schedule After Crossover  
Schedule of lerapolturev  
monotherapy  injections at the 
time of crossover  Timing of when criteria for 
crossover are met  Recommended lerapolturev 
dosing schedule  for 
combination  
Participant is receiving weekly 
injections  < 6 months from Cycle 1 Day 1  Continue weekly injections for a 
total of 7 (monotherapy + combination) followed by  [INVESTIGATOR_135] 
3 week dosing (pembrolizumab) or every 4 week dosing (nivolumab) * 
Participant is receiving injections every 3 weeks (pembrolizumab) or every 4 weeks (nivolumab)  < 6 months from Cycle 1 Day 1  Continue concurrent dosing schedule  
Participant is receiving injections every 3 weeks (pembrolizumab) or every 4 weeks (nivolumab)  ≥ 6 months from Cycle 1 Day 1  Weekly x 7 followed by [INVESTIGATOR_135] 3 week dosing (pembrolizumab) or every 4 week dosing (nivolumab)  
 
*NOTE:  Anti-PD-1 dosing begins Day 1 of crossover. F ollowing the 7th weekly injection , lerapolturev  should be 
administered Q3w  when in combination with  pembrolizumab (given Q3 or 6w) , or Q4w when in combination with 
nivolumab  (given Q2 or 4w) .  
  
3.1.2  Considerations for Modification of Dos e and/or Dosing Schedule for 
Participants receiving the Q3/4W Schedule of Injections.  
Lerapolturev Dose: All pa rticipants  receiving lerapolturev on the Q3/4W  schedule  will 
have their lerapolturev  dose adjusted as described in Se ction  5.3.  
 
Lerapolturev Schedule : Participants receiving treatment using the Q3/4W  schedule will 
have the option to receive the “induction” series of weekly x 7 injections  (ie, QW 
schedule) . If the participant chooses to receive the weekly x 7 injections, the  timing  and 
schedule of assessment s as shown in Table 1 (or Table 2 if receiving lerapolturev + 
nivolumab)  beginning with Cycle 1, Day 1 should be followed . Note that the on- study 
biopsy and blood collection timepoints outlined in the Table 1 and Table 2 will remain 
mandatory for those participants who choose to undergo “induction” injections.  
 Participants who choose not to receive the “induction” injections will continue on the every 
3 week (pembrolizumab) or every 4 week (nivolumab) schedule of injections.   
3.1.3  Determination of the  Recommended  Lerapolturev Dose  
As a primary endpoint of this P hase 2 study, the safety and tolerability of lerapolturev  
alone  or in combination with anti -PD-1 will be continually assessed.  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 53 of 109 
 Lerapol turev Dose, Q3/4W  Schedule To more  fully characterize the safety and tolerability 
of lerapolturev  monotherapy , the Sponsor will enroll a safety run- in cohort of 
6 participants . Participants enrolled in t he cohort will receive a  lerapolturev  injection into 
a maximum of 6 lesions  (maximum dose of 6 x 108 TCID 50) on Day 10  (or after , depending 
on resolution of treatment -limiting AEs)  following the single lesion “test” injection.  The 
decision to adjust  the lerapolturev  dose upon completion of the cohort  will be based on 
the presence of dose- limiting toxicit ies (DLT s) observed during the 21 day s following 
administration of Cycle 2, in consultation with the independent DSMC.  
Provided the DLT rate for the safety run- in cohort is ≤33% , it will be considered that  the 
maximum tolerated dose (MTD) for lerapolturev  has not been exceeded. However, should 
the DLT rate in the safety run- in cohort be >33%, then the recommended dose for 
single -agent lerapolturev  will be the maximum number of lesions injected (and/or TCID 50 
dose)  where the DLT rate is ≤33% . If needed, the number of  participants enrolled in the 
safety run- in cohort may be increased up to a maximum of 18 to establish the 
recommended lerapolturev  dose  prior to starting the randomized portion of the study .  The 
recommended lerapolturev  dose from this c ohort will be used in both arms of  the 
randomized portion of the tr ial (ie, single -agent  lerapolturev  or lerapolturev  in combination 
with anti- PD-1). Once [ADDRESS_1086242] been treated  and on study approximately 31 
days (ie, once [ADDRESS_1086243] cycle of multi -lesion lerapolturev  
injection  with concurrent anti -PD-1), the DSM C will perform an additional safety review to 
evaluate the prevalence of any untoward safety signals  in either treatment arm . Should 
an excessive DLT rate (ie, >33%) be detected, the lerapolturev  dose (ie, the maximum 
number of lesions and/or maximum TCID 50 dose) may be decreased in one or both 
treatment arms, in conjunction with DSM C recommendations. See Section 3.1.4  for the 
DLT definitions.  
Any participant from the safety run- in cohort is allowed to crossover to combination 
therapy  after completion of the safety run- in, as described in Section 3.1.1 . However, 
these participants will be analyzed separately, and will not contribute to the population 
enrolled to establish the anti -tumor activity of the lerapolturev /anti-PD-1 regimen.   
Lerapolturev Dose, QW Schedule:  Given the slight increase  in the  lerapolturev dose and 
increased frequency of  dosing during the first [ADDRESS_1086244] started the weekly x 7 “induction” series 
of injections  (ie, n=6 monotherapy and n=6 combination with anti -PD-1) and have cleared 
the DLT evaluation period (ie, 21 days  after Cycle 1, Day 1) . Applying the same rules as 
used for the original safety run- in, should an excessive DLT rate (ie, >33%) be detected, 
the lerapolturev dose (ie, the maximum number of lesions and/or maximum TCID 50 dose)  
and/or the number of weekly injections may be decreased in one or both treatment arms, 
based on  DSMC recommendations. See Section 3.1.4  for the DLT definitions.    
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 54 of 109 
 NOTE: For Arm 2 (lerapolturev /anti-PD-1 combination) , AEs should only be considered a 
DLT if judged by [CONTACT_788924]/frequency compared to what is expected with administration of single- agent anti -
PD-[ADDRESS_1086245] lerapolturev  injection (ie, Cycle 1, 
Day 1 ) and ends [ADDRESS_1086246] possibly related to  lerapolturev 
administration :     
• Any Grade 4 non- hematologic toxicity (not laboratory)  
• Any Grade 3 non- hematologic toxicity (not laboratory), EXCEPT:  
o Grade 3 fatigue lasting ≤[ADDRESS_1086247] of care  
•  Grade 3 or Grade 4 non- hematologic laboratory values ONLY if:  
o Clinically significant medical intervention is required to treat the participant, or 
o The abnormality leads to hospi[INVESTIGATOR_059], or  
o The abnormality persists for >1 week  after intervention  
o The abnormality results in a diagnosis of d rug-induced liver injury (DILI)  
o Exceptions: Clinically nonsignificant, treatable, or reversible laboratory abnormalities including liver function tests, uric acid, etc.  
• Any Grade 4 hematologic toxicity lasting ≥7 days, EXCEPT:  
o Grade 4 thrombocytopenia of any duration  
o Grade 3 thrombocytopenia associated with bleeding that requires a platelet transfusion  
• Febrile neutropenia Grade 3 or Grade 4 ONLY if:  
o Grade 3 is defined as ANC <1000/mm
3 with a single temperature of >38.3 
°C (101 °F) or a sustained temperature of ≥38 °C (100.4 °F) for more than 
1 hour  
o Grade 4 is defined as ANC <1000/mm3 with a single temperature of >38.3 
°C (101 °F) or a sustained temperature of ≥38 °C (100.4 °F) for more than 
1 hour, with life -threatening consequences and urgent intervention 
indicated  
• Prolonged delay (>2 weeks) in initiating the second cycle of anti -PD-1 therapy 
while on study due to lerapolturev -related toxicity.  
• Prolonged delay (> 15 weeks)  in initiating the second cycle of anti -PD-1 therapy 
while on study due to anti -PD-1-related toxicity  (12 weeks for recovery to ≤ Grade 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 55 of 109 
 1 and up to an additional 3 weeks for steroid taper of oral prednisone or equivalent 
to ≤ 10 mg/day)  
• Any treatment -related toxicity that causes the participant to discontinue treatment 
during the DLT evaluation period  
• Grade [ADDRESS_1086248] intracerebral inoculation , with a lerapolturev  dose of 5 x 109 TCID 5028. 
Likewise, lerapolturev  shedding was undetected in the stool (the main excretory pathway 
for polio) of participants  treated with lerapolturev  for rGBM following administration of  
intracerebral doses of up to 1  x 1010 TCID 50 or in melanoma participants  receiving 
3 telerapolturev  injections (1 x 108 TCID 50 each). These results combined with the 
requirement that all participants  must  receive a CDC- recommended immunizing 
vaccination against PV, as well as a PV booster prior to study entry  (which has resulted 
in extremely high levels of neutralizing anti -PV antibodies in patients tested to date) the 
risk of extra -tumoral lerapolturev  dissemination and shedding is predicted to be extremely 
low.  
However, because lerapolturev  shedding in melanoma participants  receiving repeat 
injection s of lerapolturev  at the dose levels allowed in this study  has not been fully 
characterized, the Sponsor will test for the presence of lerapolturev  in stool and on the 
surface of lerapolturev -injected lesions ( as well as on the internal and external surfaces 
of any occlusive dressings applied post -lerapolturev  injection ) for up to 25 pa rticipants  
who received lerapolturev injections using the Q3/4W  dosing schedule. For those 
participants  enrolled using QW  schedule of lerapolturev injections, viral shedding studies 
will be done in up to 25 participants as described in  the appropriate SOA  (Table 1 or 
Table 2 [Arm 2: lerapolturev + nivolumab]) .  
All samples related to the analysis of viral shedding may be collected during clinic visits, 
where feasible. Otherwise, samples may be collected at home and brought to the next 
clinic visit, as appropriate. Refer to the laboratory manual for additional details related to sample collection and storage.  
 
3.3 Justification for Lerapolturev Dose  and Schedule  
The initial dose of lerapolturev  evaluated in this trial was selected based on IND -directed 
toxicity studies and experience from ongoing studies  in participants with rGBM or anti -
PD-1 refractory melanoma ( Section 1.2.2) . Dose -range finding and toxicology studies in 
non-human primates documented the absence of viral encephalomyelitis, poliomyelitis 
and meningitis with intracerebral injection of lerapolturev  up to a dose of 5 x 10
9 TCID5039. 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086249] of inflammation is not expected to be as significant  
because cutaneous swelling is more easily managed than edema within the confines of 
the brain/skull . Data from the Phase 1 trial in anti -PD-1 refractory melanoma , as well as 
the currently available data generated during this study , has shown that a lerapolturev  
dose of up to 6 x 108 TCID 50 is very well tolerated  when given alone or in combination 
with anti -PD-1 therapy . All treatment -related AEs remain Grade 1 or 2, with no  treatment -
related SAEs, DLTs or  evidence of CRS or ICANS in participants treated at any dose 
level (Section [IP_ADDRESS] ).   
Therefore , this study has been  amended to explor e an approximately 2- fold higher 
lerapolturev  dose using a dosing schedule ( QW) with more frequent injections during the 
first 2 months of treatment followed by  [CONTACT_358038] a less frequent “maintenance” 
schedule. The rationale and data supporting this change are summarized in Section 1.3. 
3.[ADDRESS_1086250] consult with the 
Sponsor  or designee to resolve any issues prior to enroll ment .  
Screening for eligible participants will be complet ed within  28 days prior to  Day 1 . Refer 
to Section 4.3 for conditions under which repeat screening procedures are permitted.  
4.1 Inclusion Criteria  
1. ≥ [ADDRESS_1086251] poliovirus (PV), and has 
received a boost immunization with trivalent IPOL® ([COMPANY_011] -Pasteur SA) at least 1 
week, but less than 6 weeks, prior to Day 1  
a. NOTE: Patients who are unsure of their vaccination status must provide 
evidence of anti -PV immunity prior to enrollment, as applicable  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086252] dose of study drug(s) and at prespecified intervals during the study. Note the following details:  
a. Patients with ocular, acral or mucosal melanoma are not eligible  
b. Patients with M1c or M1d disease are NOT eligible  
c. Submission of an archival biopsy sample is allowed in lieu of the baseline tumor biopsy, provided the tissue is ≤4 months old and the participant received no intervening systemic/intratumoral anti -cancer therapy since the 
biopsy was acquired.  
d. Must have at least [ADDRESS_1086253] be 
safely accessible as determined by [CONTACT_788925]. Examples 
of sites considered to be of significant risk include but are not limited to the 
following: the brain, lung, mediastinum, pancreas, or endoscopic procedures extending beyond the esophagus, stomach, or bowel wall . 
 
4. Has ≥ [ADDRESS_1086254] be injectable--defined as a visible or palpable cutaneous, subcutaneous , or nodal melanoma lesion ≥ 10mm in longest diameter or 
multiple injectable melanoma lesions which in aggregate have a longest diameter of ≥ 10mm and where the minimal lesion size is ≥ 5mm.   
b. Note that visceral lesions (eg, liver, lung, retroperitoneal, subpleural lesions) are not considered injectable for the purposes of this trial.  
5. Has had confirmed progression of disease (PD)  while  receiving at least 6 weeks  
(> 1 dose)  of an FDA -approved anti -PD-1/L1 therapy (as monotherapy or in 
combination)  for the treatment of melanoma.   Note the following details:    
a. Initial PD as defined by [CONTACT_393] v1.[ADDRESS_1086255] occur by [CONTACT_119377] ≥ 4 
weeks from initial evidence of PD, in the absence of rapid clinical progression.  
c. Those who discontinue anti -PD-1/L1 therapy after at least 6 weeks (> 1 
dose)  and have confirmed PD  per iRECIST  within [ADDRESS_1086256] 
anti-PD-1/L1 dose are also eligible, provided the anti -PD-1/L1 was not 
stopped due to toxicity requiring permanent discontinuation  
d. Those treated with anti -PD-1/L1 in the adjuvant setting and who have 
biopsy -confirmed progression either while receiving anti -PD-1/L1-based 
therapy or ≤ [ADDRESS_1086257] dose of anti -PD-1/L1 therapy are 
allowed  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 58 of 109 
 NOTE: Adjuvant is defined as therapy received after surgical resection of disease such 
that the patient has no evidence of disease when the anti -PD-1/L1 therapy is initiated.  
Patients with known BRAF mutation must have also failed or refused to receive BRAF -
targeted therapy (alone or in combination with MEK inhibitor) to be eligible  
6. Eastern Cooperative Oncology Group (ECOG) status of 0- 1 
7. Serum lactate dehydrogenase (LDH) levels ≤3 x upper limit of normal (ULN)  
8. Adequate bone marrow, liver and renal function as assessed by [CONTACT_716]:  
a. Hemoglobin ≥9.0 g/dl, patients may be transfused  
b. Lymphocyte count ≥0.5 x 109/L (500 µL)  
c. Absolute neutrophil count (ANC) ≥1.5 x 109/L (1500 µL)  
d. Platelet count ≥100 x 109/L (100,000 µL) without transfusion  
e. AST, ALT, and alkaline phosphatase (ALP) ≤2.5 x upper limit of normal (ULN), with the following exceptions:  
i. Patients with documented liver metastases:  AST and ALT ≤[ADDRESS_1086258]  
ii. Patients with documented liver or bone metastases:  ALP ≤[ADDRESS_1086259]  
f. Serum bilirubin ≤1.[ADDRESS_1086260] with the following exception:  
i. Patients with known Gilbert disease:  serum bilirubin level ≤[ADDRESS_1086261]  
g. Measured or calculated (per institutional standards)  creatinine clearance 
≥30 ml/min (GFR can also be used in place of creatinine clearance)  
h. For patients not receiving therapeutic anticoagulation:  INR , PT, PTT (or 
aPTT)  ≤1.[ADDRESS_1086262]  
9. Life expectancy of >12 weeks  
10. Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for the study, and is willing/able to participate in the study   
4.2 Exclusion Criteria  
1. Has biopsy -proven ocular , acral or mucosal  melanoma  
2. Has M1c or M1d disease 
3. No more than one pr ior systemic anti -cancer regimen  (monotherapy or 
combination)  for management of melanoma. Additional details noted below:  
a. Adjuvant anti -cancer therapy administered ≥ [ADDRESS_1086263] received ≤ 2 
prior lines of systemic anti -cancer therapy  only if one of those lines of 
therapy was a BRAF -targeted regimen  (alone or in combination with MEK 
inhibitor) .  
c. A line of therapy is defined as a regimen in which at least 2 doses of systemic anti -cancer therapy  (monotherapy or combination)  was 
administered , and the regimen was discontinued because of progressive 
disease.  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086264] be 
on a stable regimen at study entry  
a. Symptomatic lesions amenable to palliative radiotherapy (eg, bone 
metastases or metastases causing nerve impi[INVESTIGATOR_20804]) should be treated prior to enrollment.  Patients should be recovered from the effects of radiation.  There is no required minimum recovery  period  
b. Asymptomatic metastatic lesions that would likely cause functional deficits or intractable pain with further growth (eg, epi[INVESTIGATOR_788893]) should be considered for loco- regional therapy if a ppropriate prior to enrollment  
5. Grade ≥2 pleural effusion, pericardial effusion, or ascites  
6. Active or history of autoimmune disease or immune deficiency within previous 2 years, with the following exceptions:  
a. History of autoimmune -related endocrinopathy (e.g. adre nal insufficiency , 
hypothyroidism, Type 1 diabetes mellitus, etc.) that is managed by [CONTACT_141523] (e.g. hydrocortisone, thyroid hormone, insulin, etc .) 
b. Eczema, psoriasis, or lichen simplex chronicus with dermatologic manifestations only (eg, patients with psoriatic arthritis are excluded), provided all of the following conditions are met:  
i. Rash must cover <10% of body surface area 
ii. Disease is well- controlled at baseline and requires only low -potency 
topi[INVESTIGATOR_788883]. No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within 12  months of Day 1  
7. History of idiopathic pulmonary fibrosis, organizing pneumonia (eg, bronchiolitis obliterans), drug- induced or idiopathic pneumonitis, or evidence of active 
pneumonitis on screening chest computed tomography (CT) scan  
a. History of radiation pneumonitis in the radiation field (fibrosis) is allowed  
8. History of a positive HIV RNA test (HIV 1 or 2 RNA by [CONTACT_954])  
9. Known active hepatitis B virus (HBV) infection (chronic or acute)  
a. NOTE: Participants with a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test are allowed  
10. Known active hepatitis C virus (HCV) infection  
a. NOTE: History of a positive HCV antibody test, but negative HCV RNA test, is allowed  
11. Active tuberculosis  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 60 of 109 
 12. Significant cardiovascular disease, such as [LOCATION_001] Heart Association Class II 
or greater cardiac disease, myocardial infarction, or cerebrovascular accident within 3 months of Day  1, unstable arrhythmia, or unstable angina  
13. Has received prior systemic anti -cancer therapy including investigational agents 
within 4 weeks or 5 elimination half -lives—whichever is shorter —prior to treatment 
or has not recovered from all AEs due to previous therapi[INVESTIGATOR_24305] ≤Grade 1 or baseline. Participants with ≤Grade 2 neuropathy are eligible  
a. Note: Anti -PD-1/L1 within [ADDRESS_1086265] recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment  
14. History of other malignancy within 2 years prior to  Day 1, with the exception of 
those with a negligible risk of metastasis or death (eg, resected cutaneous basal cell carcinoma, or other cancers with 5- year OS of >90%)  
15. Severe infection within 4 weeks prior to  Day 1, including, but not limited to, 
hospi[INVESTIGATOR_33377], bacteremia, or severe pneumonia  
a. Prophylactic antibiotics (eg, to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are allowed  
16. Prior allogeneic stem cell or solid organ transplantation  
17. Treatment with a live, attenuated vaccine within 4 weeks prior to  Day 1 
18. Treatment with systemic immunosuppressive medication within 4 weeks prior to  
Day 1, with the following exceptions:  
a. Participants who received acute, low -dose systemic immunosuppressant 
medication or a one- time pulse dose of systemic immunosuppressant 
medication (eg, [ADDRESS_1086266] allergy) are eligible  
b. Patients receiving mineralocorticoids (eg, fludrocortisone), or systemic prednisone equivalent corticosteroid doses of <10mg per day are eligible for the study  
19. Known hypersensitivity to pembrolizumab, nivolumab,  or any of the respective 
excipi[INVESTIGATOR_840]  
20. Requires therapeutic anticoagulation and cannot discontinue anticoagulation safely during the day prior, day of, and day after  each lerapolturev  injection  
a. NOTE: Participants  receiving anticoagulation with warfarin at the time of 
study entry  are allowed if they can be transitioned to an alternative 
anticoagulant (eg,  low molecular weight heparin or direct oral 
anticoagulants) prior to the first dose of lerapolturev . Anyone transitioned 
from warfarin to an oral anticoagulant prior to the first dose of lerapolturev should have an INR <1.5x upper limit of normal in order to participate.  
Antiplatelet agents (eg,  aspi[INVESTIGATOR_248], clopi[INVESTIGATOR_7745], etc.) are not considered 
anticoagulants for the purposes of this study  (ie, are allowed)  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 61 of 109 
 21. A pregnant or nursing female, or women of child- bearing potential and men who 
are sexually active and not willing/able to use medically acceptable forms of 
contraception starting from signed ICF through [ADDRESS_1086267] of the participant (eg, compromises the participant’s well -being) or that could prevent, limit, or confound protocol -
specified assessments  
 
4.3 Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study 
but are not subsequently enrolled . A minimal set  of screen failure information  
(demography, screen failure details, eligibility criteria, and any SAEs)  will be collected to  
ensure transparent reporting.  
Individuals who do not meet the criteria for participation in this study  may be rescreened.  
Rescreening is at the discretion of the Investigator.   Participants who are to be rescreened 
based on a laboratory exclusion are not required to reconsent. Otherwise, a new ICF  is 
required  before rescreening and the participant  must be assigned a new participant 
number.   
5 STUDY DRUG  (LERAPOLTUREV, NIVOLUMAB OR PEMBROLIZUMAB)  
5.1 Lerapolturev : Packaging, labeling and how supplied  
Lerapolturev  is a modified version of the serotype 1 live- attenuated (Sabin) PV vaccine 
(PV1S) and is classified as an oncolytic viral immunotherapeutic.  
Lerapolturev  is formulated in 50 mM sodium phosphate in 0.9% sodium chloride, pH 7.4 
with 0.2% human serum albumin (HSA) in phosphate buffered saline (PBS). Lerapolturev  
is provided in sterile, single use glass vials with a flip off top  containing  approximately 
0.5 mL of stock lerapolturev  (2.24 x 10
9 TCID 50).  
5.2 Preparation/Handling/Storage/Accountability  
For complete lerapolturev storag e, handling,  and preparation instructions , please refer to 
the pharmacy manual . Lerapolturev  preparation  with Sponsor -supplied vehicle must 
occur in  a biosafety cabinet or similarly contained environment  in the institution’s 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086268] with the study agent, eg,  pi[INVESTIGATOR_6343], vials, etc., should be disposed 
of as biological waste. The minimum final desired volume of the study agent for injection 
is 0.5 ml, and the maximum volume will be 3.0 ml. The final volume should be drawn into 
the intended delivery device(s) (See pharmacy manual for list of needles/syringes that 
are acceptable for lerapolturev administration) .  
5.3 Lerapolturev Dose, Schedule, and Administration 
Dose:  Lerapolturev  should  be administered at a fixed concentration of 5.33 x 108 
TCID 50/ml in accordance with the pharmacy manual (PM) . Please refer to the PM for 
complete information  regarding lerapolturev administration . The maximum volume 
injected at an individual  treatment visit will be 3  ml, which  is dependent on the number 
and size of injectable lesions . This  corresponds to a maximum lerapolturev  dose of 
1.6 x 109 TCID 50. The minimum  injection  volume is 0.5 ml ( ie, minimum lerapolturev  dose 
2.67 x 108 TCID 50). Up to 6 lesions  may be injected at  an individual treatment visit . It is 
possible that more than 1 syringe may be required to treat a single lesion, due to large 
lesion size. See Table 7 for recommended lerapolturev injection volumes. See 
Section  3.1.2  for instructions regarding lerapolturev dose for participants receiving the 
Q3/4W schedule  of injections .  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 63  of 109  
 Table 7. Recommended Lerapol turev  Injection Volumes  
Lesion Size (longest 
dimension [cm]) Maximum Injection Volume  
Per Lesion (ml) Lerapolturev 
Concentration 
(TCID 50/ml) 
≥ 5  3.0  
5.33 x 108 ≥ 4 and < 5  2.0 
≥ 3 and < 4  1.5  
≥ 2 and < 3 1.0 
0.5 to <2.0  0.5 
Schedule:  Participants will receive lerapolturev  injections using the QW schedule which 
is defined as weekly x 7 followed by [INVESTIGATOR_135] 3 weeks (pembrolizumab) or every 4 weeks 
(nivolumab).  See Section 3.1.1  for instructions of what injection schedule to use upon 
crossover.  See Section 3.1.2  for instructions of what injection schedule to use for 
participants receiving the Q3/4W  schedule.  
Key Considerations Regarding Lerapolturev Injection:  
• Where possible , at least one RECIST1.1/iRECIST target lesion should remain 
uninjected for as long as feasible  while on study  to facilitate the anti -tumor 
response assessment  of non- injected target lesions.  
• Participants with lesions known to be sensitive to intratumoral injection (ie, are 
painful, such as in transit lesions  with limited subcutaneous tissue on the shin) may 
receive reduced injection volumes relative to  the recommended volume for a given  
tumor size, per investigator’s discretion, to manage tumor -related pain. However, 
the minimum allowable injection volume for a given lesion is  0.5 ml. 
• Any lesion that is visible or palpable may be injected; lesions located in sites 
considered to be of more significant risk for complications from lerapolturev  
injection and associated inflammation (eg brain, lung, mediastinum, liver, pancreas, other visceral organs, lesions subjected to curative levels of radiation 
where radiation- associated toxicity has not healed, lesions encasing or 
immediately adjacent to major blood vessels including the carotid artery) are not to be injected in this study.  Ultrasound may be used to better  visualize the lesion 
during lerapolturev  injection to optimize participant  safety. 
• Participants may  stop receiving lerapolturev  injections upon confirmation of CR or 
upon resolution of all injectable lesions (participants in Arm 2 should continue anti -
PD-1 maintenance per manufacturer’s prescribing instructions ) and should be 
observed until progression/recurrence, at which point  retreatment with lerapolturev  
is allowed . This process of injection, discontinuing injections and retreatment with 
injection may occur for a maximum of three times.  
o Participants receiving single -agent lerapolturev with a CR or complete 
resolution of all injectable disease (ie, other non- injectable disease persists) 
can crossover to Arm 2 upon progression.  If upon progression, there are no 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 64 of 109 
 injectable lesions, the participant should begin anti -PD-1 therapy  
monotherapy  upon crossover .  
• Lerapolturev  injections should be administered concurrently with anti -PD-1 therapy  
during the “ maintenance”  schedule, (ie, Q3W for pembrolizumab and Q4W for 
nivolumab) . Note that lerapolturev  should be continued Q3W in the event 
pembrolizumab is administered on a Q6W cycle  or Q4W in the event nivolumab is 
administered on a Q2W cycle.   
• Where poss ible, participants should receive the same anti -PD-[ADDRESS_1086269] to length of exposure and/or management (eg, dose delay  or 
discontinuation) of irAEs .  
Administration: Lerapolturev  administration should be performed in accordance with the 
Pharmacy Manual. Anticoagulant and antiplatelet medications will be managed by [CONTACT_47806], per local institutional guidelines, to optimize the safety of intratumoral 
injection of lerapolturev . 
5.4 Prior/ Concomitant Therapy  
There are no currently known contraindications or drug- drug interactions for lerapolturev  
(per the IB) , pembrolizumab,  or nivolumab as per FDA -approved package labeling. All 
medical conditions should be treated by [CONTACT_941] i nvestigator per current standard of care. 
Participants may also receive medications for symptomatic relief (ie, analgesics, 
laxatives, anti -emetics).  
• NOTE:  Lerapolturev administration in combination with an anti -PD-L1 therapy is 
not allowed during this study  
Medications  the participant has received within [ADDRESS_1086270] dose of study drug(s)  should be recorded in the eCRF . This includes , but is not limited 
to, prescription medications, over -the-counter medications, injected medications, 
natural/herbal remedies, biological products, blood products, imported drugs, or “street ” 
drugs.  Subsequent anticancer therapy should be collected until the end of study.  
Prohibited Therapi[INVESTIGATOR_014]:  
Concomitant treatments that could prevent or mask potential AEs related to the investigational treatment or confound the assessment of its anti -tumor efficacy are not 
permitted, as far as the participant’s safety is protected.  
 
Administration of other systemic concomitant non- protocol anticancer therapi[INVESTIGATOR_788894], with the exception of adjuvant endocrine therapy for breast cancer or prostate cancer defined as M0 disease or PSA 
persistence/recurrence without metastatic disease. Local treatment of isolated lesion(s) 
with palliative radiation therapy or surgery is permitted to control disease symptoms but 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 65 of 109 
 not to aid in the response of the tumor. If the lesion(s) treated is being followed for 
evaluation by [CONTACT_393] (target or nontarget lesion), then “not evaluable” should be 
reported in the eCRF for this lesion at subsequent disease assessments following 
palliative radiotherapy or surgery. Participants  requiring palliative radiation may continue 
receiving study drug until documented disease progression (radiographic or clinical) if, in the Investigator’s opi[INVESTIGATOR_1649], the participant  is continuing to receive clinical benefit and they 
meet the requirements described in Section 6.2. However, for  participants  who have not 
had disease progression at the time of the need for palliative radiation therapy or surgery, 
the requirement for intervention will be regarded as disease progression in the study’s 
analyses and will be entered as such in the eCRF . 
 
The following medications are also not permitted:  
• Non-protocol specified investigational drugs.  
• Use of topi[INVESTIGATOR_788895] . 
• Anticoagulant use the day prior to, day of and the day following lerapolturev 
injection. Warfarin use is not allowed at any time  during study participation. 
Antiplatelet agents , such as  aspi[INVESTIGATOR_248], clopi[INVESTIGATOR_7745], etc. , are not considered 
anticoagulants for the purposes of this study  and are allowed.   
• Live virus vaccines (beyond lerapolturev )  
o Examples of live virus vaccines include, but are not limited to, measles, 
mumps, rubella, varicella/zoster, yellow fever, rabies, and typhoid vaccine.  
o Seasonal influenza vaccines for injection are generally killed virus vaccines 
and are allowed; however, intranasal influenza vaccines (eg, FluMist
®) are 
live attenuated vaccines and are not allowed . 
COVID -19 Vaccination : 
Vaccination against COVID -19 is allowed on  study, provided the vaccine is not based on 
a live virus (eg, the Johnson and Johnson single- dose vaccine or [COMPANY_008] vaccine).  
While on study, i t is recommended that participant s vaccinated  with non-live virus 
vaccines (eg, mRNA -based vaccines)  receive  the vaccine at least [ADDRESS_1086271] 4 weeks 
removed from vaccine administration.   
5.5 Dose Modification/Toxicity Management Guidelines  
5.5.1  Lerapolturev  
For AEs related to lerapol turev, lerapolturev  may be withheld or permanently 
discontinued based on the severity of the adverse reaction.  
 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086272] CTCAE 
Grade 1 or has returned to baseline:  
• Grade 2 or greater irAE, with the exception of  vitiligo  
• Grade 2 or greater allergic  reactions  
• any other G rade 3 or greater hematologic or non- hematologic  toxicity  
For participants receiving concurrent lerapolturev and anti -PD-1 therapy , lerapolturev and 
the anti -PD-1 therapy  can be administered independently of each other where 
appropriate. S hould the investigator determine an AE is related to anti -PD-1 therapy  and 
not lerapolturev , continuation of lerapolturev injections is allowed (or vice versa) . 
However, if the AE is determined to be related to the combination, this should be noted 
and treatment with both therapi[INVESTIGATOR_788896], as described above.  
 Permanent  Discontinuation:  
Lerapolturev should be permanently discontinued if any lerapolturev -related Grade 3 or 
greater hematologic or non- hematologic toxicity fails to resolve to Grade 1 or baseline 
OR occurs more than twice (ie,  three epi[INVESTIGATOR_1841] = permanent  discontinuation) . 
 
5.5.2  Anti-PD-1 Therapy  
For suspected  irAEs  related to anti -PD-1 therapy , the anti-PD-1 therapy  may be withheld 
or permanently discontinued based on the severity of the adverse reaction, in accordance 
with FDA-approved package labeling and physician discretion.   
 Withholding a nti-PD-1 Therapy:  
The anti -PD-[ADDRESS_1086273] be withheld for any of the following:  
• Grade 2 pneumonitis  
• Grade 2 or 3 colitis  
• Grade 3 or 4 endocrinopathies  
• Grade 2 nephritis  
• Grade 3 severe skin reactions or suspected Stevens -Johnson syndrome (SJS) or 
toxic epi[INVESTIGATOR_194] (TEN)  
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) greater than 3 and up to 5 times upper limit of normal (ULN) or total bilirubin greater than 1.[ADDRESS_1086274]  
• Any other severe or Grade 3 treatment -related AE  
 
Lerapolturev is not required to be withheld for participants enrolled in Arm 2, provided the 
investigator determines the AE requiring holding of the anti-PD-1 dose is not related to  or 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 67 of 109 
 worsened by  [CONTACT_788926] . The anti -PD-1 therapy  can resume in participants whose 
adverse reactions recover to Grade ≤ 1 or baseline.  
Permanent  Discontinuation:  
Anti-PD-1 therapy should be permanently discontinued for any of the following AEs   
• Any life -threatening adverse reaction (excluding endocrinopathies controlled with 
hormone replacement therapy)  
• Grade 3 or 4 pneumonitis or recurrent pneumonitis of Grade 2 severity  
• Grade 3 or 4 nephritis  
• Grade 4 severe skin reactions or confirmed SJS or TEN  
• AST or ALT greater than [ADDRESS_1086275] or ALT increases by [CONTACT_13801] 50% relative to baseline and lasts for at least 1 week  
• Total bilirubin greater than [ADDRESS_1086276].  
• Grade 3 or 4 infusion- related reactions  
• Inability to reduce corticosteroid dose to 10 mg or less of prednisone or 
equivalent per day within 12 weeks  
• Persistent Grade 2 or 3 adverse reactions (excluding endocrinopathies controlled with hormone replacement therapy) that do not recover to Grade [ADDRESS_1086277] dose of the anti -PD-1 
• Any severe or Grade 3 treatment -related adverse reaction that recurs  
 
Management of anti -PD-1-related  irAE:   
Always refer to the manufacturer’s prescribing information for the most current recommendations for management of irAE. Additional information can also be found in 
the NCCN Guidelines for Management of Immunotherapy -Related Toxicities
40.  
• Suspected pneumonitis:  Participants should be evaluated with radiographic 
imaging. They will receive corticosteroids (initial dose of 1 to 2 mg/kg/day 
prednisone or equivalent followed by a taper) for Grade [ADDRESS_1086278] be withheld for moderate ( Grade 2) pneumonitis, and 
permanently discontinued for severe (Grade 3), life- threatening (Grade 4), or 
recurrent moderate (Grade 2) pneumonitis.  
• Colitis:  Participants must be monitored for signs and symptoms of colitis and 
administered corticosteroids (initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed by a taper) for Grade [ADDRESS_1086279] 
be withheld for moderate ( Grade 2) or severe (Grade 3) colitis, and permanently 
discontinued for life- threatening (Grade 4) colitis.  
• Hepatitis:  Participants must be monitored for changes in liver function tests. They 
must receive corticosteroids (initial dose of 0.5 to 1 mg/kg/day [for Grade 2 
hepatitis] and 1 to 2 mg/kg/day [for Grade 3 or greater hepatitis] prednisone or 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 68  of 109  
 equivalent followed by a taper) and, based on severity of liver enzyme elevations, 
the anti -PD-[ADDRESS_1086280] be discontinued.  
• Hypophysitis (including hypopi[INVESTIGATOR_44791]):  Participants 
must be monitored for signs and symptoms of endocrine origin. They will receive 
corticosteroids and hormone replacement as clinically indicated. The anti -PD-[ADDRESS_1086281] be withheld for moderate (Grade 2) and severe (Grade 3) hypophysitis and must be discontinued for severe (Grade 3) hypophysitis that does not recover or 
life-threatening (Grade 4) hypophysitis.  
• Thyroid disorders:  Anti-PD-[ADDRESS_1086282] be followed 
for changes in thyroid function (at the start of treatment, periodically every 4 to  6 
weeks during treatment, and as indicated based on clinical evaluation) and for clinical signs and symptoms of thyroid disorders  per the SOA ( Table 1 or Table 2 
[Arm 2 lerapolturev + nivolumab] ). Hypothyroidism  will be treated by [CONTACT_788927]. Hyperthyroidism will be managed with thionamides and beta- blockers 
as appropriate. The anti -PD-[ADDRESS_1086283] be withheld or discontinued for severe 
(Grade 3) or life- threatening (Grade 4) hyperthyroidism.  
• Hyperglycemia:  Participants must be regularly monitored for blood glucose or 
other parameters of Type [ADDRESS_1086284] be treated with insulin and the 
anti-PD-1 withheld. In case of severe (Grade 3) hyperglycemia, they will receive 
anti-hyperglycemics.  
• Nephritis:  Participants must be evaluated for renal function. They will be given 
corticosteroids (initial dose of 1 to 2 mg/kg/day prednisone or equivalent followed 
by a taper) for Grade [ADDRESS_1086285] be withheld for 
moderate (Grade 2) n ephritis and must be permanently discontinuation for 
severe (Grade 3) or life- threatening (Grade 4) nephritis.  
• Skin disorders:  Immune -mediated rashes, including Stevens -Johnson Syndrome 
(SJS) and Toxic Epi[INVESTIGATOR_19342] (TEN) (some cases with fatal outcome), exfoliative dermatitis, and bullous pemphigoid, can occur. Participants must be 
monitored for suspected severe skin reactions and exclude other causes. Based 
on the severity of the adverse reaction, the anti -PD-[ADDRESS_1086286] be withheld or 
permanently discontinued. Participants with Grade 2 or higher dermatologic 
toxicity will receive topi[INVESTIGATOR_80129]/or systemic corticosteroids (initial 
dose 0.5 – 1.0 mg/kg/d prednisone or equivalent) . For signs or symptoms of SJS 
or TEN, the anti -PD-[ADDRESS_1086287] be permanently discontinued.  
• Infusion related reactions:  During infusion, monitor patients for signs and 
symptoms of infusion- related reactions including rigors, chills, wheezing, pruritus, 
flushing, rash, hypotension, hypoxemia, and fever. For severe (Grade 3) or life -
threatening (Grade 4) infusion- related reactions, stop infusion and permanently 
discontinue pembrolizumab. Follow the recommend management practices noted 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 69  of 109  
 in the current package insert or in keepi[INVESTIGATOR_788897]-PD-1 agent  infusion.  For severe or  
life-threatening  infusion related reactions,  this may include IV 
dexamethasone  followed by [CONTACT_13215]. Other immunosuppressive treatment 
should also be initiated if  the reaction cannot be controlled 
by [CONTACT_788928].   
Management of AEs related to CRS or I CANS:  
Administration of lerapolturev  has not been associated with CRS or ICANS in the limited 
number of melanoma patients treated to date , or in the 190 patients treated with 
lerapolturev  in other indications (Istari data on file) . However, the current study is 
investigating lerapolturev  in conjunction with concurrent anti -PD-[ADDRESS_1086288] (AE SI) 
will occur in this trial, which are each defined in Section 9.2. This includes reporting any 
AESI of CRS or ICANS within 24 hours of awareness of the event, regardless of severity 
or seriousness.    
NOTE:  Per the American Society for Transplantation and Cellular Therapy (ASTCT) 
consensus guidelines41, symptoms of CRS or ICANS are primarily experienced in the first 
two weeks of therapy.  
Participants with suspected CRS should have lerapolturev and/or anti-PD1 therapy held , 
and a blood sample should be  obtained and sent to the central laboratory for cytokine 
profiling . Therapy may resume upon resolution of CRS -related AEs to Grade 1 or 
baseline, per investigator discretion.  ASTCT41 and/or institutional guidelines for treatment 
should be applied  for management of CRS , including the use of corticosteroids and 
tocilizumab for Grade [ADDRESS_1086289] lerapolturev 
and/or  anti-PD-[ADDRESS_1086290] a neurological exam that includes the 
Immune Effector Cell -Associated Encephalopathy (ICE) screening tool ( Appendix I ) per 
ASTCT guidelines , as well as a blood sample obtained for cytokine profiling as above.  
ASTCT
41 and/or institutional  treatment guidelines should be followed for ICANS -related 
AE management , including the administration of corticosteroids, or whether or not to 
resume study therapy upon AESI resolution .   
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 70 of 109 
 6 DISCONTINUATION OF STUDY TREATMENT , TREATMENT BEYOND 
PROGRESSION , PARTICIPANT COMPLETION AND WITHDRAWAL , AND 
STUDY  TERMINATION 
6.1 Discontinuation of Study Treatment  
Study drug(s) (defined as lerapolturev, nivolumab or pembrolizumab)  will be discontinued 
if any of the following events occur during the study:  
• A participant  suffers an AE that, in the judgment of the Investigator, Sponsor, or 
Medical Monitor, presents an unacceptable risk to the participant  
• General or specific changes in the participant’s  condition (eg, a significant 
intercurrent illness or complication) that, in the judgment of the Investigator, are 
unacceptable for further administration of study drug  
• Occurrence of pregnancy during the study  
• Significant noncompliance with protocol requirements  
• The Sponsor or legal representative of the Sponsor requests the participant  to 
withdraw  
• Withdrawal of consent  
 
• Lost to follow -up 
 
• Participant  has radiologically documented disease progression and the physician 
determines the participant  is not deriving clinical benefit as defined in Section 6.2 
• Where permanent discontinuation of all study drugs is indicated in the dose modifications guidelines ( see Section 5.5) 
At the time of study drug discontinuation, an EOT visit  should be completed with 
assessments performed as shown in appropriate General Schedule of Assessments 
(Table 1 or Table 2 depending on treatment group). The Investigator or Designee will 
document the reason for study drug discontinuation on the applicable electronic case 
report form  (eCRF ). When discontinuation is due to a SAE or a Grade 3 or 4 toxicity 
considered to be related to study drug(s), the Investigator should follow the event until resolution, return to baseline, or it is deemed that further recovery is unlikely. Data on 
these events should be collected in  the eCRF. In the event a participant discontinues due 
to pregnancy, the Investigator or designee should notify the Medical Monitor by [CONTACT_155417] 24 hours of pregnancy confirmation (see Section 7.3.5).  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086291] 1.1 should 
only be considered if a participant  is clinically stable and has the following:  
• Evidence of clinical benefit as assessed by [CONTACT_941] I nvestigator ; assessment of clinical 
benefit should take into account whether the participant  is clinically deteriorating 
and unlikely to receive further benefit from continued treatment  
• Absence of symptoms and signs (including worsening of laboratory values; eg, new or worsening hypercalcemia) indicating unequivocal progression of disease  
• No decline in ECOG performance status that can be attributed to disease progression  
• Absence of tumor growth at critical anatomical sites (eg, leptomeningeal disease) that cannot be managed by [CONTACT_990] -allowed medical interventions  
Decisions to continue treatment beyond initial progression per RECIST 1.1 may be 
discussed with the medical monitor and should be documented in the study records.  
Participants  with radiographic disease progression confirmed at a subsequent tumor 
assessment  (ie, iCPD)  may be considered for continued study treatment at the discretion 
of the investigator if they continue to meet the criteria above and have evidence of clinical benefit.  
6.3 Participant Withdrawal from the Trial  
Participants may be withdrawn from the study under any of the following circumstances:  
 
• Withdrawal of consent  
• Lost to follow -up 
• Administrative reasons (eg, Sponsor decision)  
• Major violation of the protocol  
• If in the opi[INVESTIGATOR_2511] i nvestigator , it is in the best interest of the participant  
• Non-compliance  
• Termination of the study  
Participant follow -up should continue as specified in the protocol until the scheduled date 
of study completion, or until recovery or stabilization of an AE, whichever comes last. A ll 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 72 of 109 
 participants that permanently discontinue study treatment should be followed for survival 
and disease progression outcomes; these assessments may be made via telephone 
contact [CONTACT_788929] -up is not possible.  A t minimum, all  participants  should have  an EOT 
visit that includes  tumor measurements  (imaging and cutaneous measurements) and a 
focused physical assessment  prior to study withdrawal . Chemistry and hematology 
should be collected, if possible. Investigators should also provide a final and best over all 
anti-tumor response assessment with the eCRF.  
Lost to Follow -up 
A participant will be considered lost to follow -up if they fail to return for [ADDRESS_1086292] be taken if 
a participant fails to return to the clinic for a required study visit : 
• The site must attempt to contact [CONTACT_2299], reschedule the missed visit as 
soon as possible, counsel the participant on the importance of maintaining the 
assigned visit schedule, and ascertain whether the participant wishes to and/or 
should continue in the study.  
• Before a participant is deemed lost to follow -up, the i nvestigator or designee 
must make every effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if necessary, a certified letter to the participant’s last 
known mailing address or local equivalent methods). These contact [CONTACT_13140]’s medical record.  
• Should the participant continue to be unreachable, they will be considered to 
have withdrawn from the study.  
Participants  who are lost to follow -up may be replaced at the Sponsor’s discretion.  
6.4 Study Termination  
The entire study may be terminated by [CONTACT_788930]:  
• Upon discussion with the Data and Safety Monitoring Committee, the occurrence 
of AEs unknown to date with respect to their nature, severity, and duration, or an 
unexpected increase in the incidence of known AEs.  
• Medical or ethical reasons affecting the continued performance of the study  
• Difficulties in the recruitment of participants  
• Cancellation of the drug development program  
• Sponsor decision for other reasons  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 73 of 109 
 7 STUDY ASSESSMENTS AND PROCEDURES  
Study procedures and their timing are summarized in the S OAs (Table 1 and Table 2 
[Arm 2: lerapolturev + nivolumab] ). Adherence to the study design requirements, including 
those specified in the S OA, is essential and required for study conduct.  Immediate safety 
concerns should be discussed with the S ponsor immediately upon occurrence/ awareness 
to determine if the participant should continue or discontinue the study  drug treatments .  
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria  prior to randomization. The investigator will maintain 
a screening log to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.  
Procedures conducted as part of the participant’s routine clinical management (eg, blood count , scans) and obtained before signing of the ICF may be utilized for screening 
purposes provided the procedures met the protocol -specified criteria and were performed 
within the time frame defined in the S OA.  
7.1 Efficacy Evaluations  
Anti-tumor evaluations will be conducted as specified in the appropriate SOA (Table 1 
and Table 2 [Arm 2: lerapolturev + nivolumab] ). Unscheduled assessments should be 
considered if clinically indicated, and results collected in the eCRF. The anti -tumor activity 
evaluations include the following:  
• Tumor measurements:  All participants will undergo an extent of disease evaluation 
consisting of a chest, abdomen and pelvis CT, a brain MRI  and skin caliper 
measurement  (with photograph)  of target lesions. Designation of which lesions are 
to be target lesions  for assessment of anti -tumor response should be based on 
RECIST  1.1 guidelines. All participants will undergo repeat evaluations of their 
extent of disease per the S OA, or as clinically indicated. Imaging modalities should 
remain consistent throughout study. Evaluation of treatment response by [CONTACT_788931]/or caliper /ruler  measurement will be performed according to RECIST  1.1 
criteria  (NOTE: evaluation of tumor response per iRECIST is exploratory). Where 
possible, t arget lesions for assessment of  tumor response should be separate from 
lesions chosen for biopsy (injected or non -injected).  RECIST/iRECIST target 
lesions are not required to be lesions injected with lerapolturev . Participants 
without evidence of CNS disease at screening are not required to have brain MRI 
while on study, provided they remain without clinical evidence of progression in the 
CNS space.  
o NOTE: All MRIs should be performed with and without contrast, provided 
the participant  can tolerate the contrast agent.  A CT of the brain (with IV 
contrast if not contraindicated)  may be performed in lieu of an MRI for those 
participants unable to receive an MRI .  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 74 of 109 
 • Long term follow -up: Study personnel will obtain survival information and 
radiographic scans (if the participant discontinued study for any reason other than 
radiographic progression or death) per SOC  during the follow -up phase. Personnel 
should collect this information  (including post -study anti -cancer therapi[INVESTIGATOR_014])  during 
a participant’s routine clinic visit, review of the local medical records, by 
[CONTACT_788932], or review of the Social Security 
Death I ndex . 
7.2 Safety Assessments  
7.2.1  Physical Examination  and Vital Signs  
The screening physical examination will be a complete physical exam of major body 
systems and include, the general appearance of the participant , height and weight, vital 
signs (temperature, blood pressure (systolic and diastolic blood pressure [mmHg]) , 
respi[INVESTIGATOR_697], and heart rate (bpm) ), examination of the skin, ears, nose, throat, lungs, 
heart, abdomen, extremities, musculoskeletal system, lymphatic system, and nervous system. During the Treatment Phase and at the EOT visit, focused and symptom -direc ted 
physical examination and weight assessment should be performed per the corresponding  
SOA (Table 1 and Table 2 [Arm 2: lerapolturev + nivolumab])  or as clinically indicated. In 
addition, an evaluation of all skin lesions, including those injected with lerapolturev at the 
previous treatment visit, should be performed prior to subsequent lerapolturev injection 
while on study. Only clinically relevant abnormalities found during the screening physical 
examination should be recorded and reported in the  medical history  eCRF . Clinically 
relevant abnormalities that present during study participation should be reported as AEs, 
where appropriate.  
7.2.2  Clinical Safety Laboratory Assessments  
Laboratory assessments that will be conducted during the study are listed below:  
• Hematologic assessments include c omplete blood count with differential , which 
measures the following:  
• Hemoglobin  
• WBC count with differential   
• Platelet count  
• Chemistry assessments including  the following analytes:  
• LDH 
• Glucose   
• Calcium  
• Sodium  
• Potassium   
• Bicarbonate  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 75 of 109 
 • Chloride  
• BUN 
• Creatinine  
• Total protein  
• Albumin  
• ALP 
• AST 
• ALT 
• Total bilirubin  
• Amylase  
• Lipase  
• INR, PT, PTT (or aPTT) , as performed/reported per institutional standards  
• Beta-hCG, if applicable, within 2 days prior to  Day 1  and approximately every 12 
weeks  thereafter, while on study  
• TSH, free T 4, and free T3  
All protocol -required laboratory assessments, as outlined above, must be conducted in 
accordance with the laboratory manual and the appropriate SOA  (Table 1  and Table 2 
[Arm 2: lerapolturev + nivolumab]) . The investigator must review the laboratory report, 
document this review, and record any clinically relevant changes occurring during the 
study as AEs in the eCRF. The laboratory reports must be filed with the source 
documents. Clinically significant abnormal laboratory findings are those which are not associated with the underlying disease, unless judged by [CONTACT_788933] t he participant's condition.  
All laboratory tests with values considered clinically significantly abnormal after the first 
lerapolturev injection through EOT visit  should be repeated approximately weekly until 
the values return to Grade 1 or baseline,  or are no longer considered clinically significant 
by [CONTACT_10982].  
If such values do not return to ≤Grade 1 or  baseline within a period of time judged 
reasonable by [CONTACT_093], the etiology should be identified  and entered as an AE (as 
applicable) , and the Sponsor notified.  
If laboratory values from non- protocol specified laboratory assessments performed at the 
institution’s local laboratory require a change in participant management or are considered clinically significant by [CONTACT_093] (eg, SAE , AE, or dose modification), 
then the results must be recorded in the e CRF.  
NOTE:  Only report clinically significant laboratory abnormalities as AE  when a diagnosis  
for the condition resulting in the laboratory abnormality  is not available/not possible.  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086293]  and Serious Adverse Events  
Potential AEs will be spontaneously solicited from the participant  (or, when appropriate, 
by a caregiver, surrogate, or the participant 's legally acceptable representative) for the 
duration of the study.  
The definitions of an AE , irAE, AESI, or SAE can be found in Section 9.2.  
The investigator and any qualified designees are responsible for detecting, documenting, 
and recording events that meet the definition of an AE , irAE, AESI, or SAE and remain 
responsible for following up AEs that are serious, considered related to lerapolturev 
and/or lerapolturev in combination with anti -PD-[ADDRESS_1086294]   
Table 4 provides an overview of the time periods and frequency for AE,  irAE,  SAE, and 
AESI reporting. Any AEs and SAEs related to screening procedures that are not SOC 
(eg, PV vaccination booster)  will be collected from signing of the ICF. All other 
AEs/AESI/SAEs will be collected upon commencement of lerapolturev administration (ie,  
events that are treatment emergent). Collection of AEs will continue until 30 days  and 
SAEs and AESIs for 90 days  after completion of the participant's last dose of study 
drug(s) , including any contact [CONTACT_20687] -up of safety  (Note: treatment -related SAEs will 
be followed until resolution or stabilization ). The investigator will immediately report to the 
Sponsor any SAE  (whether or not considered study drug- related, including t hose listed in 
the protocol or I B) and must include an assessment of whether there is a reasonable 
possibility that lerapolturev  caused the event.  
Disease progression is not to be reported as an AE/SAE.  
 
  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 77  of 109  
 Table 8. Time Windows and Frequency for Reporting Based on AE Type  
 Reporting  
 Start  End Timeframe  
SAE Signing of ICF  ≤[ADDRESS_1086295] 
dose of 
lerapolturev or 
anti-PD-1:  all SAE  
 Within 24 hours of awareness  
AE • During screening, 
only AE deemed 
related to PV 
booster  or 
mandatory per 
protocol biopsy  
• All other  AE after 
1st lerapolturev  
injection  ≤[ADDRESS_1086296] dose of lerapolturev or 
anti-PD-1 Per study agreement  
AESI  & 
irAE • During screening, only if deemed 
related to PV 
booster  
• After 1
st 
lerapolturev  
injection  ≤[ADDRESS_1086297] 
dose of 
lerapolturev or 
anti-PD-1 • For irAE: Per study agreement  
• For CRS or ICANS  ONLY :  
o Within 24 hours of 
awareness  
• For ISR: 
o Grade 3/4:  Within 24 
hours of awareness  
o Grade1/2 ISR: Per 
study agreement  
 
All SAEs will be recorded and reported to the S ponsor or designee within 24 hours, as 
indicated in Section 9.2. The investigator will submit any updated SAE data to the S ponsor 
within 24 hours of it being available.  In addition, any AESI of CRS , ICANS , or Grade 3  or 
4 injection site reaction ( ISR), should also be reported to the Sponsor within 24 hours, 
regardless of seriousness  per the study ’s safety reporting guidelines . An AESI of Grade 
1 or 2 ISR should be reported in accordance with the site’s study agreement .  
Investigators are not obligated to actively seek AE s, irAEs, AESIs  or SAE s after 
conclusion of the study participation. However, if the investigator learns of any SAE, 
including a condition resulting in death, at any time after a participant has been discharged 
from the study, and he/she considers the event to be reasonably related to lerapolturev , 
lerapolturev in combination with anti -PD-[ADDRESS_1086298] 
promptly notify the S ponsor  or designee. 
The method of recording, evaluating, and assessing causality of AE s, irAEs, AESIs  and 
SAEs, and the procedures for completing and transmitting SAE reports , are provided in 
Section 9.2. 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086299]  and S erious Adverse Events 
Care will be taken not to introduce bias when detecting AEs , irAEs, AESIs  and/or SAEs. 
Open- ended and non- leading verbal questioning of the participant is the preferred method 
to inquire about AE occurrences.  
7.3.[ADDRESS_1086300]  and Serious Adverse Events  
After the initial AE/ irAE/AESI/ SAE report, the investigator is required to proactively follow 
each participant at subsequent visits/contacts. All SAEs  and non- serious irAEs  and AESI s 
(see Section  9.2) will be followed until satisfactory resolution, the investigator deems the 
event to be chronic, the participant is stable, or the participant is lost to follow -up (as 
defined in Section  6.3). Supporting documentation of the event may be requested by [CONTACT_788934]. Further information on follow -up 
procedures is provided in Section 9.2. 
7.3.4  Regulatory Reporting Requirements for S erious Adverse Events 
The investigator is required to prompt ly (ie, within 24 hours)  notify the Sponsor of the 
occurrence of an SAE, so that legal and ethical  obligations  towards the safety of 
participants and the safety of a study drug  under clinical investigation are met.  
The Sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study drug  under clinical investigation. 
The Sponsor will comply with country -specific regulatory requirements relating to safety 
reporting to the regulatory authority, Institutional Review Boards (IRB)/Independent 
Ethics Committees (IEC), and investigators.  
Investigator safety reports must be prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R s) according to local regulatory requirements and S ponsor policy and 
forwarded to investigators as necessary.  
An investigator who receives an investigator safety report describing a n SAE or other 
specific safety information (eg, summary or listing of SAEs) from the Sponsor will review 
and then file it along with the I B and will notify the IRB/IEC, if appropriate,  according to 
local requirements.  
  
7.3.[ADDRESS_1086301] immunization of trivalent inactivated 
IPOL ™, risk of lerapolturev  transmission from mother to fetus after intratumoral injection 
is expected to be limited.  Because risk is unknown, all participants will be required to 
utilize contraception during receipt of lerapolturev injections.  In addition , use of PD -[ADDRESS_1086302] dose received.  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086303] dose.  If a 
pregnancy is reported, the investigator should inform the Sponsor within 24 hours  of 
learning of the pregnancy.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs . 
7.4 Tissue and Blood- Based Biomarker  and Cytokine Analyses  
Tissue Biopsy Collection: P articipants are required to submit a baseline tumor biopsy  to 
enroll in the study.  Submission of archival tissue is allowed if collected within 4 months 
prior to Cycle 1,  Day 1 , and the participant received no intervening  systemic/intratumoral  
anti-cancer  therapy  between biopsy collection and Cycle 1, Day 1 (eg, focal RT of  non-
biopsied lesions is  allowed).  If no archival tissue meeting these requirements  is available, 
a baseline tumor biopsy should be collected during the Screening Period. During study 
participation, mandatory biopsies  should be collected from inject ed lesions, non-injected  
lesion s, and draining lymph nodes  per the corresponding SOA (Table 1 and Table 2 [Arm 
2: lerapolturev + nivolumab] ). For pa rticipants in Arm 1  that crossover to Arm 2, additional  
mandatory biops ies of an injected lesion, non- injected lesion, and draining lymph node  
should be performed at the time of crossover and on treatment as described in the 
treatment group’s SOA (Table 1  and Table 2 [Arm 2: lerapolturev + nivolumab]) .  
At all timepoints, biopsies from all three sites  (injected lesion, noninjected lesions and 
draining lymph nodes)  should be collected i f the biopsy is  technically feasible and does 
not put the participant at significant  risk. Examples of biopsy sites considered to be of 
significant risk include , but are not limited to  the following : biopsies of the brain, lung, 
mediastinum, pancreas, or endoscopic procedures extending beyond the esophagus, 
stomach, or bowel wall.  For those situations where the investigator determines biopsy of 
a lesion would (1 ) lead to a significant decrease in the size of the lesion such that 
response assessment by [CONTACT_393]  1.1 would be confounded,  or (2) increase the risk of 
lerapolturev leakage from the lesion, the mandatory  biopsy for that timepoint can be 
waived . In addition, complet e resection of target lesions is prohibited unless necessary 
for participant’s safety as determined by [CONTACT_093].    
Tissue samples may be analyzed by  [CONTACT_788935], RNA and/or DNA 
sequencing, and other molecular techniques to confirm  the presence of lerapolturev , and 
to determine the presence or absence o f biomarkers that may (1) predict response to 
lerapolturev , (2) measure the associated immune response and/or changes in immune 
cell function over time,  or (3) to further characterize lerapolturev’s mechanism of action . 
Samples  (blood and tissue) may be stored and used for future research for up to 10 years . 
Blood Biopsy Collection:  Mandatory blood samples should be drawn during the screening 
period and while on study, as described in the appropriate SOA (Table 1 and Table 2 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 80 of 109 
 [Arm 2: lerapolturev + nivolumab]) , to facilitate evaluation of immune cell function and 
cytokine profiles before and after study treatment  administration . Participants in Arm 
[ADDRESS_1086304] blood samples collected at the time of 
crossover and on treatment as described in the requisite  SOA (Table 1 and Table 2 
[Arm 2: lerapolturev + nivolumab]) . In addition, an additional sample is to be drawn in 
the event any participant (regardless of treatment arm) experiences an AESI of CRS 
or ICANS. This sample should be drawn as soon as possible after learning of the 
event, to facilitate the interrogation of potentially relevant changes in circulating 
cytokine levels.  
Blood samples may be interrogated by [CONTACT_788936], RNA 
and/or DNA sequencing, and other molecular techniques  to evaluate signatures of anti -
tumor immune response to lerapolturev in circulation. In addition, v arious immune cell 
types, including peripheral blood mononuclear cells, may be isolated and assayed via genetic and proteomic techniques to evaluate any changes in cell function following 
treatment with lerapolturev with or without concurrent anti -PD-1. These samples will be 
stored under the appropriate conditions  as described in the laboratory manual  and 
analyzed as a group by [CONTACT_788937] .  Samples (blood 
and tissue) may be stored and used for future research for up to 10 years . 
8 STATISTICAL CONSIDERATIONS  
8.1 Stratification Factors  
Participants receiving lerapolturev injections using the Q3/4W  schedule ± anti -PD-1 
therapy will be stratified based on time since prior anti PD -1/L1 exposure (≤6 weeks 
versus >6 weeks) and baseline LDH (normal versus >ULN).  
Participants receiving lerapolturev injections using the QW  schedule ± anti -PD-1 therapy 
will be stratified based on type of anti -PD-1/L1 resistance (primary versus secondary as 
defined in Kluger et al
7) and baseline LDH (normal versus >ULN).  
8.2 Statistical Hypotheses 
Lerapolturev administered in combination with anti -PD-1 therapy  on the QW  injection 
schedule to participants with anti -PD-1 refractory melanoma will result in an ORR of 
≥ 33%.   
8.3 Sample Size Determination  
The determination of sample size in this two-arm, randomized open -label Phase 2 trial 
was based on feasibility and logistical considerations.  As discussed in Section 1.1, the 
Sponsor estimates that the true activity of anti -PD-1 re-challenge in the  anti-PD-1 
refractory  population eligible for this study is less than 10%. Therefore, lerapolturev 
administered  in combination with anti -PD-[ADDRESS_1086305] anti -tumor activity  in the anti -PD-1 refractory melanoma population  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 81  of 109  
 if the lower bound of the 95% CI is above 10%. W e estimate the sample size for 
participants receiving lerapolturev ( QW schedule) ± anti-PD-1 therapy  to be 
approximately 30 participants (n=15 per arm). Therefore, 5  of 15 participants (ie, 33 %) in 
Arm 2  treated with the lerapolturev /anti-PD-1 combination (QW schedule)  must have an 
objective response for the 95% CI to be greater than 10% (95% CI: 11.8% to 61.6%).  
Additional comparisons (eg, Arm 1 versus Arm 2; Q3/4W schedule vs QW schedule for 
each Arm  etc.) are  planned. However, no formal hypothesis will be tested. Additional 
detail will be provided in the statistical analysis plan (SAP) . 
8.4 Populations for Analyses  
For participants receiving the QW schedule of lerapolturev injections , enrollment will be 
stratified based on baseline LDH levels (normal versus >ULN) and type of anti -PD-1/L1 
resistance (primary versus secondary), primarily for the purpose of balancing key 
participant descriptors between the treatment arms. For purposes of analysis, the 
following key populations are defined; additional populations may be defined in the SAP : 
Population  Description  
Intent- to-treat  All participants who sign the ICF  and are randomized  
Efficacy--QW  
Schedule  Participants receiving at least one lerapolturev  injection  on the 
QW schedule and at least [ADDRESS_1086306] -baseline evaluation  
Efficacy—Q3/4W  
Schedule  Participants receiving at least one lerapolturev  injection  on the 
Q3/4W schedule and at least [ADDRESS_1086307] -crossover 
evaluation  
Safety —QW 
Schedule  Participants receiving at least one lerapolturev  injection  on the 
QW schedule  
Safety —Q3/4W  
Schedule  Participants receiving at least one lerapolturev  injection  on the 
Q3/4W schedule  
8.[ADDRESS_1086308]  1.1. ORR 
will be  described as the overall number (%) of participants  in each treatment arm  with CR 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 82 of 109 
 or PR and will be presented along with  the respective 95% confidence interval s (CI) for 
each arm . For Arm 1, the primary analysis will include participant response prior to anti -
PD-1 re-challenge (eg, before crossover to Arm 2) .  ORR by [CONTACT_788938], as will other pre- determined subgroups 
defined in the SAP.  
Additional secondary endpoints, including DOR, DRR, DCR , PFS  and OS will also be 
summarized. DRR will be presented as the number (%) of participants  with CR or PR 
lasting ≥6 months, along with 95% CI. DCR will be shown as the number (%) of 
participants  with SD, PR, or CR together with the 95% CI. DOR , PFS  and OS will be 
described using the Kaplan- Meier method.  Additional details will be included in the SAP.  
8.5.2  Translational Analyses  
As a primary objective, markers of immune activation in response to lerapolturev 
treatment  (with or without anti -PD-1) will be evaluated  in both injected and non- injected 
lesions . Participants with a baseline and at least [ADDRESS_1086309] -treatment  biopsy  will be analyzed 
for changes in the number of CD8+ TILs located within the TME , as well as for changes 
in PD- L1 expression. Additional exploratory analyses will be performed to characterize 
changes in other important markers of immune function following treatment with single-agent  lerapolturev or with the lerapolturev / anti-PD-[ADDRESS_1086310]-treatment  tissue  biops ies will be assayed for changes in immune cell density  by 
[CONTACT_788939] (eg, flow cytometry) . Changes in T cell receptor 
repertoire,  and chemo kine and/or cytokine profiles  in blood samples and/or tissue  will also 
be assayed at the  gene and/or protein expression level , as appropriate. All results will be 
described by [CONTACT_788940].  
 
8.5.[ADDRESS_1086311] one lerapolturev  injection will be analyzed for safety. Any 
AEs reported after the initiation of study treatment and ≤ [ADDRESS_1086312] dose of 
study treatment are defined as treatment emergent.  For each treatment -emergent AE, 
the maximum grade experienced by [CONTACT_788941]. A dverse event  tabulations will include all treatment emergent events 
(regardless of attribution), and a tabulation for all study -related interventions that are at 
least possibl y related to lerapolturev . Adverse event s occurring during screening due to 
lerapolturev -related procedures that are not standard of care (eg, PV booster) will be 
considered related to lerapolturev  and summarized separately .  
8.5.4  Exploratory Analyses  
Exploratory objectives evaluating subgroup analyses, such as outcomes for participants 
based on BRAF status,  primary versus secondary resistance, time since prior anti -PD-1 
administration , response s following Arm 1 to Arm 2 crossover (ie, anti -PD-1 re-challenge) , 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 83 of 109 
 baseline LDH levels  or others (as described in Section 2.1) will be summarized by 
[CONTACT_788942], including DOR, DRR, DCR, PFS  and OS. DRR will be presented as the 
number (%) of participants  with CR or PR lasting ≥6 months, along with 95% CI. DCR will 
be shown as the number (%) of  participants  with SD, PR, or CR together with the 95% 
CI. DOR , PFS  and OS will be described using the Kaplan- Meier method.  For the analysis 
of response following crossover from Arm 1 to Arm 2, the baseline for anti -tumor response 
in this subgroup will based on the size of the tumor at the time of crossover  and will be 
summarized separately. A nti-tumor response (ie, ORR, DOR, and DRR) based on 
iRECIST will also be summarized with descriptive statistics, as appropriate.  
In addition, a per -protocol population (no major protocol deviations, etc.)  and predictors 
of lerapolturev  response and/or changes in markers of immune function will be 
summarized by [CONTACT_148216], as appropriate.  Additional details regarding these and 
other analyses will be described in the SAP.  
8.6 Interim Analysis  (IA) 
No interim analysis will be conducted for this study . Rather, efficacy results for 
participants receiving the Q3/4W  schedule and QW  schedule will be summarized 
separately  for participants receiving either lerapolturev monotherapy or lerapolturev  in 
combination with anti -PD-1 therapy , as described in the SAP.  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 84 of 109 
 9 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
9.1 Regulatory, Ethical, and Trial Oversight Considerations  
9.1.1  Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with the 
following:  
o Consensus ethical principles derived from international guidelines including the Declaration of Helsinki and applicable ICH Good Clinical Practice (GCP) 
Guidelines  
o Applicable federal, state, and local regulations   
• The protocol, ICF, I B, and other relevant documents (eg, advertisements) must 
be submitted to an IRB/IEC by [CONTACT_22843]/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.  
• The investigator will be responsible for the following:  
o Providing oversight of the conduct of the study at the site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, and all other applicable local regulations.  
o Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by [CONTACT_1201]/IEC . 
o Notifying the IRB/IEC of SAEs or other significant safety findings as required by [CONTACT_1744]/IEC procedures . 
9.1.[ADDRESS_1086313] be informed that their participation is voluntary. The investigator or his/her representative will provide full and adequate written and oral explanation of  the 
nature of the study to the participant or his/her legally authorized representative (LAR)  
and answer all questions regarding the study.  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086314] (HIPAA) requirements, where applicable, and the 
IRB/IEC or trial center.  
The medical record must include a statement that written informed consent was obtained before the participant was screened for  the study and the date the written consent was 
obtained. The authorized person obtaining the informed consent must also sign the ICF.  
Participants must be re- consented to the most current version of the ICF(s) during their 
participation in the study , when required.  
A copy of the ICF(s) must be provided to the participant  or the LAR .  
9.1.[ADDRESS_1086315] 
parties working on behalf of the Sponsor . Every effort will be made to maintain the 
confidentiality of any personal information that identify the participant  by [CONTACT_2300] (eg, signed 
ICF, laboratory reports, clinic charts), except to the extent necessary to allow  monitoring 
or auditing by [CONTACT_16015], and auditing by [CONTACT_1622], or other regulatory 
authorities.    
To protect participant privacy, coded information will be labeled in a way that will not 
identify the participant to  the Sponsor and others who may see the information at the 
Sponsor location. The participant must be informed that his/her medical records may be 
examined by  [CONTACT_1750],  Clinical Quality Assurance auditors , other authorized 
personnel appointed by [CONTACT_941] S ponsor , by [CONTACT_6667]/IEC members, and by [CONTACT_57764]. The participant must also be informed that his/her personal study -related data will be used by [CONTACT_941] S ponsor in accordance with local data protection 
law. The level of disclosure must also be explained to the participant.   
This confidentiality is extended to cover testing of biological samples and genetic tests in 
addition to the clinical information relating to participants.  
9.1.5  Data and Safety Monitoring Committee  
An external DSM C has been engaged to closely monitor  the safety of the interventions  
under investigation during this  study .  The DSMC was tasked to review the data during 
(1) the safety run -in, (2) once 12 participants  treated with the Q3/4W schedule were  
randomized and completed  the DLT period (eg, after approximately six participants have 
been treated with lerapolturev plus anti -PD1 therapy) , (3) at the  previously planned 
interim analysis (IA) and (4) approximately every 4 months after the IA .  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 86 of 109 
 As mentioned  in Section 3.1, the DSMC met on 20 December 2021  to review all available 
safety data collected following clearance of the DLT monitoring period  of the 12th 
participant randomized (all receiving Q3/4W  schedule)  (18 participants total: n=6 from the 
safety run- in and n=12 randomized [n=6 per arm] ), as well as to discuss the feasibility of 
increasing the lerapolturev dose and changing the dos ing schedule (ie, max dose of 
1.6 x 109 TCID 50 administered using the QW schedule) . Given the favorable tolerability 
profile  of lerapolturev, when  given alone or in combination with anti -PD-1, the DSMC 
supported the Sponsor’s  recommendation to change the lerapolturev dose and schedule, 
with the agreement that the next DSMC meeting should occur once 12 participants (n=6 
per arm) have received  the QW lerapolturev dosing schedule and have cleared the DLT 
period.  As before, t he DSMC will make recommendations  regarding whether adjustments 
to lerapolturev dose are warranted, as well as whether  to continue the study as planned. 
Based on this agreement with the  DSMC and other logistical considerations , the DSMC 
will no longer meet to review data at the previously planned IA. Once the planned QW 
schedule safety  evaluation is complete, the DSMC will continue to meet approximately 
every [ADDRESS_1086316] of the trial ; and 
may provide additional recommendations with regard to lerapolturev dose and/or other 
modifications to study conduct . For example, dosing of current participants  may be held 
to evaluate S[LOCATION_003]Rs that have not been described to date with respect to their nature, 
severity, and duration, or if there is an unexpected increase in the incidence of known 
AEs in excess of expectations (with lerapolturev  and/or anti -PD-1 therapy) . The DSM C 
may also formulate recommendations relating to the selection, recruitment, and retention 
of participants and their management. Additional details regarding the responsibility of 
the DSM C/its chair will be provided in a DSM C charter document, as applicable.  
9.1.6  Data Quality Assurance  
All participant data relating to the study will be recorded on eCRF unless transmitted to 
the Sponsor or designee electronically (eg, imaging data). The investigator is responsible 
for verifying that  all data entries are correct  and must maintain accurate documentation 
(source data) that supports the information entered in the eCRF. The investigator must  
also permit study -related monitoring, audits, IRB/IEC review, and regulatory agency 
inspections and provide direct access to source data documents.  Investi gators will keep 
personal medical records and a list that links each participant’s name [CONTACT_788949].   
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086317] be 
retained by [CONTACT_788943]:  
• At least [ADDRESS_1086318] marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region; or  
• At least [ADDRESS_1086319] elapsed since the formal discontinuation of clinical development 
of the study drug  
These documents should be retained for a longer period,  if required by [CONTACT_788944]. It is 
the responsibility of the Sponsor  to inform the investigator/institution as to when these 
documents no longer need to be retained. The executed clinical trial agreement will govern if language differs from that contained herein.  No records may be transferred to 
another location or party without written notification to the Sponsor .  
9.1.7  Protocol Deviations  
A protocol deviation is any noncompliance w ith the clinical trial protocol or  ICH GCP . The 
noncompliance may be either on the part of the participant, the investigator, or the study site staff. As a result of deviations, corrective actions may be developed by [CONTACT_90478].  
It is the responsibility of the site investigator to use continuous vigilance to identif y and 
report deviations according to ICH and/or Sponsor  requirements . All deviations must be 
addressed in study source documents and reported to the S ponsor. Protocol deviations 
must be sent to the reviewing IRB/IEC , per their policies. The site investigator is 
responsible for knowing and adhering to the reviewing IRB/IEC requirements.  
9.1.8  Source Documents  
Source documents are necessary to provide evidence for the existence of the participant 
and to substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  Source data includes (but is not limited to): in -patient hospi[INVESTIGATOR_1332], 
clinic notes, out -patient records, original tests results,  pathology reports,  laboratory data, 
worksheets, investigational product accountability records, consent forms, etc.  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086320] of the study.  In addition, remote monitoring visits may 
also be performed, as needed.  
9.1.9  Study and Site Closure  
The Sponsor or designee reserves the right to  temporarily suspend or  close the study , 
either at a single site or  all sites,  at any time for any reason. If such action is taken, the 
Sponsor  will discuss this with the investigator (including the reasons for taking such 
action) at that time. The Sponsor  will promptly inform all other investigators  and 
institutions conducting the study if the study is suspended or terminated for safety reasons . The Sponsor  will also inform necessary  regulatory authorities of the suspension 
or termination of the study and the reason(s) for the action. If required by [CONTACT_5279], the investigator must inform the IRB/IEC promptly and provide the reason f or 
the suspension or termination.  
Study sites will be closed upon study completion. A study site is considered closed when 
all required documents /records are complete,  study supplies (including study drug) have 
been collected and/or are accounted for, remaining data issues are clarified or resolved, 
and study -site closure visit has been performed.  
Reasons for the early closure of a study site by [CONTACT_941] S ponsor or investigator may include 
but are not limited to:  
• Failure of the investigator to comply with the protocol, the requirements of the IRB/IEC or local health authorities, the Sponsor's procedures /SOPs , or GCP 
guidelines . 
• Inadequate recruitment of participants by [CONTACT_093] . 
• Discontinuation of further lerapolturev development . 
9.1.10  Confidentiality and Publication Policy  
The investigator and other study site personnel will keep confidential any information 
provided by [CONTACT_788945] (including this protocol) and all data and 
records generated while  conducting the study . The investigational site will not use the 
information, data, or records for any purpose other than conducting the study, in keepi[INVESTIGATOR_788898].  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 89 of 109 
 • The results of this study may be published or presented at scientific meetings , only 
with documented Sponsor approval . The investigator is required to submit all 
manuscripts or abstracts to the Sponsor  for review or approval  before submission.  
• In accordance with standard editorial and ethical practice, the S ponsor will generally 
support publication of multicenter studies only in their entirety and not as individual 
site data. In this case, a coordinating investigator [INVESTIGATOR_9231].  
• Authorship will be determined by [CONTACT_23531].  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 90  of 109  
 9.2 Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting 
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study drug(s) , whether or not considered 
related to the study drug (s). 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drug(s). 
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) 
or other safety assessments (eg, ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically 
significant in the medical and scientific judgment of the investigator (ie, not related to progression of underlying disease).  
• Exacerbation of a chronic or intermittent pre- existing condition, including either an 
increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study drug (s) administration even 
though it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug- drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study drug(s) or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.  
• "Lack of efficacy" or "failure of expected pharmacological action" per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae resulting 
from lack of effic acy will be reported as AE or SAE if they fulfil the definition of an 
AE or SAE.  
 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 91  of 109  
 Events NOT Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by 
[CONTACT_19448]’s condition.  
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the participant’s condition.  
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospi[INVESTIGATOR_307]
, including elective/planned medical 
procedures ). 
• Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) 
present or detected at the start of the study that do not worsen.  
Definition of SAE : 
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, 
death due to progression of disease).  
An SAE is defined as any untoward medical occurrence that, at any dose:  
• Results in death  
• Is life -threatening  
 
The term 'life- threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.  
• Requires inpatient hospi[INVESTIGATOR_788899], hospi[INVESTIGATOR_19949] (usually 
involving at least an overnight stay) at the hospi[INVESTIGATOR_22771]/or treatment that would not have been appropriate in the physician’s office or  
outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a 
complication prolongs hospi[INVESTIGATOR_9236], the event is 
serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the 
AE should be considered serious.  
Hospi[INVESTIGATOR_5187] a pre- existing condition that did not worsen 
from baseline is not considered an AE.  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 92  of 109  
 • Results in persistent disability/incapacity  
The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions. This includes abnormal birth outcomes (spontaneous abortion, 
fetal death, stillbirth, congenital anomalies, etc.) from pregnancies of participants who 
became pregnant (either female participants or female partners of male study 
participants). This definition is not intended to include experiences of relatively minor 
medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
• Is a congenital anomaly/birth defect  
Other situations:  
 
Medical or scientific judgment should be exercised in deciding whether SAE reporting 
is appropriate in other situations such as important medical events that may not be 
immediately life -threatening or result in death or hospi[INVESTIGATOR_10913]. These events should usually be consid ered 
serious.  
Examples of such events include intensive treatment in an emergency room or at 
home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in 
hospi[INVESTIGATOR_059], or development of drug dependency or drug abuse.  
Definition of Immune- Related Adverse Events (irAEs):  
An irAE is defined as:  
• Any adverse event affecting an organ system through an autoimmune or 
inflammatory mechanism , whereby [CONTACT_788946]. Examples of irAEs , as well as recommendations for study drug management 
in the event of an irAE are described in Section 5.5.  
Definition of Adverse Events of Interest  (AESI):  
An AESI is defined as:  
• Any AE (serious or non -serious) of scientific and medical concern for which 
ongoing monitoring and communication by [CONTACT_941] i nvestigator to the Sponsor  or 
designee  may be appropriate. Such events may require further investigation to 
characterize and understand them. Any AE SI should be entered in the eCR F.  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 93 of 109 
 Because lerapolturev is an immunotherapeutic administered by [CONTACT_707256] , 
AESIs fall into 2  categor ies: 1.) AEs related to lerapolturev administration (ie, ISR) , and 
2.) AEs related to CRS  and ICANS , which can occur when the body’s immune cells 
release a bolus of inflammatory cytokines in response to an immunotherapeutic44. AESI 
related to CRS and ICANS should be reported to the Sponsor within 24 hours, 
regardless of severity or seriousness. AESI related to ISR does not require expedited 
reporting (ie, within 24 hours), unless considered an SAE. A brief overview of each 
AESI is outlined below.   
AEs associated with ISR : 
To more completely describe t he signs and symptoms  associated with ISR, additional 
information related to the parameters outline below should be collected, which have 
been adapted from FDA guidance for evaluating ISR in vaccine trials45 (see 
Appendix  I), as well as past clinical experience with lerapolturev in melanoma.    
• Erythema  
• Induration  
• Pruritus  
• Ecchymosis/bruising/skin discoloration  
• Pain   
Each symptom will be graded on a scale of 1 to 4, as described in Appendix I , which  
may represent a measure of intensity, not seriousness . Thus, a Grade 3 or Grade 4 
sign or symptom may be severe, but not necessarily serious.  Therefore, although all 
Grade 3/4 AEs of ISR should be reported within 24 hours , only AEs of ISR  meeting the 
criteria for seriousness (see SAE definition above for a definition of seriousness) should 
be reported as an SAE.  Where appropriate, reporting of symptoms may  also require a 
measurement recorded as a continuous variable (ie, diameter of erythema).  
AEs associated with CRS  and ICANS :  
The management of signs and symptoms of CRS and ICANS are described in 
Section  5.5 (Management of CRS and ICANS). CRS has been associated with 
administration of other immunotherapeutics, including oncolytic viruses, such as T -
VEC19 and CAR T cell therapi[INVESTIGATOR_014] , but has not been detected in any participants treated 
with lerapolturev to data (Istari data on file) . The ASTCT consensus guidelines describe 
that t he onset of s ymptoms of CRS  typi[INVESTIGATOR_380618] 2 weeks of treatment41, and  
may include (but are not limited to):  
• Fever ( required; ≥ 38°C) not attributable to any other cause or underlying 
condition  
• Hypoxia  
• Tachycardia  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 94 of 109 
 • Hypotension  
• Dyspnea  
 
Per the ASTCT consensus guidelines41, symptoms of ICANS are defined as AE s that 
result in “a pathologic process involving the CNS following any immune therapy that 
results in activation or engagement of endogenous or infused T cells and/or other 
immune effector cells. ” AEs related to ICANS can include  (but may not be limited to)  
the following:  
• Cerebral edema  
• Seizure  
• Motor weakness  
• Aphasia  
• Altered level of consciousness  
• Impaired cognition  
As stated, a dministration of lerapolturev has not been  associated with CRS or ICANS 
in any participant  treated with lerapolturev to date, regardless of indication (Istari data 
on file) . Because  the current study is investigating lerapolturev in conjunction with 
concurrent anti -PD-1 therapy , additional steps are being taken to characterize the 
occurrence of, duration of, and response to interventions for signs and symptoms of 
CRS  and/or ICANS , should they occur . This includes reporting any AESI of CRS or 
ICANS within [ADDRESS_1086321] consensus guidelines  (see Appendix I ).  
If any individual sign or symptom meet s the criteria for seriousness ( ie, results in new 
hospi[INVESTIGATOR_059], prolonged hospi[INVESTIGATOR_059], death, persistent or significant 
disability/incapacity, a life -threatening condition, or an event of medical significance), it 
should be reported as an SAE , as described in Section 7.3.4.  
 
  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 95  of 109  
 Recording and Follow -Up of AE , AESI  and/or SAE  
AE, irAE, AESI  and SAE Recording  
• When an AE/ irAE/AESI/ SAE occurs, it is the responsibility of the investigator to 
review all documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and 
diagnostics reports) related to the event  and report the event within the appropriate 
timeframe . 
• The investigator will then record all relevant AE/ irAE/AESI/ SAE information in the 
eCRF.  
• It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s 
medical records to the Sponsor/designee in lieu of completion of the necessary  
eCRF page  and/or  any other  safety event reporting form (if applicable)  noted in the 
study’s safety reporting guidelines . 
NOTE: AESI of CRS or ICANS  should be recorded in eCRF  with the verbatim term 
of CRS or ICANS, rather than the individual signs and symptoms related to the 
AESI. The underlying signs and symptoms associated with the AESI should be 
reported per the study’s safety reporting guidelines and/ or as part of the descriptive 
narrative, rather than as individual AEs .    
• There may be instances when copi[INVESTIGATOR_788900]/designee. In this case, all participant identifiers, except for  
the participant number, will be redacted on the copi[INVESTIGATOR_590997]. 
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/symptoms) will be documented as the AE/ AESI/SAE.  
Assessment of Intensity  
With the exception of AESIs related to CRS or ICANS, t he investigator will assess  
severity grade for each AE , irAE, AESI (ISR only)  and SAE reported during the study 
using the National Cancer Institute – Common Terminology Criteria for Adverse 
Events (NCI -CTCAE) version [ADDRESS_1086322] guidelines41 (see Appendix I ). Any AE not listed in the 
NCI-CTCAE will be graded according to the investigator’s clinical judgment using the 
standard grades as follows:  
• Grade 1 (Mild): Awareness of symptoms that are easily tolerated, causing 
minimal discomfort and not interfering with everyday activities.  
• Grade 2 (Moderate): Sufficient discomfort is present to cause interference with 
normal activity.  
• Grade 3 (Severe): Extreme distress, causing significant impairment of 
functioning or incapacitation. Prevents normal everyday activities.  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 96  of 109  
 AE, irAE, AESI  and SAE Recording  
• Grade 4, (Life-threatening ): Urgent intervention indicated.  
• Grade 5: Death.  
The investigator should use clinical judgment in assessing the severity of events not 
directly experienced by [CONTACT_198670] (eg, laboratory abnormalities).  
 
Assessment of Causality  
• The investigator is obligated to assess the relationship between study drug(s) and 
each occurrence of each AE/ irAE/AESI/SAE  and to record this determination in the 
eCRF . The AE must be characterized as unrelated, unlikely to be related, possibly 
related, probably related, or definitely related.  
o "Definitely related" conveys the adverse event has a timely relationship to 
administration of study treatment and there is no apparent, potential alternate etiology.  
o “Probably related” conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.  
o “Possibly related” suggests that the association of the AE with the study 
treatment is unknown; however, the AE is not reasonably supported by [CONTACT_100097].  
o “Unlikely to be related” suggests that only a remote connection exists between 
the study treatment and the AE. Other conditions, including chronic illness, 
progression or expression of the disease state or reaction to concomitant 
therapy, appear to explain the reported AE.  
o “Unrelated” is used if there is not a reasonable possibility that the study treatment 
caused the AE  
• The investigator should use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study drug(s)  
administration will be considered and investigated.  
• The investigator should consult the I B during his/her assessment.  
• For each AE /irAE/ AESI/ SAE, the investigator must  document in the medical notes 
that he/she has reviewed the AE/ irAE/AESI/ SAE and has provided an assessment 
of causality, along with indication of the key pi[INVESTIGATOR_788901] . 
• There may be situations in which an AESI or SAE occurs , and the investigator has 
minimal information to include in the initial report to the Sponsor/designee. 
However, it is very important that the investigator always make an 
assessment of causality for every SAE  before the initial transmission of the  
AESI or  SAE to  the Sponsor . 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 97  of 109  
 Assessment of Causality  
• The investigator may change his/her opi[INVESTIGATOR_9242] -up 
information and  may submit  the relevant  follow -up information  with the updated 
causality assessment  for the AESI or SAE . 
• The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.  
 
Follow -up of AEs , irAEs,  AESIs  and SAEs  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_618983]/or causality of the AE , irAEs, AESI  or SAE as 
fully as possible. This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care 
professionals.  
• New or updated information will be recorded in the originally completed e CRF.  
• The investigator will submit any updated AESI (for AESI related to CRS , ICANS , or 
Grade 3/4 ISR ONLY) or SAE data to the S ponsor within 24 hours of receipt of the 
information.  
 
 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086323]  American Society for Transplantation and Cellular Therapy  
BPM  Beats per minute  
CBC  Complete blood count  
CI Confidence interval  
CNS  Central nervous system  
CR Complete response  
CRF case report form(s) (paper or electronic as appropriate for this study)  
CRS  Cytokine release syndrome  
CT Computed tomography  
CTCAE  Common Terminology Criteria for Adverse Events  
CTL Cytotoxic T lymphocytes  
CTLA -[ADDRESS_1086324]  
HSA Human serum albumin  
IA Interim analysis  
IB Investigator’s brochure  
ICANS  Immune effector cell -associated neurotoxicity syndrome  
ICF informed consent form  
ICH International Council for Harmonization  
IEC Independent Ethics Committee  
IgG Immunoglobulin G  
INR International normalized ratio  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086325]  Modification of diet in renal disease  
MRI Magnetic resonance imaging  
ORR  Overall response rate  
OS Overall survival  
PBS Phosphate buffered saline  
pCR Pathologic complete response  
PD Progressive disease  
PD-1 Program death receptor - 1 
PD-L1 Programmed death -ligand 1  
PK pharmacokinetic(s)  
PQC  Product Quality Complaint  
PR Partial response  
PT Prothrombin time  
PTT Partial thromboplastin time 
PV Poliovirus  
PV1S  Poliovirus serotype [ADDRESS_1086326] Upper limit of normal  
WBC  White blood cell  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 100 of 109 
 11 REFERENCES  
1.  Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipi[INVESTIGATOR_399255]. N Engl J Med . 2015;372(26):2521- 2532. 
doi:10.1056/NEJMoa1503093  
2.  Robert C, Long GV, Brady B, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med . 2015;372(4):320- 330. 
doi:10.1056/NEJMoa1412082  
3.  Ribas A, Hamid O, Daud A, et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA . 
2016;315(15):1600- 1609. doi:10.1001/jama.2016.4059  
4.  Larkin J, Chiarion- Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipi[INVESTIGATOR_686903]. N Engl J Med . 2015;373(1):23- 34. 
doi:10.1056/NEJMoa1504030  
5.  Cancer Statistics Review, 1975- 2015 - Previous Version -  SEER Cancer Statistics 
Review. SEER. Accessed June 30, 2020. https://seer.cancer.gov/archive/csr/1975_2015/index.html  
6.  Beasley GM, Nair SK, Farrow NE, et al. Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment -refractory melanoma. J Immunother Cancer . 
2021;9(4):e002203. doi:10.1136/jitc -2020- [ADDRESS_1086327] blockade: recommendations from the first meeting of the SITC 
Immunotherapy Resistance Taskforce. J Immunother Cancer . 2020;8(1):e000398. 
doi:10.1136/jitc -2019- [ADDRESS_1086328] relapse in stage III melanoma patients: implications for follow -up guidelines. J Clin 
Oncol Off J Am Soc Clin Oncol . 2010;28(18):3042- 3047. 
doi:10.1200/JCO.2009.26.2063  
9.  Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapi[INVESTIGATOR_014]: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463- 482. 
doi:10.1038/nrclinonc.2017.43  
10.  Larkin J, Ascierto PA, Dréno B, et al. Combined Vemurafenib and Cobimetinib in 
BRAF -Mutated Melanoma. N Engl J Med . 2014;371(20):1867- 1876. 
doi:10.1056/NEJMoa1408868  
11.  Robert C, Karaszewska B, Schachter J, et al. Improved Overall Survival in 
Melanoma with Combined Dabrafenib and Trametinib. N Engl J Med . 
2015;372(1):30- 39. doi:10.1056/NEJMoa1412690  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 101 of 109 
 12.  Saleh K, Khalifeh- Saleh N, Kourie HR. Is it possible to rechallenge with PD -1/PD -
L1 inhibitors after progression? Immunotherapy . 2018;10(5):345- 347. 
doi:10.2217/imt -2017- [ADDRESS_1086329] Progression. Lancet 
Oncol . 2018;19(2):229 -239. doi:10.1016/S1470- 2045(17)[ZIP_CODE]- X 
14.  Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in 
patients with advanced melanoma who progressed after anti -CTLA -4 treatment 
(CheckMate 037): a randomised, controlled, open- label, phase 3 trial. Lancet Oncol . 
2015;16(4):375- 384. doi:10.1016/S1470- 2045(15)[ZIP_CODE]- 8 
15.  Hamid O, Robert C, Daud A, et al. Five- year survival outcomes for patients with 
advanced melanoma treated with pembrolizumab in KEYNOTE -001. Ann Oncol . 
2019;30(4):582- 588. doi:10.1093/annonc/mdz011  
16.  Pi[INVESTIGATOR_788902] I, Ahmed T, Lo S, et al. Ipi[INVESTIGATOR_125] (IPI) alone or in combination 
with anti -PD-1 (IPI+PD1) in patients (pts) with metastatic melanoma (MM) resistant 
to PD1 monotherapy. J Clin Oncol. 2020;38(15_suppl):[ZIP_CODE]- [ZIP_CODE]. 
doi:10.1200/JCO.2020.38.15_suppl.[ZIP_CODE]  
17.  Brown MC, Holl EK, Boczkowski D, et al. Cancer immunotherapy with 
recombinant poliovirus induces IFN -dominant activation of dendritic cells and tumor 
antigen– specific CTLs. Sci Transl Med . 2017;9(408). 
doi:10.1126/scitranslmed.aan4220  
18.  Desjardins A, Gromeier M, Herndon JE, et al. Recurrent Glioblastoma Treated 
with Recombinant Poliovirus. N Engl J Med . 2018;379(2):150- 161. 
doi:10.1056/NEJMoa1716435  
19.  Andtbacka RHI, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec 
Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin 
Oncol Off J Am Soc Clin Oncol . 2015;33(25):2780- 2788. 
doi:10.1200/JCO.2014.58.3377  
20.  Ribas A, Dummer R, Puzanov I, et al. Oncolytic Virotherapy Promotes 
Intratumoral T Cell Infiltration and Improves Anti -PD-1 Immunotherapy. Cell. 
2017;170(6):1109- 1119.e10. doi:10.1016/j.cell.2017.08.027  
21.  Ribas A, Chesney J, Long G, et al. 1037O MASTERKEY -265: A phase III, 
randomized, placebo (Pbo) -controlled study of talimogene laherparepvec (T) plus 
pembrolizumab (P) for unresectable stage IIIB –IVM1c melanoma (MEL). Ann Oncol . 
2021;32:S868- S869. doi:10.1016/j.annonc.2021.08.1422  
22.  Gromeier M, Solecki D, Patel DD, Wimmer E. Expression of the human poliovirus 
receptor/CD155 gene during development of the central nervous system: 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 102 of 109 
 implications for the pathogenesis of poliomyelitis. Virology . 2000;273(2):248- 257. 
doi:10.1006/viro.2000.0418  
23.  Chandramohan V, Bryant JD, Pi[INVESTIGATOR_6683] H, et al. Validation of an 
Immunohistochemistry Assay for Detection of CD155, the Poliovirus Receptor, in 
Malignant Gliomas. Arch Pathol Lab Med. 2017;141(12):1697- 1704. 
doi:10.5858/arpa.2016 -0580- OA 
24.  Brown MC, Dobrikova EY, Dobrikov MI, et al. Oncolytic polio virotherapy of 
cancer. Cancer . 2014;120(21):3277- 3286. doi:10.1002/cncr.[ZIP_CODE]  
25.  Brown MC, Dobrikov MI, Gromeier M. Mitogen- Activated Protein Kinase-
Interacting Kinase Regulates mTOR/AKT Signaling and Controls the Serine/Arginine- Rich Protein Kinase- Responsive Type 1 Internal Ribosome Entry 
Site-Mediated Translation and Viral Oncolysis. J Virol . 2014;88(22):[ZIP_CODE]- [ZIP_CODE]. 
doi:10.1128/JVI.[ZIP_CODE] -14 
26.  Mosaheb MM, Dobrikova EY, Brown MC, et al. Genetically stable poliovirus 
vectors activate dendritic cells and prime antitumor CD8 T cell immunity. Nat Commun . 2020;11(1):524. doi:10.1038/s41467- 019-[ZIP_CODE]- z 
27.  Brown MC, Mosaheb MM, et al. Viral infection of the tumor microenvironment 
mediates antitumor immunotherapy via selective TBK -1-IRF3 signaling. Nat 
Commun . (submitted for review May 2020).  
28.  Dobrikova EY, Goetz C, Walters RW, et al. Attenuation of Neurovirulence, 
Biodistribution, and Shedding of a Poliovirus:Rhinovirus Chimera after Intrathalamic Inoculation in Macaca fascicularis. J Virol . 2012;86(5):2750- 2759. 
doi:10.1128/JVI.[ZIP_CODE] -11 
29.  World Health Organization. Polio Vaccines: WHO position paper. Wkly Epi[INVESTIGATOR_786316]. 2016;91:145- 168. 
30.  Rümke HC, Oostvogel PM, Van Steenis G, Van Loon AM. Poliomyelitis in The 
Netherlands: a review of population immunity and exposure between the epi[INVESTIGATOR_788903] [ADDRESS_1086330] . 1995;115(2):289- 298. 
31.  Rodas IM, Saiag P, Merino L de la C, et al. [ADDRESS_1086331] progressive disease on anti -PD-1-based therapy. J 
Immunother Cancer . 2021;9(Suppl 2). doi:10.1136/jitc -2021- SITC2021.961  
32.  Kirkwood J, Zakharia Y, Davar D, et al. 950 Final analysis: phase 1b study 
investigating intratumoral injection of toll -like receptor [ADDRESS_1086332] vidutolimod ± 
pembrolizumab in patients with PD -1 blockade– refractory melanoma. J Immunother 
Cancer . 2021;9(Suppl 2). doi:10.1136/jitc -2021 -SITC2021.950  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 103 of 109 
 33.  Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With 
Unresectable Melanoma | Journal of Clinical Oncology. Accessed January 13, 2022. 
https://ascopubs.org/doi/10.1200/JCO.20.[ZIP_CODE]  
34.  Ranki T, Pesonen S, Hemminki A, et al. Phase I study with ONCOS -102 for the 
treatment of solid tumors –  an evaluation of clinical response and exploratory 
analyses of immune markers. J Immunother Cancer . 2016;4(1):17. 
doi:10.1186/s40425- 016-0121- [ADDRESS_1086333], et al. FORTITUDE –  A phase [ADDRESS_1086334] 
antibody: monotherapy dose escalation results. :1.  
36.  Brachtlova T, Abramovitch A, Giddens J, et al. 954 Clinical results from a phase I 
dose escalation study in treatment -naïve early stage prostate cancer patients with 
ORCA -010, a potency enhanced oncolytic replication competent adenovirus. J 
Immunother Cancer . 2021;9(Suppl 2). doi:10.1136/jitc -2021- SITC2021.954  
37.  Park JC, Soliman H, Falchook G, et al. 511 Initial results of a phase 1 study of 
intratumoral ONCR- 177, an oncolytic herpes -simplex virus -1 expressing five 
immunomodulatory transgenes, in subjects with advanced injectable tumors. J Immunother Cancer . 2021;9(Suppl 2). doi:10.1136/jitc -2021- SITC2021.511  
38.  Hu JCC, Coffin RS, Davis CJ, et al. A phase I study of OncoVEXGM -CSF, a 
second -generation oncolytic herpes simplex virus expressing granulocyte 
macrophage colony -stimulating factor. Clin Cancer Res Off J Am Assoc Cancer 
Res. 2006;12(22):6737 -6747. doi:10.1158/1078- 0432.CCR -06-0759  
39.  Sweeney TR, Abaeva IS, Pestova TV, Hellen CUT. The mechanism of 
translation initiation on Type 1 pi[INVESTIGATOR_788904]. EMBO J . 2014;33(1):76- 92. 
doi:10.1002/embj.[ADDRESS_1086335] Consensus Grading for 
Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant . 
2019;25(4):625- 638. doi:10.1016/j.bbmt.2018.12.758  
42.  Nishino M, Giobbie -Hurder A, Gargano M, Suda M, Ramaiya NH, Hodi FS. 
Developi[INVESTIGATOR_007] a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19(14):3936- 3943. doi:10.1158/1078- 0432.CCR -13-
0895  
43.  Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune 
therapy activity in solid tumors: immune- related response criteria. Clin Cancer Res 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 104 of 109 
 Off J Am Assoc Cancer Res . 2009;15(23):7412- 7420. doi:10.1158/1078- 0432.CCR -
09-1624  
44.  Shimabukuro- Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release 
syndrome. J Immunother Cancer . 2018;6. doi:10.1186/s40425- 018-0343- 9 
45.  Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent 
Volunteers Enrolled in Preventive Vaccine Clinical Trials. :10.   
  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086336] Consensus Grading for CRS adapted from Lee et al., 201941 
CRS 
Parameter  Grade 1  Grade 2  Grade 3  Grade 4  Grade 5  
Fever1 Temperature 
≥38°C  Temperature 
≥38°C  Temperature ≥38°C  Temperature ≥38°C  
Death due to 
CRS, where 
another factor is not the principle 
cause  With 
Hypotension  None  Not requiring 
vasopressors  Requiring a 
vasopressor with or without vasopressin Requiring multiple 
vasopressors (excluding 
vasopressin)  
And/or2 
Hypoxia  None  Requiring low -flow 
nasal cannula3 or 
blow-by [CONTACT_13198] -flow 
nasal cannula3, 
facemask, 
nonrebreather mask, or 
Venturi mask  Requiring positive 
pressure (eg, CPAP, BiPAP, intubation and mechanical ventilation)  
Organ toxicities associated with CRS may be graded according to CTCAE v5.0, but do not influence CRS grading.  
1. Fever is defined as temperature ≥38°C not attributable to any other cause. In patients who have CRS then receive antipyretic or anticytokine therapy such as tocilizumab or steroids, fever is no longer required to grade subsequent CRS severity. In thi s 
case , CRS grading is driven by [CONTACT_13199]/or hypoxia.  
2. CRS grade is determined by [CONTACT_13200]: hypotension or hypoxia not attributable to any other cause. For example, a patient with temperature of 39.5°C, hypotension requiring 1 vasopressor, and hypoxia requiring low -flow nasal cannula is 
classified as grade 3 CRS.  
3. Low-flow nasal cannula is defined as oxygen delivered at ≤6 L/minute. Low flow also includes blow -by [CONTACT_13201], 
sometimes used in pediatrics. High- flow nasal cannula is defined as oxygen delivered at >6 L/minute.
 
 
ASTCT Consensus Grading for ICANS adapted from Lee et al., [ADDRESS_1086337] severe event (ICE score  [see below], level of consciousness, seizure, motor findings, raised 
ICP/cerebral edema) not attributable to any  other cause; for example, a patient with an ICE score of 3 who has a generalized 
seizure is classified as grade 3 ICANS.  N/A indicates not applicable.  
1. A patient with an ICE score of 0 may be classified as grade 3 ICANS if awake with global aphasia, but a patient with an ICE 
score of 0 may be classified as grade 4 ICANS if unarousable.  
2. Depressed level of consciousness should be attributable to no other cause (eg, no sedating medication).  
3. Tremors and myoclonus associated with immune effector cell therapi[INVESTIGATOR_13005] v5.0, but they do not influence ICANS grading.  
4. Intracranial hemorrhage with or without associated edema is not considered a neurotoxicity feature and is excluded from ICANS grading. It may be graded according to CTCAE v5.0.  
 
 Neurotoxicity 
Domain  Grade 1  Grade 2  Grade 3  Grade 4  Grade 5  
ICE score1 7 to 9  3 to 6  0 to 2  0 (patient is unarousable and 
unable to perform ICE)  
Death due 
to 
ICANS 
where 
another cause is not 
the 
principle 
factor 
leading to this 
outcome  Depressed level 
of consciousness2 Awakens 
spontaneously  Awakens 
to voice  Awakens only to tactile 
stimulus  Patient is unarousable or 
requires vigorous or reptitive tactile stimuli to arouse. Stupor 
or coma  
Seizure  N/A N/A Any clinical seizure focal or 
generalized that resolves rapi[INVESTIGATOR_788905]-threatening prolonged 
seizure (>5min); or repetitive 
clinical or electrical seizures 
without return to baseline in 
between  
Motor findings3 N/A N/A N/A Deep focal motor weakness 
such as hemiparesis or 
paraparesis  
Elevated 
ICP/cerebral edema  N/A N/A Focal/local edema on 
neuroimaging4 Diffuse cerebral edema on 
neuroimaging; decerebrate or decorticate posturing; or 
cranial nerve VI palsy; or 
papi[INVESTIGATOR_044]; or Cushing’s triad  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.[ADDRESS_1086338]  Mild (Grade 1)  Moderate (Grade 2)  Severe (Grade 3)  Potentially Life -
Threatening (Grade 4)  
Pain Does not interfere with 
activity  Repeated use of non -
narcotic pain reliever 
>24 hours or interferes 
with activity  Any use of narcotic 
pain reliever or prevents daily activity  Emergency room (ER) 
visit or hospi[INVESTIGATOR_788906]/Redness1 2.5 to 5cm  5.1 to 10cm  >10cm  Necrosis or exfoliative 
dermatitis  
Induration/Swelling2 2.5 to 5cm and does not 
interfere with activity  5.1 to 10cm or 
interferes with activity  >10cm or prevents 
daily activity  Necrosis  
 
1. In addition to grading the measured local reaction at the greatest single diameter, the measurement should be recorded as a 
continuous variable.  
2. Induration/Swelling should be evaluated and graded using the functional scale as well as the actual measurement  
  Category  Task  Score  
Orientation  Orientation to year, month, city, hospi[INVESTIGATOR_307]  4 points  
Naming  Ability to name 3 objects (eg, point to clock, pen, button)  3 points  
Following 
Commands  Ability to follow simple commands (eg, “show me 2 fingers ” or “Close your 
eyes and stick out your tongue”)  [ADDRESS_1086339] sentence (eg, “Our national bird is the bald eagle”)  1 point  
Attention  Ability to count backwards from 100 by 10  1 point  
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 107 of 109 
 13 APPENDIX II 
Amendment Summary of Changes  
 
Amendment 4.0, 14January2022  
Protocol Amendment 4 includes the below major changes:  
- Updated PVSRIPO to lerapolturev throughout  
- Modified lerapolturev dose and dosing schedule  
o Modified other study assessment timepoints impacted by [CONTACT_788947]  
o Added DSMC review once [ADDRESS_1086340] been treated on new dose and schedule (6 to each arm) and clear the DLT period  
- Modified the stratification factor  of time since prior anti -PD-1/L1 exposure 
(≤6 weeks versus >6 weeks)  to type of anti -PD-1/L1 resistance (primary versus 
secondary)  
- Modified crossover criteria 
- Modified study participant inclusion and exclusion criteria as per the below:  
o Patients with ocular, acral or mucosal melanoma are now excluded  
o Patients with M1c or M1d disease are now excluded  
o Inclusion criterion 5 was modified to clarify definition of resistance to anti -
PD-1/L1- based therapy  
o Patients must have not failed  more than one prior anti -PD-1/L1- based  
regimen  
- Removed study interim analysis after 20 participants randomized  
 Amendment 3.0, 23April2021  
Protocol Amendment 3 includes the below major changes:  
- Added a new  primary objective : To evaluate the effect of PVSRIPO on the TME 
of injected and non- injected lesions when administered with and without 
anti-PD-1 therapy . 
- The primary safety endpoint of “anti-PD-1 AESI ” was changed to “ anti-PD-1 
irAEs ” and an irAE definition was added to Section 9.2.   
- Modified study participant inclusion and exclusion criteria in Section 4 and the 
synopsis as per the below:  
o Inclusion criterion 3 was modified to clarify the melanoma  subtypes 
eligible for study participation, requirements for qualifying biopsy and/or 
archival tissue, and to add the requirement  that at least one melanoma 
lesion is amenable to biops y while on study.  
o Inclusion criterion 8 no longer includes a minimum serum albumin 
requirement . 
o Exclusion criterion 1 was added to state exclusion of ocular melanoma  
o Exclusion criter ia related to uncontrolled/symptomatic hyper calcemia and 
worsening steroid myopathy were removed.  
o Added exclusion criterion  20 to clarif y that participants unable to interrupt  
anticoagulant use the day prior, the day of , and the day after each 
PVSRIPO injection are ineligible for the study . 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 108 of 109 
 - Modified pregnancy testing for women of childbearing potential from 
approximately every 6 months to approximately every 12 weeks  during study 
participation.  
- Clarified t he timing of thyroid function monitoring (along with allowable time 
windows) around were clarified . 
- Added m andatory on- study tissue biopsies of injected  and non- injected lesions, 
as well as draining lymph nodes , at multiple timepoints . The types  of lesions and 
conditions under  which  lesions should  be biops ied was clarified throughout.  
- Added m andatory blood samples at multiple timepoints on- study. The Day [ADDRESS_1086341] the 
requirement to report Grade 3 or 4 ISR within 24 hours of awareness of the 
event.  
- Added Section 8.4.3 to outline the statistical approach to analysis of primary and exploratory translational medicine objectives . 
 Amendment 2.0, 08November 2020  
Protocol Amendment 2 includes the below major changes:  
- Added additional supporting information regarding the PV booster timing in Section 1.3.1.  
- Clarified or modified study participant inclusion and exclusion criteria in S ection 4 
as per the below:  
o Inclusion criterion [ADDRESS_1086342] able and minimal l esion size is 5mm. Clarified  that visceral lesions 
(eg liver, lung, retroperitoneal, subpleural lesions) are not considered 
injectable for the purposes of this trial.  
o Inclusion criterion [ADDRESS_1086343] 
and added allowance of failure on anti -PD-L1 therapy .   
o Exclusion criterion  13 clarified permissible timeframe for receiving 
received prior systemic anti -cancer therapy to within 4  weeks or 5 
elimination half -lives, whichever is shorter - prior to treatment . 
Istari Oncology, Inc    
LUMINOS -102 ( PVSRIPO ICI M201 )  Protocol Amendment 4.0 14JAN2022  
Confidential   Page 109 of 109 
 - For participants crossing over from Arm 1 to Arm 2, added requirement for 
complete tumor burden assessment (ie,  scan s or measurements)  within [ADDRESS_1086344] treatment in Arm 2 (PVSRIPO/anti -PD-1 combination)  
- Clarified that qualifying scans prior to and during screening should be submitted 
to central imaging vendor, where possible  
- Expanded Section [ADDRESS_1086345] dose of study therapy  or upon 
resolution/stabilization for AESI and SAEs.  
- Added amylase testing to biochemistry laboratory assessments in Section 7.2.2.  
- Modified DSMC meeting frequency in Section 9.1.5 to clarify IA meeting and 
allow for continued regular meetings approximately every 4 months following the IA. 
 
In addition, the study protocol number  was modified  from PVSRIPO ICI M201  to 
LUMINOS -102. 
 Amendment 1.0, 09October2020  
The PVSRIPO ICI M201 study protocol Amendment 1 includes the below major changes : 
- Addition of a safety run -in of at least  [ADDRESS_1086346] 1.1 criteria.  
- Modified Inclusion Criterion 6 to specify radiographic confirmation of disease progression on prior anti -PD-1.  
- Additional safety monitoring for CRS and ICANS . 
- Mandatory blood biopsy samples at screening, prior to study treatment administration at Cycle 3, and upon crossover to Arm 2, where applicable.  
In addition, the nomenclature of study visits was updated from “Day” to “Cycle” for 
clarity and additional clarifications were  added to various study visits and procedures to 
clarify requirements . 
  